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SUMMARY 
 
In this study a structure–function analysis has been employed to analyze transcriptional 
regulation through the Mediator subunit MED25. A relationship could be established 
between predicted structural domains and functional characteristics of this protein. Most 
critically the region responsible for interaction of MED25 with the Mediator was 
identified. Immunoprecipitation experiments demonstrated that the so–called VWA 
domain (von–Willebrand A domain, amino acids 1–290) is both sufficient and required 
for this contact. Site–directed mutagenesis indicates that this binding reaction involves 
the non–conserved loop SR2, which is protruding from this domain. Based on the results 
of this analysis a model was proposed, in which the primary contact is established by 
ionic forces and is further stabilized by hydrophobic interactions. 
The previously identified ACID domain was reported to bind to VP16. Targeted 
mutagenesis of four different motifs in this region impaired not only transcriptional 
activation through MED25 but also led to reduced binding to VP16. In particluar a 
lysine–rich motif is also present in two domains of PTOV1, a close homolog of MED25. 
Noteworthy, K518 is not conserved in the PTOV1_B domain, which in contrast to 
PTOV1_A and the ACID domain of MED25 does not bind to VP16. This led to the 
hypothesis that K518 is critically involved in the binding of VP16 to MED25. 
Furthermore it could be demonstrated that MED25 contains an intrinsic transcriptional 
activation capacity, which is localized in the region 290–715. This indicates additional 
recruitment of other factors to promoters through this region. Together with the Mediator 
binding VWA–domain and the VP16–interaction domain this region might facilitate 
transcriptional activation. 
A genome–wide screen showed downregulation of c–Jun and FosB following 
overexpression of MED25. Interestingly, expression of GSK3β, a downstream target of 
which is cyclin D1, seems to be stimulated by MED25. Together with the finding that 
overexpression of MED25 leads to activation of a p21 reporter, this raises the possibility 
that MED25 is involved in cell cycle control.  
An overlap has been discovered by comparison of MED25 target genes and genes 
identified previously as target for the viral activator EBNA2. The close homology 
between the activation domains of EBNA2 and VP16 implies a common mechanism of 
 
transcriptional activation by these two viral proteins through MED25. The involvement of 
MED25 in gene activation by viral activators might indicate a role for this Mediator 
subunit in viral transcription. 
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1. INTRODUCTION 
 
1.1 Eukaryotic gene expression: from genes to proteins 
 
The process of gene expression is a broad and complex event characterized by a 
number of steps in the pathway from gene sequence to active protein. The expression 
level of most genes is regulated by transcription factors which can be considered the 
starting point of the transcription process in the nucleus. Once activated, transcription 
factors bind to gene regulatory elements and, through interaction with other components 
of the transcription machinery, promote access to DNA and facilitate the recruitment of 
the RNA polymerase enzymes to the transcriptional start site. Three RNA polymerase 
enzymes function in eukaryotes: RNA polymerase I, II, III. Transcription of protein–
coding genes is catalysed by RNA polymerase II. The transcription "initiation" process 
characterized by the generation of a nascent RNA is soon followed by the "capping" 
process during which the newly generated RNA is modified by the addition of a "cap" 
structure at its 5' end. This structure protects the new transcript from attacks by 
nucleases and later serves as a binding site for proteins involved in export of the mature 
mRNA into the cytoplasm and its translation into protein. The capping process seems 
also to promote the transition from initiation to "elongation", in which RNA polymerase II 
moves from 5' to 3' along the gene sequence and extends the transcript. Upon reaching 
the end of a gene, the newly synthesized RNA is cleaved and a polyadenosine tail is 
added to the 3' end of the transcript. These three steps are called "termination", 
"cleavage" and "polyadenylation" respectively. Since genes are composed of coding 
sequences (exons) which are interrupted by uncoding sequences (introns), the introns 
are removed from the transcripts in a step called pre–mRNA "splicing". In eukaryotes 
"transcription", the process by which information is transferred from DNA to RNA, takes 
place in the nucleus. By contrast "translation", the process by which the information is 
transferred from RNA to protein takes place in the cytoplasm. Therefore processed 
mRNA molecules are "packaged" by factors that bind to them in the nucleus and direct 
them into the cytoplasm through interactions with proteins that line the nuclear pores. 
Translation of mRNA into proteins takes place on large ribonucleoprotein complexes 
called ribosomes and is mechanistically analogous to transcription. The nascent 
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polypeptide chain undergoes "folding" and often "posttranslational modification" to 
generate the final active protein.  
 
 
Figure 1. A contemporary view of gene expression (from Orphanides and Reinberg, 2002) 
 
The complexity of each of the steps in the pathway from gene to protein has required 
that they be studied in isolation, mostly by the use of classical biochemistry. While this 
type of approach has been very useful, on the other end it shows some limitations. Each 
step is studied separately, forcing to look at the different processes in the pathway as if 
they would be unconnected events. In contrast to this traditional view of gene 
expression, in recent years a growing number of genetic studies have revealed 
functional links between the protein factors that carry out the different steps in the gene 
expression pathway. Similarly, conventional biochemical approaches and large–scale 
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mapping of protein–protein interaction networks have uncovered physical interactions 
between the various machineries. The picture that is emerging is one in which most 
steps are physically and functionally connected ensuring efficient transfer from one 
manipulation to the next (Orphanides and Reinberg, 2002). Figure 1 illustrates this 
contemporary view of gene expression.  
 
1.2 Eukaryotic transcription  
 
While the transcription machinery of eukaryotes is much more complex than that of 
prokaryotes or archaea, the general principals of transcription and its regulation are 
conserved. Bacteria and archaea have only one polymerase, while eukaryotes utilize 
three nuclear enzymes to synthesize different classes of RNA:  
• RNA polymerase I transcribes rRNA 
• RNA polymerase II transcribes mRNA 
• RNA polymerase III transcribes tRNA and other small RNAs. 
The promoters for RNA polymerases I and II are mostly upstream of the start point while 
some promoters for the RNA polymerase III lie downstream of the start point. Each 
promoter contains characteristic sets of short conserved sequences that are recognized 
by the appropriate class of factors. Both, RNA polymerase I and III recognize a relatively 
restricted set of promoters, and rely upon a small number of accessory factors. In 
contrast, class II genes promoters which are utilized by RNA polymerase II show a 
higher complexity in their structure. Achieving transcription in these promoters requires 
the integration of several variables: cis–acting factors (DNA and chromatin), trans–
acting factors (transcription activators and associated complexes), the basal 
transcription machinery (RNA polymerase II and general transcription factors), three 
dimensional structures and nuclear organization (Asturias, 2004; van Driel et al., 2003). 
 
1.2.1 Promoter structure 
 
Eukaryotic genes transcribed by RNA polymerase II are categorized as class II genes. 
The promoters of these genes are composed of sequences which serve as recognition 
sites for the recruitment of the different regulators involved in the transcriptional process. 
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These sequences are conventionally divided in core elements and distal regulatory 
elements.  
 
Core promoter elements 
Core promoter elements define the site for assembly of the transcription preinitiation 
complex (PIC) and include the TATA element, the initiator element (Inr), the downstream 
promoter element (DPE) and the TFIIB recognition element (BRE). Most promoters 
contain one or more of these elements, but none of these elements is absolutely 
essential for promoter function.  
The TATA box is represented by an AT–rich sequence which is located upstream of the 
start site. The distance of the TATA box from the transcriptional start site varies with the 
species being 40 to 120 base pairs in yeast and 25 to 30 base pairs in higher eukaryes. 
The TATA sequence is the binding site for the TATA–binding–protein (TBP). Mutational 
analysis and random selection for functional TATA elements defined TATAAA as the 
consensus TATA sequence in yeast (Chen, 1988; Singer et al., 1990; Wobbe and 
Struhl, 1990). However, the tremendous flexibility of TBP to bind variants of the TATA 
sequence makes it difficult to identify genuine TBP–binding sites from sequence alone 
(Lee and Young, 2000). In contrast to the initial belief that most class II genes promoters 
contain a TATA element, only about 30% of mRNA genes analysed in Drosophila 
contain a recognizable TATA (Ohler et al., 2002). In Drosophila and human many of 
these non–TATA containing promoters contain some combination of Inr and DPE 
elements (Smale and Kadonaga, 2003).  
The Inr element can be defined as the DNA sequence encompassing the transcriptional 
start site. Inr elements have been identified at many promoters, both TATA–containing 
and TATA–less, and have been implicated in transcriptional control by directing accurate 
initiation in a TATA–independent manner (Weis and Reinberg, 1992). Various factors 
can bind to Inr element and these may facilitate recruitment of the transcription 
apparatus (Lee and Young, 2000). Inr and DPE likely serve as binding sites for the TBP 
Associated Factor (TAF) subunits of the general factor TFIID. Cross link experiments 
have shown that TAF1 and TAF2 are normally positioned close to Inr (Oelgeschlager et 
al., 1996) and that TAF6 and TAF9 lie close to the DPE (Burke and Kadonaga, 1997). 
Proper function of a DPE containing promoter requires an Inr element, probably 
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because these elements cooperatively promote the correct binding of TFIID (Burke and 
Kadonaga, 1997). 
The BRE element is a sequence contributing to high affinity binding of TFIIB and TFB to 
the human and archaeal TBP–DNA complex (Lagrange et al., 1998; Qureshi and 
Jackson, 1998). In archaeal the BRE is the primary determinant of transcription 
orientation (Bell et al., 1999; Littlefield et al., 1999). 
 
Distal regulatory elements 
The second category of promoter elements, the distal regulatory elements, is gene–
specific sequences that control the rate of transcription initiation since they are bound by 
transcriptional regulators. Transcription factors bound at these elements influence the 
initiation of transcription by contacting other factors of the basal apparatus directly or 
indirectly through the binding to a transcriptional co–factor which in turn contacts the 
basal apparatus. Distal regulatory elements include upstream activating sequences 
(UASs), enhancers, LCRs, upstream repressing sequences (URSs), silencers, insulators 
and MARs.  
UAS and enhancers serve as recognition site for activators. In metazoans enhancers 
can be located hundreds of kilobases from their target genes and function independently 
from the orientation and the distance from the core promoter. In contrast to the enhancer 
element, the yeast UAS elements localize within few hundred base pares of the 
transcription start site and work only when positioned upstream of the TATA box 
(Blackwood and Kadonaga, 1998; Guarente and Hoar, 1984; Struhl, 1984). A locus 
control region (LCR) is defined as a set of elements that is sufficient to fully activate a 
linked gene in a tissue–specific, copy–number–dependent manner, independent from its 
position of integration in a transgenic mouse. While an enhancer is typically marked by 
one DNAse I hypersensitive site (DHS) where transcription factors interact, LCR is 
characterized by a number of such sites that can be clustered or scattered. Activities 
commonly attributes to LCRs include chromatin opening activity, enhancer activity, and 
capability to establish domains of histone modification. Moreover LCRs elements are 
implicated in establishment of replication timing and DNA demethylation (Simon et al., 
2001). Recent findings demonstrated that GTFs and RNA polymerase II bind to 
enhancers and LCRs before the activation of gene transcription in functional gene 
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expression domains. Founded on these observations, a new theory attributes at least to 
some of these regulatory domains a role as nucleation centres for PIC assembly to 
regulate timing of gene activation during development, differentiation and the cell cycle 
(Szutorisz et al., 2005). 
URSs are DNA sequences bound by sequence–specific repressors. Inhibition of 
transcription mediated by URS–repressor complexes can take place in different fashions 
including interference with the activator–UAS binding, interference with the activation 
domain of an activator–UAS complex and finally targeting directly the core 
transcriptional machinery or indirectly recruiting an additional complex which targets the 
core transcriptional machinery blocking it (Johnson, 1995). Silencers are sequence 
elements that can repress promoter activity in an orientation and position–independent 
manner. Silencing proteins are thought to interact with histones to coat the targeted 
DNA sequence therefore repressing transcription in this region.  
Insulators are elements that prevent the passage of activating or inactivating effects. 
They have been identified in two circumstances: when an insulator is placed between an 
enhancer and a promoter it prevents the enhancer from activating the promoter; 
alternatively, when an insulator is placed between an active gene and heterochromatin, 
it protects the gene against the inactivating effect that spreads from the 
heterochromatin. Usually insulators possess both properties. 
Matrix attachment regions (MARs), sometimes also called scaffold attachment regions 
(SARs), are AT–rich sequences that act as anchor to the nuclear matrix. MARs can 
either form selective and transient or permanent anchors and have been proposed 
among other functions to facilitate transcription by positioning adjacent genes in the 
vicinity of the transcriptional machinery (Bode et al., 2003; Heng et al., 2004). 
 
1.2.2 Chromatin 
 
The DNA in the cells is packaged into a highly organized and compact nucleoprotein 
structure known as chromatin. The basic organizational unit of chromatin is the 
nucleosome, which consists of 146 bp of DNA wrapped almost twice around a protein 
core containing two copies each of four histone proteins: H2A, H2B, H3 and H4 (Luger 
and Richmond, 1998). These small positively charged proteins show high conservation 
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among eukaryotes and are the protein building blocks of our chromosomes. In contrast 
to the original view which was referring to chromatin as a static organizational 
framework for DNA, it is becoming nowadays more and more clear that chromatin plays 
an essential role in regulating gene transcription by modulating access of the 
transcriptional apparatus to genes (Narlikar et al., 2002). Chromatin is not uniform with 
respect of gene distribution and transcriptional activity. It is organized into domains 
defined as euchromatin and heterochromatin which have different chromosomal 
architecture, transcriptional activity and replication timing. Heterochromatin is thought to 
consist of regular nucleosomal arrays, which impede access by nucleases and contain a 
high proportion of transcriptionally inactive repetitive sequences interrupted by relatively 
few genes (Elgin and Grewal, 2003; Grewal and Moazed, 2003). In contrast to 
heterochromatin, euchromatin is considered to be decondensed because it is 
characterized by irregular nucleosome spacing, is relatively gene rich and is potentially 
transcriptionally active (Elgin and Grewal, 2003). However, these differences are not 
always clear–cut as a recent analysis of the human genome showed that some 
pericentromeric regions (considered examples of constitutive heterochromatin) are 
decondensed and that some euchromatic regions are condensed (Gilbert et al., 2004). 
Tissue specific gene expression patterns and global gene silencing are established and 
maintained by so called epigenetic mechanisms which are represented by chromatin 
modification and chromatin remodelling. Epigenetic marks of silent chromatin in higher 
eukaryotes are histone hypoacetylation, di–or trimethylation of lysine 9 at histone H3 
(H3K9 di–or trimethylation) as well as cytosine methylation (Fischle et al., 2003; Grewal 
and Moazed, 2003; Wu et al., 2005). Euchromatin is characterized by histone 
hypercetylation and dimethylation of lisyne 4 at histone H3 (H3K4 dimethylation) 
(Fischle et al., 2003). 
 
1.2.2.1 Chromatin modification and chromatin remodelling 
 
The covalent modification of nucleosomal DNA and core histones, and ATP–dependent 
chromatin remodelling are important in the regulation of gene expression, DNA 
replication and many other biological processes. Increasing evidences indicate that the 
proteins involved in these processes do not act alone but interact with one another, 
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often forming large complexes that regulate higher order chromatin structure and the 
accessibility of chromatin to various factors 
 
Histone modification enzymes 
Modifications of core histones at the lysine, arginine, and serine residues that lie in their 
amino–terminal tails include acetylation, methylation, phosphorylation and ubiquitylation. 
Several classes of enzymes appear to be involved in these mechanisms: histone 
acetyltransferases (HATs), histone deacetylases (HDACs), histone methyltransferases 
(HMTs) and histone kinases (Narlikar et al., 2002). Recruitment of HATs and HMTs to 
promoters by activators is crucial for the activation of many classes of genes (Jenuwein 
and Allis, 2001; Roth et al., 2001; Struhl, 1998; Turner, 2000; Zhang and Reinberg, 
2001). Conversely, recruitment of HDACs by transcriptional repressors leads to 
deacetylation of the histone tails and is required for repression. Several transcription co–
activators such as p300/CBP, Gcn5, PCAF, TAF250 and the p160 family nuclear 
receptor display intrinsic histone acetyltransferase (HAT) activity. Among HMTs 
enzymes, those that target arginine residues have been up to date associated with 
activation of transcription, whereas those implicated in lysine modification are context 
dependent. Methylation of lysine 9 of histone H3 (H3K9) by SUV39 is associated with 
repression (Richards and Elgin, 2002) while methylation of lysine 4 by Set 1 complex in 
yeast (Roguev et al., 2001) or Set 9 in human (Nishioka et al., 2002) leads to 
transcriptional activation. Interestingly, it appears that methylation at lysine 9 can be 
converted from a repressive signal to an active signal by methylation of lysines 4 or 27 
on the same tails. It appears like the transcriptional consequence of any individual 
histone tail modification is influenced by other modification on the same tail (Strahl and 
Allis, 2000; Turner, 2000). Considering the number of modification that can occur at 
different histone tails it becomes quiet obvious how complex is the relationship between 
histone tail modification and gene expression. This observation has led to the proposal 
that the modification state of the histone tail make up a so called histone code read by 
proteins that modulate transitions between the different chromatin states (Strahl and 
Allis, 2000; Turner, 2000). Several examples are given that support the hypothesis that 
histone modifications may create specific binding sites for accessory proteins. The 
heterochromatin protein 1 (HP1) uses its chromodomain to recognise the histone H3 
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lysine 9 modification. Polycomb, a protein with similarity to HP1 belonging to the 
Polycomb group (PcG) proteins, recognizes and binds methylated histones and the 
histone methyltransferases responsible for their methylation (Craig, 2005). Many 
proteins involved in modulating chromatin structure use their bromodomain for the 
recognition of histone tails acetylated at specific lysines (Doerks et al., 2001; 
Jeanmougin et al., 1997). It is likely that bromodomains and chromodomains have 
evolved to recognize histone tails carrying specific modifications, although it is important 
to point out that not all proteins containing these domains possess this function. 
 
ATP–dependent remodelling complexes 
ATP–dependent chromatin remodelling complexes facilitate access of DNA binding 
proteins to DNA by repositioning nucleosomes at the promoter or by inducing 
conformational changes in nucleosomes (Narlikar et al., 2002). They function using the 
energy of ATP hydrolysis to introduce superhelical torsions into nucleosomal DNA, 
which leads to the formation of nucleosomes that contain exposed DNA bulges or loops 
(Narlikar et al., 2002). In mammalian cells three classes of chromatin–remodelling 
protein complexes have been identified. SWI/SNF/Brm, ISWI and Mi–2/NuRD contain 
different ATPase subunits and associated proteins (Peterson, 2002). 
 
DNA methylation  
Together with histone modifications, DNA methylation serves as an epigenetic mark for 
active or inactive chromatin. DNA methylation regulates gene expression through 
several distinct mechanisms. It can directly block transcription regulatory factors from 
binding to their target sequences or, alternatively, it can repress gene expression 
through several methyl–CpG–binding proteins (MECPs) that "read" DNA–methylation 
patterns. In mammals, the proteins identified up to date which are involved in this type of 
transcriptional regulation have been divided in two classes: DNA cytosine 
methyltransferases (Dnmt1, Dnmt2, Dnmt3a and Dnm3b) and Methyl–CpG–binding 
proteins (MECP2, MBD1, MBD2, MBD3, MBD4 and Kaiso). The first group of proteins is 
characterized by highly conserved cytosine–methyltransferase motifs in their catalytic 
domain. Dnmt1 is a maintenance methyltransferase, which restores DNA–methylation 
patterns by methylating hemi–methylated CpG sites after DNA replication (Bestor, 
INTRODUCTION  10 
1992). Dnmt3a and Dnm3b are required to initiate de novo methylation and establish 
new methylation patterns during development (Okano and Li, 2002). Both Dnmt1 and 
Dmnt3a have been shown to interact with histone deacetylases (HDACs) and can 
repress transcription (Burgers et al., 2002). The second group of proteins contain a 
methyl–CpG–binding domain (MBD) except for Kaiso which binds methylated CGCG 
through its zinc–finger domain (Prokhortchouk et al., 2001). There are several examples 
of complexes between Methyl–CpG–binding proteins and histone deacetylases. For 
instance, MECP2 forms a complex with HDACs and the co–repressor protein Sin3a to 
repress transcription in a methylation dependent manner (Jones et al., 1998; Nan et al., 
1998). Moreover, together with the ATP–dependent remodelling complex NuRD, which 
contains also histone deacetylase activity, MBD2 forms a complex able to repress 
methylated promoters and to remodel methylated chromatin with high efficiency (Feng 
and Zhang, 2001; Ng et al., 1999; Wade et al., 1999; Zhang et al., 1999b). These two 
complexes provide a mechanistic link between DNA hypermethylation and histone 
deacetylation in transcriptional repression.  
 
1.2.3 RNA Polymerase II  
 
RNA Polymerase II (Pol II) lies at the centre of the transcription machinery interacting 
with general transcription factors in the preinitiation complex (PIC), breaking these 
interactions upon initiation and promoter clearance and associating with another set of 
factors during elongation and termination. The high resolution structures of bacterial 
polymerase and of yeast Pol II have given the first detailed insight about the molecular 
mechanism used by the transcriptional machinery (Cramer et al., 2000; Cramer et al., 
2001; Gnatt et al., 2001; Zhang et al., 1999a). Yeast Pol II is composed of 12 subunits 
encoded by RPB1 to RPB12 genes. Based on structural similarities found in between 
Pol II and either the other two polymerases or the bacterial polymerase, Pol II subunits 
can be classified into three categories: subunits of the core domain having homologous 
counterparts in bacterial polymerase (Rpb1, 2, 3, and 11); subunits shared between all 
three nuclear polymerases (Rpb5, 6, 8, 10, and 12); subunits specific to Pol II but not 
essential for transcription elongation (Rpb4, 7, and 9) (Hahn, 2004). Pol II subunits 
organize in four mobile elements termed Core, Clamp, Shelf and Jaw Lobe that move 
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relative to each other. There is extensive structural conservation among the subunits of 
eukaryotic RNA polymerase II. Indeed six subunits of human Pol II can functionally 
replace their homologs in yeast ref (McKune et al., 1995). The two largest Pol II 
subunits, Rpb1 (about 200 kDa) and Rpb2 (about 150kDa) are the most highly 
conserved subunits and they are also homologous to the β' and β subunits, respectively, 
of bacterial RNA polymerase. Mutations at the genes encoding for these two subunits, 
RPB1 and RPB2, have revealed their involvement in specific functions of Pol II, namely 
the selection of the start site during transcription initiation (Arndt et al., 1989; Berroteran 
et al., 1994; Hekmatpanah and Young, 1991) and the overcoming of transcriptional 
arrest during transcription elongation (Archambault et al., 1992; Powell and Reines, 
1996). As for Rpb1 and Rpb2, mutations at the level of RPB9 gene affect the accuracy 
of initiation probably explainable with the interaction between Rpb9 subunit and TFIIB 
(Sun et al., 1996). The Rpb4 and Rpb7 are functionally related. These two subunits can 
be dissociated from Pol II. In vitro studies performed using an Rpb4 null mutant of Pol II, 
which lacks Rpb7 as well, have demonstrated the role played by these two subunits in 
transcription initiation but not elongation. Moreover, it seems like these two subunits can 
shuttle between RNA polymerase II molecules (Edwards et al., 1991).  
 
1.2.3.1 The carboxyl–terminal domain (CTD) 
 
The largest subunit of Pol II contains a carboxyl–terminal domain (CTD) characterized 
by a tandem repeat of the consensus sequence Tyr–Ser–Pro–Thr–Ser–Pro–Ser. Ser2 
and Ser5 are both sites of phosphorylation. Despite the high conservation of CTD 
among eukaryotes, the length of the repeats varies from 26 in yeast to 52 in human, 
suggesting that length increases with increasing genome complexity (Hampsey, 1998). 
In mammals CTD appears to be unstructured in crystallographic studies (Cramer et al., 
2001). The CTD acts as a platform for assembly of factors that regulate the different 
phases of transcription, initiation, elongation, termination and mRNA processing (Hirose 
and Manley, 2000; Proudfoot et al., 2002; Shatkin and Manley, 2000). This special 
function of CTD might require the existence of a mechanism by which the CTD can 
"signal" to the machinery the phase of transcription it is engaged in and, therefore, the 
status of its transcript. Two observation provided support for the existence of such a 
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mechanism. First, the phosphorylation pattern of the CTD changes during transcription. 
After recruitment of a hypophosphorylated Pol II to promoters during PIC formation, 
phosphorylation of serine 5 in the CTD motif occurs between transcription initiation and 
disruption of the interactions between Pol II and the promoter (promoter clearance). 
Differently, modification of serine 2 is found only when the polymerase is associated with 
the coding region (Komarnitsky et al., 2000). Second, different processing factors 
recognize distinct regions of the CTD (Fondell et al., 1996). Therefore a "CTD code" 
may exist by which changes in CTD phosphorylation triggered upon completition of each 
stage of transcription or mRNA processing reaction may create docking sites for 
enzymes that catalyse the next processing step (Orphanides and Reinberg, 2002). Two 
cyclin dependent kinases target the CTD for phosphorylation: the CDK7 subunit of the 
general transcription factor TFIIH and the CDK8 component of the Mediator complex 
(Lee and Young, 2000). Even though positive regulation of transcription was originally 
attributed only to CDK7, new findings have proven that both kinases can promote 
transcription and that both kinases are required for maximal inhibition of transcription 
(Liu et al., 2004). Phosphorylation of the CTD by these kinases also destabilizes the PIC 
leading to formation of the so–called Scaffold complex, composed of GTFs and 
cofactors remaining at the promoter after Pol II departure. After initiation, another factor 
such as the positive transcription elongation factor b (P–TEFb), which contains the 
Cdk/cyclin pair CDK9 and cyclinT, promotes phosphorylation of Ser2 resulting in 
recruitment of the RNA processing and polyadenilation/termination factors to elongating 
Pol II (Ahn et al., 2004; Bentley, 2002). A phosphatase activity responsible for 
dephosphorylation of CTD has been associated to the protein Fcp1. (Chambers and 
Dahmus, 1994). CTD phosphatase activity is regulated by TFIIB and TFIIF. The RAP74 
subunit of TFIIF stimulates CTD phosphatase activity whereas TFIIB inhibits the 
stimulatory activity of TFIIF. Since the dephosphorylated form of Pol II preferentially 
enters the PIC, Pol II CTD might regulate Pol II recycling (Hampsey, 1998). 
 
1.2.4 General transcription factors 
 
Unlike the prokaryotic enzymes, eukaryotic RNA polymerases cannot recognize the 
promoters of their target genes. Therefore they rely on a series of accessory factors 
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known as the general transcription factors (GTFs) (Orphanides et al., 1996; Roeder, 
1996). GTFs include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH. Pol II and GTFs position 
at core promoters in a state termed the preinitiation complex PIC. Pol II and GTFs were 
originally identify as independent, chromatographically distinct factors. Later on, 
however, the purification of preassembled complexes from yeast and human cells 
generated the idea that GTFs, Pol II and other regulatory factors are recruited at 
promoters as a preformed complex, in the form of a holoenzyme. Recently, this model 
has been questioned by reports demonstrating that certain holoenzyme components are 
recruited to some promoters independently of Pol II, (Bhoite et al., 2001; Cosma et al., 
2001). These observations rather support a view where the transcriptional machinery 
assemblies in a step–wise manner at promoters. Once assembled, the transcription 
apparatus is still in an inactive state. A dramatic conformational change occurs in which 
11–15 bp surrounding the transcription start site are melted and form a single strand 
bubble (open complex formation) (Wang et al., 1992). Initiation of transcription begins 
with synthesis of the first phosphodiester bond of RNA. Pol II goes repeatedly through 
this process generating multiple short RNAs (abortive initiation) before it productively 
initiates synthesis of full length RNAs (promoter clearance). After pausing 25–30 bp from 
the start site Pol II is thought to release its contacts to the core promoter and the rest of 
the transcription machinery (promoter escape) and enters the stage of transcription 
elongation. In vitro, after initiation of transcription by Pol II many of the transcription 
factors remain behind at the promoter in the scaffold complex, which can then rapidly 
recruit the remaining general factors to promote transcription reinitiation. 
 
TFIID: TBP and TAFs.  
TFIID is a complex composed of TBP (TATA binding protein) and about 14 TAFs (TBP 
associated factors). TBP is a universal transcription factor required for initiation by all 
three eukaryotic RNA polymerases (Hernandez, 1993). TBP recognizes the TATA box 
element therefore helping the transcription machinery to correctly position at core 
promoters. Resolution of the crystal structure revealed that TBP resembles a 
symmetrical saddle which sits on the DNA inducing a sharp DNA bend accompanied by 
a partial unwinding of base pairs that may be instrumental in the process of initiation 
(Lee and Young, 2000). TBP has shown to play an important role in transcriptional 
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activation via direct interaction with the activation domain of many gene–specific 
activators (Nikolov and Burley, 1994). TAFs function in promoter recognition as well as 
in positive and negative regulation of transcription. TAFs have been shown to be 
functional targets of transcriptional activators in vitro. Some TAFs are also subunits of 
complexes lacking TBP involved in covalent chromatin modification and transcriptional 
coactivation such as yeast SAGA and SLIK/SALSA (Spt–Ada–Gcn5–Acetylase and 
SAGA–like complex) and the human complexes pCAF and STAGA (p300/CBP and Spt–
TAF–Gcn5–Acetylase). Although most genes are dependent on at least some TAFs for 
normal regulation, an important class of promoters seems independent of any TAF. In 
yeast, these completely TAF–independent promoters recruit TBP but not the TAFs upon 
gene activation. It is possible that at these genes TFIID is replaced by another TAF–
containing complex such as SAGA (Hahn, 2004).  
 
TFIIA 
One of the major functions of TFIIA is stabilizing the TBP–DNA interaction while binding 
to TBP. TFIIA interacts with numerous activators and it might be critical for 
transcriptional activation and to antagonize transcriptional repressors. In fact, it has 
been shown that TFIIA displaces blocks of several negative transcriptional regulators 
from the TFIID complex (Lee and Young, 2000). 
 
TFIIB 
TFIIB is involved in the selection of transcription start sites, as demonstrated by the 
observation that mutations in TFIIB cause a shift in the transcription start site ref 40, 
452. TFIIB enters the PIC after TBP and as a prerequisite for recruitment of Pol II. Not 
only TFIIB interacts directly with TBP and Pol II but also with other GTFs including the 
RAP30 and RAP74 subunits of TFIIF and the TAFII40 subunit of TFIID. TFIIB has also 
been implicated as the direct target of many gene–specific transcriptional activators, 
leading to the proposal that certain activators stimulate transcription by TFIIB 
recruitment (Hampsey, 1998). 
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TFIIF 
TFIIF is composed of two subunits, RAP30 and RAP74. TFIIF has several 
characteristics reminiscent of bacterial sigma factor. These include tight binding to Pol II, 
suppression of non–specific DNA binding and stabilization of the preinitiation complex. 
TFIIF is critical for tight wrapping of DNA, possibly inducing torsional strain in the DNA, 
thereby facilitating promoter melting. TFIIF can also stimulate polymerase elongation 
rates by suppressing transient pauses during transcription. As mentioned above, RAP74 
stimulates CTD phosphatase activity. Even though RAP30 and RAP74 were originally 
thought to function exclusively in initiation and in elongation, respectively, both subunits 
are now known to function in both processes (Hampsey, 1998; Lee and Young, 2000). 
 
TFIIE 
TFIIE interacts directly with the unphosphorylated form of Pol II, with both subunits of 
TFIIF and with TFIIH. TFIIE is also a direct target of certain transcriptional activators. 
Biochemical analyses revealed that human TFIIE is composed of two subunits (TFIIEα 
and TFIIEβ) that form a α2β2 heterodimer. Functions attributed to TFIIE include 
recruitment of TFIIH to the PIC, stimulation of TFIIH–dependent phosphorylation of the 
Pol II CTD and stimulation of TFIIH–dependent ATP hydrolysis. TFIIE is likely to play a 
role in melting of promoter DNA. It contains a zinc ribbon motif that is implicated in DNA 
binding and TFIIE can bind regions of single stranded DNA, suggestive of a role in 
opening or maintaining an open promoter complex. The requirement of TFIIE seems to 
be promoter–specific (Hampsey, 1998; Lee and Young, 2000). 
 
TFIIH 
TFIIH shows at least three enzymatic activities: DNA–dependent ATPase, ATP–
dependent helicase and CTD kinase. These activities are distributed in two domains, a 
core domain containing two DNA helicase activities (XPB and XPD) and a kinase 
domain containing a kinase/cyclin pair (CDK7/cyclin C). The helicase activity found in 
XPB is essential for promoter opening (open complex formation), and also for transition 
from abortive to productive elongation. In general, helicases act by destabilizing double 
stranded nucleic acid through the ATP hydrolysis–dependent motion of two separate 
domains that interact with single and double stranded nucleic acids. Using this 
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mechanism, the XPB helicase binding to promoter DNA as a subunit of TFIIH, likely 
initiates unwinding by introducing tortional strain in the DNA near the transcription start 
site. However the exact mechanism of XPB helicase action is still not completely 
clarified (Hahn, 2004). While XPB appears to be the primary helicase involved in 
transcription, XPD is required for nucleotide excision repair. Mutations in the XPB and 
XPD helicases are responsible for several genetic diseases in humans including 
xeroderma pigmentosum, Cockayne's syndrome, and trichothiodystrophy. The TFIIH 
kinase CDK7 phosphorylates serines at the CTD of Pol II. In mammalian systems but 
not in yeast the TFIIH kinase also functions as Cdk activating kinase (CAK) and 
regulates cell cycle transitions (Lee and Young, 2000). 
 
1.2.5 The Mediator complex 
 
The initiation of eukaryotic messenger RNA synthesis is an elaborate process catalysed 
by RNA polymerase II and the general transcription factors (GTFs). This process, 
however, is further complicated by the requirement of a very large multisubunit "adaptor" 
that bridges RNA polymerase II and its myriad DNA binding regulatory proteins and 
transduces both positive and negative signals that turn on and off messenger RNA 
synthesis in response to the ever changing microenvironment of the cell. This adaptor 
which is ubiquitously expressed and evolutionarily conserved from yeast to man has 
been named Mediator for its role in mediating transcription signals from DNA binding 
transcription factors bound at upstream promoter elements and enhancers to RNA 
polymerase II and the general initiation factors bound at the core promoter surrounding 
the transcriptional start site.  
Early studies of activator functions in systems reconstituted with DNA templates and 
purified RNA polymerase II and corresponding GTFs revealed that additional 
"coactivator" or "mediator" activities were required for activator function but not for basal 
(activator–independent) transcription (Flanagan et al., 1991; Meisterernst et al., 1991). 
In human cell, the USA (Upstream Stimulatory Activity) coactivator activity was resolved 
into a number of negative cofactors and positive cofactors that act jointly both to 
selectively repress basal transcription and to facilitate activator–dependent transcription 
(Meisterernst et al., 1991). The Mediator complex was identified and first purified from S. 
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cervisiae by Kornberg and co–workers, by virtue of its ability to promote activator–
dependent transcription by purified RNA polymerase II and the GTFs in vitro (Kim et al., 
1994a). This study brought to light for the first time the complexity of the complex which 
in yeast is composed of about twenty subunits. In addition to defining the subunit 
composition of the yeast Mediator complex, Kornberg and co–workers' characterization 
of the biochemical properties of their purified Mediator preparations led to the initial 
identification of the known Mediator associated activities. They and others provided 
direct evidence that Mediator binds tightly not only to the transcriptional activation 
domains of DNA binding transcription factors (Hengartner et al., 1995; Koh et al., 1998) 
but also to RNA polymerase II to form the so called "holoenzyme" (Kim et al., 1994b; 
Koleske and Young, 1994). Moreover, the binding of Mediator to Polymearse II was 
found to stimulate phosphorylation of the CTD heptad repeats by TFIIH–associated CTD 
kinase and, in the same work, yeast Mediator was shown to stimulate transcription 
initiation in an activator–independent fashion (Kim et al., 1994a). Very recently in vitro 
experiments have shown that Mediator enhances basal transcription facilitating the 
recruitment of TFIIB during PIC assembly (Baek et al., 2006). 
 
1.2.5.1 Mammalian Mediator 
 
Since its original description in yeast cells as the reversibly associating coactivator 
component of the Polymerase II holoenzyme, multiprotein Mediator–like complexes 
have been isolated from mammalian cells using diverse approaches and include the 
thyroid hormone receptor–associated proteins/SRB–Med containing cofactor 
(TRAP/SMCC) (Fondell et al., 1999; Gu et al., 1999; Ito et al., 1999; Malik et al., 2000), 
activator–recruited factor–large (ARC–L) (Naar et al., 1999; Taatjes et al., 2002), vitamin 
D receptor–interacting proteins (DRIP) (Rachez et al., 1999), positive cofactor 2 (PC2) 
(Malik et al., 2000), cofactor required for Sp1 activation (CRSP) (Ryu et al., 1999; 
Taatjes et al., 2002), mouse Med (Jiang et al., 1998) and rat Med (Brower et al., 2002; 
Sato et al., 2003a; Sato et al., 2003b; Tomomori-Sato et al., 2004) complexes. Despite 
significant similarities in the subunit compositions of mammalian Mediator complexes 
isolated in different laboratories, apparent differences were notable. Although the reason 
for these differences is not known, recent proteomic analyses suggests that most of the 
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Mediator–associated proteins identified in different laboratories are bona fide subunits of 
the complex (Sato et al., 2004).  
Up to date the mammalian Mediator contains 28–30 subunits (Sato et al., 2004) the 
nomenclature of which has recently been revised (Table 1) (Bourbon et al., 2004).  
 
Table1. Mediator subunit nomenclature according to Bourbon et al., 2004 
 
New name S. cervisiae  H. sapiens Location 
MED1 Med1 TRAP220 middle 
MED2 Med2 – tail  
MED3 Pgd1/Hrs1/Med3 – tail 
MED4 Med4 TRAP36/DRIP36 middle 
MED5 Nut1 – middle/tail 
MED6 Med6 hMED6/Drip33 head 
MED7 Med7 hMed7/Drip34 middle 
MED8 Med8 Arc32 head 
MED9 Cse/Med9 Med25 middle 
MED10 Nut/Med10 hNut2/hMed10 middle 
MED11 Med11 HSPC296 head 
MED12 Srb8 TRAP230/DRIP240 kinase 
MED13 Srb9 TRAP240/DRIP250 kinase 
MED14 Rgr1 TRAP170/DRIP150/CRSP150 tail 
MED15 Gal11 ARC105 tail 
MED16 Sin4 TRAP95/DRIP92 tail 
MED17 Srb4 TRAP80/DRIP77/CRSP77 head 
MED18 Srb5 P28B head 
MED19 Rox3 LCMR1 head 
MED20 Srb2 hTRFP/p28a head 
MED21 Srb7 hSrb7/p21 middle 
MED22 Srb6 Med24/Surf5 head 
MED23 – TRAP150β/DRIP130/CRSP130/hSur2 ? 
MED24 – TRAP100/DRIP100/CRSP100 ? 
MED25 – ARC92/ACID1 ? 
MED26 – ARC70/CRSP70 ? 
MED27 – TRAP37/CRSP347 ? 
MED28 – Fksg20 ? 
MED29 – Hintersex ? 
MED30 – TRAP25 ? 
MED31 Soh1 hSoh1 middle 
CDK8 Srb10/Ssn3/Ume5 hSrb10/CDK8 kinase 
Cyclin C Srb11/Ssn8/Ume3 hSrb11/CycC kinase 
 
In yeast, genetic (Lee et al., 2000), biochemical (Myers and Kornberg, 2000), and 
structural (Dotson et al., 2000) studies have provided evidences that the subunits of the 
Mediator complex organize into sub–modules. A number of observations seem to point 
to an analogous structural organization within the mammalian Mediator complex as well. 
Twenty of these subunits, which are invariably found in PC2, are conserved in all 
eukaryotes, seem to be tightly associated and probably form the central core of the 
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complex. Among the subunits which show weaker association to the complex, MED16, 
MED23 and MED24 form apparently a module as suggested by knock out experiments 
that show interdependent loss of these factors (Ito et al., 2000; Stevens et al., 2002). 
Also MED13, MED12, CDK8 and Cyclin C are poorly represented in PC2, which is 
consistent with the ability of these four subunits to form a genetic, functional and 
physically separable module within the yeast complex (Borggrefe et al., 2002), to which 
a negative regulation of transcription has been attributed (Gu et al., 1999; Sun et al., 
1998). Finally, MED26 and MED25 are found in association with subpopulations of 
Mediators and therefore define additional human Mediator variants termed CRSP and 
A–MED respectively (Mittler et al., 2003; Taatjes et al., 2002; Taatjes et al., 2004).  
At present, MED21–MED7 subunits of the core module represent the only part of 
Mediator for which the X–ray structure was resolved at high level (Baumli et al., 2005). 
Nevertheless a raw draft has been developed through the mapping of protein–protein 
interactions as well as biochemical and EM analysis (Asturias et al., 1999; Dotson et al., 
2000; Guglielmi et al., 2004; Sato et al., 2003a; Sato et al., 2003b). On the basis of the 
close similarity in the overall 3D structure, deduced from cryo–electron microscopy 
(cryo–EM) studies of the mammalian and yeast Mediator complexes, it is possible to 
discern defined parts which are called "head", "middle" and "tail". A schematic view of 
the mammalian Mediator complex is given in figure 2. 
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Figure 2. The Mediator complex. Core complex subunits found in most PC2 are indicated in red. Subunits 
loosely associated to the core are depicted in blue. The Kinase module subunits are in yellow. In green is 
shown MED25, the subunit studied in this work (adapted from Malik, 2005) 
 
1.2.5.2 Mediator–activator interaction 
 
Although Mediator functions as a general coactivator complex required for most Pol II 
driven transcription in eukaryotes, different parts of Mediator seem to regulate distinct 
sets of genes via the activator–specific function of individual Mediator proteins. Even 
though the genetic analysis of Mediator function in higher eukaryotes is limited 
compared with the extensive studies in yeast, investigations in C. elegans (Kwon et al., 
1999; Moghal and Sternberg, 2003; Singh and Han, 1995; Wang et al., 2004; Zhang and 
Emmons, 2000) Drosophila (Boube et al., 2000; Gim et al., 2001; Janody et al., 2003; 
Kim et al., 2004; Park et al., 2001a; Park et al., 2003; Park et al., 2001b; Treisman, 
2001) and mouse (Ge et al., 2002; Ito et al., 2000; Lau et al., 2003; Stevens et al., 2002) 
demonstrate that specific activator–gene functions of individual Mediator subunits are 
required to regulate particular developmental processes (Table 2).  
 
 
MED12
MED13
CDK8
CycC
MED17
MED11
MED20
MED22
MED19MED18
MED30 MED6
MED4
MED31 MED10
MED27 MED26 MED15
MED14
MED21
MED7
MED1
MED23MED25
MED24 MED16
MED8
head
tail
middle
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Table 2. Mediator–interacting activators. Adapted from (Blazek et al., 2005) 
 
Activator Mediator subunit  
ERα and ERβ MED1 
AR MED1 
GR MED1, MED14 
TRα MED1, MED21 
TRβ MED1 
VDR MED1 
RARα MED1 
RXRα MED1 
PPARα MED1 
PPARγ MED1 
HNF–4 MED1, MED14 
FXR MED1 
RORα MED1 
STAT2 MED14, MED17 
Elk–1 MED23 
Esx/Elf–3 MED23 
C/EBPβ MED23 
SMAD2/SMAD3/SMAD4 MED15 
DSXF MED29 
SOX9 MED12 
Dif MED17, MED16, MED23, MED25 
E1A–13S MED23 
RTA MED12 
VP16 MED25, MED17 
Myc Cdk8  
p53 MED1, MED17 
BRCA1 MED1 
HSF MED17, MED23, MED25 
Aryl HC receptor MED1 
SREBP–1a MED14 
 
The best understood mechanism of Mediator recruitment by activators is given by the 
nuclear receptors. The activation function 2 (AF2) contained in the activation domain of 
nuclear receptors binds one or both of the so–called nuclear receptor boxes (LXXLL) of 
the MED1 subunit to recruit the entire Mediator complex. To date several nuclear 
receptors have been shown to bind the MED1 subunit in this fashion (Table 2). Gene 
targeting of MED23 revealed an essential role in MAP kinase signalling through Elk–1, 
as well as for activation by the adenoviral E1A protein (Stevens et al., 2002). Studies in 
Xenopus embryos have revealed that the MED15 subunit is required for the function of 
SMAD2–SMAD4 and SMAD3–SMAD4 complexes. Another well studied example of 
activator–Mediator interaction is provided by Herpes simplex VP16, which interacts with 
MED17 (Ito et al., 1999), and MED25 (Mittler et al., 2003). Moreover, a recent study 
carried out by Kim et al. in Drosophila using the siRNA approach, has revealed that 
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particular sets of Mediator proteins are required for expression of specific genes 
whereas others are required generally (Kim et al., 2004). Screening for activator–binding 
Mediator subunits, Kim et al have also demonstrated that a group of Drosophila 
Mediator subunits MED16, MED17, MED23 and MED25 bind HSF and Dif activators, 
acting as an activator–interacting module as previously shown in yeast (Lee et al., 
1999). 
Taking all together these data it is tempting to speculate that in addition to the 
recruitment of Mediator at promoters mediated by the interaction with activators, multiple 
activators targeting distinct Mediator subunits could lead to synergistic effects (Malik and 
Roeder, 2000). Alternatively, subtle changes in Mediator conformation resulting from 
interactions with distinct activators could confer activator–specific properties (Taatjes et 
al., 2002). 
 
1.2.5.3 Mediator–Pol II interaction 
 
Because of the original isolation of the yeast Mediator complex as a component of the 
Pol II holoenzyme, it has been assumed that the predominant role of Mediator is to 
nucleate PIC assembly via interaction with Pol II. In fact, it has been proved that 
mammalian Mediator can interact and be isolated with Pol II (Malik et al., 2005; Sato et 
al., 2004; Wang and Berk, 2002). Moreover it has been demonstrated that CRSP 
interacts with the CTD of the largest subunit Rpb1 of Pol II (Naar et al., 2002). In 
addition to these findings, evidence is mounting that there might be other domains of Pol 
II that play an important role in Mediator's function. The high resolution structural 
analysis of Pol II (Cramer et al., 2001) and the electron microscopy analysis of Mediator 
(Davis et al., 2002), both conducted in yeast, have provided new information regarding 
the orientation of these two molecules respect to each other and within the preinitiation 
complex. The tail Mediator domain extends away from Pol II while middle and head 
Mediator modules show multiple contacts with Pol II. In the Pol II complex these 
interactions are centred on Rpb3, Rpb11 subunits but additionally involve portion of 
Rpb1, Rpb2, Rpb6 and Rpb12 subunits. Although the contacts between Pol II and 
Mediator are extensive, a large fraction of Pol II surface remains available for interaction 
with other components of the PIC (Chadick and Asturias, 2005). Dramatic 
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conformational changes are observed when yeast Mediator interacts with Pol II, 
compared to those observed when human Mediator binds activators. The fact that 
Mediator undergoes different type of conformational changes depending on the 
interaction–partner could be interpreted as a possible mechanism of signal integration 
carried out by Mediator in transcription regulation. Despite the existence of a 
holoenzyme form where Mediator is found in a pre–complex with Pol II, several 
observations reported a temporal disjunction in the order of recruitment of the two 
molecules at target genes (Park et al., 2001b; Shang et al., 2000; Sharma and Fondell, 
2002). Therefore, Mediator and Pol II might exist in equilibrium between associated and 
free forms, which could enable step–wise assembly of a PIC. 
 
1.2.6 Activators  
 
Activation of transcription is achieved by the contribution of transcriptional regulator 
proteins that bind to short sequence motifs found in the promoter and enhancer regions 
of genes. The regulatory sequences of most eukaryotic genes contain binding sites for 
multiple transcription factors, allowing each gene to respond to multiple signalling 
pathways and facilitating the fine tuning of transcript levels (Lefstin and Yamamoto, 
1998; McKenna and O'Malley, 2002). As a minimum, activator and other transcription 
factors that bind specific consensus sequences in DNA are characterized by two 
different domains: a DNA binding domain that recognizes and binds a specific DNA 
sequence and an activation domain capable of interacting with coactivators in the 
transcriptional initiation complex in a manner that increases the rate of transcription.  
Common identified motifs of DNA binding domain include: 
 
• helix–turn–helix (HTH): this motif is characterized by one alpha helix which lies in 
the wide groove of DNA and a second one which lies at an angle across DNA. 
• zinc finger: contains a cluster of histidine and/or cysteine residues that form a 
coordination complex with zinc ion to fold the protein into a short finger–like loop. 
• leucine zipper: consists of a stretch of amino acids with a leucine residue in every 
seventh position. Through this motif two proteins are bound to form a dimer. The 
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stretch of positively charged residues adjacent to each zipper is involved in DNA 
binding.  
 
Among identified activation domains very well defined are the glutamine–rich domain 
(Sp1, CREB), the acidic activation domain (VP16, p53, E1A, GAl4, NFkB), the proline–
rich domain (SMAD4, AP–2) and the serine–/threonine–rich domain (Sox–2, Sox–4). 
The activity of transcription factors can be regulated in different fashions. One of them 
is the transport of the protein between the nuclear and cytoplasmic compartments. This 
transport occurs through nuclear pores which, in the proteins, recognize specific 
sequences called nuclear export signal (NES) and nuclear localization signal (NLS). 
Simply masking a NLS or NES by covalent modification or through binding of a 
transport inhibitor prevents the recognition of these signals by the transport machinery. 
Another important way of regulating transcription factors is represented by 
ubiquitination. Recently, many reports have linked the ubiquitination protease activity to 
both activation and degradation of transcription factors. In yeast, ubiquitination 
potentiates the activity of the activation domain of VP16 and also targets it for 
destruction (Salghetti et al., 2001). In addition to protein ubiquitination, a number of 
other posttranslational modifications play important roles in regulating transcription 
factors activity. These include protein phosphorylation, acetylation of lysine residues 
and methylation of arginine and lysine residues (Zhang and Reinberg, 2001). 
 
1.2.6.1 The viral activator VP16 
 
The acidic activator of the herpes simplex virus (VP16) is one of the most widely used 
model for activators. The virion protein VP16 does not contain a domain which binds 
directly the DNA. However, a specific consensus sequence is recognized by a complex 
where VP16 interacts directly with the DNA binding protein Oct–1 and the accessory 
protein HCF–1 (Gerster and Roeder, 1988; Katan et al., 1990; Kristie et al., 1989; 
O'Hare and Goding, 1988; Xiao and Capone, 1990). The transcriptional activation 
domain (TAD) of VP16 resides within the carboxyl terminal residues 411–490 (Greaves 
and O'Hare, 1989; Triezenberg et al., 1988a; Triezenberg et al., 1988b; Werstuck and 
Capone, 1989). Within the same domain are two subregions, spanning amino acids 
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411–456 (VP16H1) and amino acids 450–490 (VP16H2), either of which can function to 
activate expression of target genes (Regier et al., 1993; Tal-Singer et al., 1999; Walker 
et al., 1993). Both subdomains have been studied by mutational analysis, indicating key 
roles for specific hydrophobic and acidic residues (Cress and Triezenberg, 1991; Regier 
et al., 1993; Sullivan et al., 1998; Walker et al., 1993). Of special importance are several 
aromatic residues, the mutation of which revealed to be critical for activation of 
transcription. These amino acid residues include Phe 442 (mutated to Pro) located in the 
H1 subregion and Phe 473/475/479 (mutated to Ala) located in the H2 region (figure 3).  
 
 
Figure 3. Schematic view of the VP16 transactivation domain (TAD). The two subdomains, H1 and H2, 
are indicated in different colours and can function indipendently from each other. The amino acid residues 
critical for activation of transcription are indicated in bold. 
 
The mechanism of transcription activation by VP16 TAD has been extensively 
investigated. It promotes the enhancement of transcription rates and increases the 
number of functional active promoters (Ghosh et al., 1996; Ranish et al., 1999). It 
facilitates open complex formation (Jiang et al., 1994) and increases the processivity of 
RNA polymerase II (Yankulov et al., 1994). Moreover it promotes the assembly of the 
pre–initiation complex through interaction with TFIID (TAF9 and TBP) and/or TFIIB (Chi 
et al., 1995; Choy and Green, 1993; Ingles et al., 1991; Lin and Green, 1991; Stringer et 
al., 1990). The TAD of VP16 has been shown to interact with other basal transcription 
factors including TFIIA, TFIIF and TFIIH (Triezenberg, 1995; Zhu et al., 1994). VP16 
activation domain binds also the positive cofactor PC4 (Ge and Roeder, 1994; 
Kretzschmar et al., 1994). In yeast, two mechanisms of chromatin modification have 
been attributed to VP16 TAD. In the first one, it relieves nucleosome–mediated 
repression by recruitment of the histone acetyltransferase (HAT) complexes SAGA and 
NuA4 (Ikeda et al., 1999; Utley et al., 1998). In the second one, it targets the Swi/Snf 
complex facilitating chromatin remodelling (Memedula and Belmont, 2003; Neely et al., 
1999). Evidences for interaction with p300 have also been reported (Herrera and 
Triezenberg, 2004; Ikeda et al., 2002; Kraus et al., 1999). Importantly, among the other 
411 F442
H2H1
490456 F473/475/479
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target of the transcriptional machinery, VP16 TAD has been found to specifically interact 
with the Mediator complex through two subunits, MED17 (Ito et al., 1999) and MED25, 
(Mittler et al., 2003). In particular, the critical role of MED25 in VP16 activated 
transcription has been demonstrated by the dominant negative effect exerted by its 
functional domain ACID (Mittler et al., 2003). 
 
1.2.6.2 The Epstein–Barr virus nuclear antigen 2 (EBNA2) 
 
The DNA tumour virus Epstein–Barr virus (EBV) was the first virus to be isolated from a 
tumour biopsy sample and to be implicated in the development of human cancer. EBV is 
able to infect and immortalize resting B cell transforming them in a lymphoblastoid cell 
line (LCL). Among the about 80 genes encoded by this virus, only nine are translated 
and are acting in concert to induce and maintain B cell proliferation. These nine genes 
include six EBV nuclear antigens (EBNA1, –2, –3A, –3B, –3C, –LP) and three latent 
membrane proteins (LMP1, –2A, –2B) localized in the plasma membrane of the infected 
B cells. (Zimber-Strobl and Strobl, 2001). In immortalized B cells all the viral genes are 
expressed under the control of the viral transcription factor EBNA2. EBNA2 has been 
identified in two variants, EBNA2A and EBNA2B which share about 50% sequence 
homology.  
 
Figure 4. Structural organization of EBNA2 in functional domains. The protein contains a negatively 
charged region which likely plays a role in homodimerization (Dim), a prolyne strech (Pro), a diversity 
region (Diversity), a RBP–J interaction domain (RBP–J), an arginine–glycine rich stretch (ArgGly), a 
transactivation domain (TAD) and a nuclear localization signal (NLS). (After Zimber–Strobl and Strobl, 
2001) 
 
EBNA2 is structured in characteristic domains: a negatively charged region at the 
amino–terminus which likely plays a role in dimerization (Dim); a polyproline stretch 
(Pro); a diversity region where the homology between the two variants is very low; a 
RBP–J binding domain (RBP–J); a 18 amino acid arginine– glycine rich stretch (ArgGly); 
a negatively charged transactivating domain (TAD); a nuclear localization signal at the 
Pro Diversity RBP-J ArgGly TAD NLSDim
1 200 400300100 487aa
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carboxyterminus (NLS) (figure 4) (Bornkamm and Hammerschmidt, 2001; Zimber-Strobl 
and Strobl, 2001).  
EBNA2 lacks the capability to directly bind DNA. To transactivate cellular and viral 
genes, EBNA2 needs to bind RPB–J, a protein also known as CBF–1 (Cp–binding factor 
1) (Grossman et al., 1994; Henkel et al., 1994; Waltzer et al., 1994; Zimber-Strobl et al., 
1994). RPB–J is a DNA binding protein ubiquitously expressed and highly conserved in 
evolution. It is also the downstream target of the cell–surface receptor Notch (Artavanis-
Tsakonas et al., 1999). In the absence of EBNA2 and the intracellular part of Notch, 
(Notch–IC), RBP–J acts as a transcriptional repressor by recruiting a histone 
deacetylase (HDAC) coreceptor complex to the promoter (Hsieh et al., 1999; Kao et al., 
1998). In addition, RBP–J has been shown to interact with two factors of the basal 
transcription machinery, TFIIA and TFIID, leading to the destabilization of the TFIIA–
TFIID interaction which is required for initiation of transcription (Olave et al., 1998). Both, 
EBNA2 and Notch–IC bind to the trascriptional repression domain of RBP–J thereby 
relieving repression by replacing the HDAC corepressor complex by their transactivation 
domain (Hsieh and Hayward, 1995; Hsieh et al., 1999; Kao et al., 1998). The interaction 
of RBP–J with EBNA2 is necessary but not sufficient to induce gene expression. Other 
factors involved in promoter activation have not yet been identified. Only in the LMP1 
promoter, the binding of the factor PU.1 (and Spi–B) which is supposed to interact with 
EBNA2, is absolutely necessary for EBNA2 mediated transactivation (Johannsen et al., 
1995; Laux et al., 1994; Sjoblom et al., 1995). Interestingly, functional and structural 
homologies have been reported in between the viral proteins EBNA2 and VP16. In fact, 
the chimeric virus where the acidic activation domain of EBNA2 is replaced by the acidic 
activation domain of VP16 can still efficiently transform B cells and transactivate 
expression of EBV and B–cell genes (Cohen, 1992; Cohen and Kieff, 1991). Like VP16 
and many other transcriptional activator proteins, EBNA2 is able to interact with 
components of the basal transcription machinery, including TFIIB, TAF40, TFIIH as well 
as with coactivator complexes like hSNF5, p300, CBP and PCAF (Tong et al., 1995a; 
Tong et al., 1995b; Wang et al., 2000; Wu et al., 1996). In a new study it has been 
reported that EBNA2 stimulates RNA polymerase II recruitment and CDK9–mediated 
phosphorylation of Ser5 of the CTD (Bark-Jones et al., 2006). The antiapoptotic effect 
provoked by EBNA2–induced LMP1 in B cells is mediated by the induction of the 
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antiapoptotic proteins Bcl–2, Mcl–1 and A20 (Gregory et al., 1991; Henderson et al., 
1991; Laherty et al., 1992). Moreover, recent results obtained using a genome wide 
array approach provided new insights about EBNA2 target genes (Zhao et al., 2006).  
 
1.3 PTOV1 
 
PTOV1 (Prostate Tumour Overexpressed Protein 1) was identified as a novel gene and 
protein during a differential display screening for gene expression in prostate cancer 
(Benedit et al., 2001). PTOV1 is overexpressed in 71% of prostate carcinoma and barely 
detectable in normal prostate epithelium (Santamaria et al., 2003). PTOV1 gene is 
located in the 19q13.3 chromosome and encodes for a protein that consists of two 
highly related sequence blocks arranged in tandem that are conserved from Drosophila 
to humans. Each of the two domains of PTOV1 shows a very high homology sequence 
to the ACID domain of the Mediator subunit MED25 (figure 5 and supplementary figure 
1), the gene of which is also located in the 19q13.3 chromosome. 
 
 
Figure 5. Schematic view of the functional domains of MED25 and PTOV1. PTOV1 contains two domains 
which show a very high homology with each other and with the ACID domain of the Mediaotr subunit 
MED25. 
 
However, while the ACID domain of MED25 interacts physically with the activation 
domain of the viral activator VP16 (Mittler et al., 2003), it has been demonstrated that 
this is not the case for the tandem repeat of PTOV1 (Yang F. 2003). In a recent study, a 
yeast two–hybrid screen analysis has yielded to the identification of a PTOV1 specific 
partner, the lipid–raft associated protein flotillin–1 (Santamaria et al., 2005). In the same 
study, PTOV1 and flotillin–1 are shown to be strong inducers of cell proliferation and 
both required for normal cell proliferation. Moreover they have been shown to act in a 
mutual interdependence in order to achieve their mitogenic effect, which is strictly 
related to their nuclear localization. PTOV1 physically interacts with flotillin–1 and 
MED25 ACIDVWA
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depletion of PTOV1 by RNA interference prevents the nuclear localization of flotillin–1 
(Santamaria et al., 2005). While PTOV1 contains two putative consensus bipartite 
nuclear localization signals (Benedit et al., 2001), flotillin–1 lacks any putative NLS. 
Therefore it is possible that PTOV1 provides the signal for nuclear import of flotillin–1 
(Santamaria et al., 2005). To date there are no evidences that link PTOV1 function to 
MED25. It is however tempting to speculate that the double repeat of ACID domains in 
the PTOV1 protein could serve as an interaction site to titrate out the recruitment of 
proteins that act through the binding with MED25, thereby modulating their function. 
 
1.4 The Charcot–Marie–Tooth (CMT) disease  
 
Charcot–Marie–Tooth (CMT) disease or hereditary motor and sensory neuropathy 
(HMSN) represents a group of frequent genetically and clinically heterogeneous 
peripheral neuropathies (Mostacciuolo et al., 1991; Shy et al., 2005; Skre, 1974). CMT 
has historically been divided into predominantly demyelinating and predominantly axonal 
forms, CMT1 and CMT2, respectively (Vance, 2000). Mutation in the gene encoding for 
the transcription factor Krox 20 (EGR2), which is absolutely necessary for the transition 
from promyelinating to myelinating stage of Schwann cell development, has been shown 
to cause CMT1. Two other forms of CMT1 disease, CMT1A and CMT1B have been 
related to point mutations in the genes encoding the myelin proteins PMP22 and P0, 
respectively (Kamholz et al., 1999). Autosomal recessive demyelinating and autosomal 
recessive axonal forms of CMT have been described. For the latter form, ARCMT2, 
mutations on the LMNA and GDAP1 (ganglioside–induced differentiation–associated 
protein 1) genes have been identified (Cuesta et al., 2002; De Sandre-Giovannoli et al., 
2002).  
Recently, a new autosomal recessive CMT variant has been identified in an extended 
Costa Rican family (CR–P) with Spanish and Amerindian ancestors (Berghoff et al., 
2004; Leal et al., 2001). The neuropathy maps to the 19q13.3 chromosome and has 
been related to a mutation in the Mediator subunit MED25. The MED25 mutation 
A335V, which is located within a predicted SH3–recognition motif, seems to be the 
major responsible for the CMT2B2 form of CMT disease (Leal. et al., submitted). 
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1.5 Engineering of the mouse 
 
One powerful method to understand the role of human genes is to investigate the 
function of homologous genes in model organisms. In addition to the fact that almost 
every human gene has a counterpart in the mouse genome, the mouse is unique in its 
applicability to human horganogenesis, immunology, neurobiology, reproduction, 
behaviour and epigenetics. The use of the mouse model to explore gene function 
depends on the methodologies available to manipulate the genome.  
 
1.5.1 The advent of ES cells 
 
A major technical breakthrough in manipulating the mouse genome was the advent of 
embryonic stem (ES) cells. These cells were first isolated from the inner cell mass of 
mouse blastocysts to generate permanent cell lines in 1981 (Evans and Kaufman, 1981; 
Martin, 1981). The contribution of ES cells to both, somatic and germ line tissues, was 
shown after their reintroduction into a blastocyst (Bradley et al., 1984). A significant step 
was represented by the development of gene–targeting, a strategy based on the 
introduction of DNA sequences into a chromosome by homologous recombination 
(Capecchi, 1989; Smithies et al., 1985). The genetic background of ES cells mostly used 
is the inbred strain 129/Sv (Hooper et al., 1987), however ES cells derived from other 
strains were also generated (i.e. C57BL/6 and Balb/c). ES cells derived from different 
strains show a different capability to undergo homologous recombination and germ line 
transmission. In order to maintain ES cells lines in a uncommitted state they have to be 
cultured in the presence of differentiation inhibiting factors. These factors are provided 
by mitotically inactivated feeder cells, which serve as a matrix for ES cells and by the 
addition of Leukaemia Inhibitory Factor (LIF) to the culture medium (Hilton, 1992). A 
routinely used method for generation of chimeric mice is the injection of ES cells derived 
from 129/Sv mouse strain (white colour coated) and carrying the desired alteration into 
the blastocoel of blastocysts isolated from female C57BL/6 donors (black colour coated) 
(Bradley et al., 1984). To test male ES cell chimeras for germ line contribution they are 
bred to wild– type C57BL/6 females. If the targeted ES cells contributed to the germ line, 
the offspring will exhibit an agouti coat colour. Other strain combinations of ES cells 
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versus blastocysts are possible. It is, however, important to choose the right 
combination in order to allow immediate and efficient recognition of ES derived mice 
from the coat colour.  
 
1.5.2 Traditional gene–targeting 
 
To generate a knock–out (KO) mouse, the traditional gene–targeting strategy is to 
replace the target gene, or at least an essential part of it (up to about 20 kilobases (Zou 
et al., 1994)) with a positive selection marker, usually the neomycin phosphotransferase 
gene (neo), permitting isolation of recombinant ES cells in culture. A standard 
replacement vector contains the positive selection marker flanked by genomic DNA 
homologous to the target. A negative selection gene, usually the herpes simplex virus 
thymidine kinase (HSV–tk) or the diphteria toxin A subunit (DTA) gene, is placed on one 
end of the vector. The negative selection marker enriches for the desired homologous 
recombination event over random integrations by killing cells that have retained the 
negative selection gene. The traditional method of gene–targeting presents two potential 
pitfalls. The first one is that many genes serve an essential function, and therefore the 
elimination of their activity throughout the entire animal can result either in early 
embryonic lethality, precluding the analysis of gene function at later stages, or, 
alternatively, a masking of the full mutant phenotype due to genetic compensatory 
mechanisms. The second pitfall is the maintenance of the positive selection cassette 
within the targeting gene. Its presence can cause a number of problems, such as the 
disruption of neighbouring gene expression due to strong transcriptional regulatory 
elements frequently present in selection cassette (Lerner et al., 1993; Ohno et al., 
1994).  
 
1.5.3 Site–specific recombinase (SSR) technology 
 
The problems related to the traditional gene–targeting method have been overcome by 
the advent of the site–specific recombinase (SSR) technology. The revolutionary 
approach is based on the use of the so–called λ integrases Cre (causes recombination 
of the bacteriophage P1) and Flp (named for its ability to invert of "flip" a DNA segment 
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in S. cervisiae). Both Cre and Flp are able to recombine with high fidelity specific 
sequences of DNA, called loxP and FRT respectively. (Dymecki, 1996; Stark et al., 
1992). Cre and Flp share a common mechanism of DNA recombination that involves 
strand cleavage, exchange, and legation (Sadowski, 1995). Although distinct at the 
nucleotide level, loxP and FRT sites share an overall structure which includes two 13 
base pair palindromic sequences, or inverted repeats, separated by an 8 base pair 
asymmetric core, or spacer, sequence (Branda and Dymecki, 2004). With the use of 
site–specific recombinases a new concept of mouse engineering was introduced. The 
main feature of conditional knock–out mice is that the deletion of a special gene of 
interest can be controlled in a spatial or temporal manner. To achieve this type of 
control, a target gene is engineered which contains loxP or FRT sequences flanking the 
gene segment of interest. A strain bearing a conditional allele of a single gene can be 
crossed to several lines with differing recombinase expression patterns allowing to study 
the role of a gene in different tissues, while the target gene will remain intact in other 
cells of the mouse where the recombinase is not expressed (figure 6).  
 
 
Figure 6. Scheme for recombinase–based gene modifications. A mouse expressing the recombinase in 
selected tissues or lineages (effector mouse) is crossed to a mouse carrying a gene segment flanked by 
recognition target sites (target mouse) to generate a mouse where the target gene is deleted in the cells 
expressing the recombinase. 
 
Therefore, conditional gene modification provides the potential for careful analysis of 
gene inactivation in specific cell lineages. In many cases, however, gene inactivation is 
not complete due to a failure of the recombinase to modify the target gene in all cells 
expressing the recombinase. Such a phenomenon, called mosaicism, precludes an 
analysis of a null phenotype in the target lineage, due to the existence of wild–type cells 
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that may mask a potential defect. To easily detect in which cells recombination has 
taken place it is possible to include a reporter construct (such as one that encodes 
LacZ) downstream of the floxed region, so that recombination both inactivates the target 
gene and activates the reporter (Moon and Capecchi, 2000). The positive selection 
marker is also flanked by either of loxP or FRT sequences. Two main strategies are 
applied while creating a conditional allele where the positive selection marker can be 
removed (figure 7). In the dual–recombinase strategy the targeting vector carries two 
different site–specific recombinase systems, one flanking the gene segment of interest 
and the other one flanking the positive selection marker. This strategy offers the 
advantage to remove the positive selection cassette without influencing the removal of 
the gene segment of interest. Alternatively, in the tri–lox approach both, the selection 
cassette and the gene segment, are flanked by loxP sites (Gu et al., 1993). With this 
alternative approach, however it is difficult to obtain a partially deleted allele in which the 
gene segment remains floxed but the positive selection cassette has been removed 
(Kaartinen and Nagy, 2001). Recently, the problem has partially been solved with the 
identification of a new Cre recombinase, MeuCre40 (Leneuve et al., 2003). 
 
 
Figure 7. Strategies for removing the selection cassette from a conditional allele by the use of SSR. The 
dual–recombinase strategy offers the advantage that the cassette can be excised leaving the exon in 
place (see text).  
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The removal of the selection cassette can be achieved either in vivo or in vitro. A benefit 
of removing the positive selection marker in ES cells is that the second allele can be 
subsequently modified with the same targeting vector to create homozygous for the 
desired alteration. On the other hand, retaining the selection cassette leaves the 
opportunity to create a so called "hypomorphic allele" characterized by the presence of 
the neor cassette which can partially disrupt gene expression. In this case, if the dual–
recombinase strategy was applied to create the targeting vector, three mouse lines can 
be generated: the original lines expressing the hypomorphic allele (if the neo interferes 
with gene expression); one line expressing only the floxed allele, generated by mating 
the original line to a FLP–expressing mouse; one line carrying a null allele, generated by 
breeding the original line to a cre–expressing mouse (Lewandoski, 2001). 
Recently, a number of groups have launched large–scale, random mutagenesis screens 
using either gene–trap vectors in ES cells (Hansen et al., 2003; Stryke et al., 2003) or 
the chemical agent N–ethyl–N–nitrosourea (ENU) in vivo (Coghill et al., 2002; Herron et 
al., 2002; Hrabe de Angelis et al., 2000; Nolan et al., 2000). The two strategies differ in 
the types of mutations produced. A standard gene–trap vector contains a promotorless 
reporter gene flanked by an upstream splice acceptor and a downstream 
polyadenylation (polyA) signal sequence (Gossler et al., 1989). When inserted into an 
intron, transcriptional activation of the "trapped" gene will result in a fusion transcript 
composed of upstream coding sequences and the reporter (usually a β–gal–Neo fusion 
cassette). This gene– trap design generally produces a null allele while simultaneously 
revealing the expression of the endogenous gene. Variations in the design of gene–trap 
have increased the efficiency and selectivity of gene trapping in ES cells (Stanford et al., 
2001). Currently, BayGenomics (http://bygenomics.ucsf.edu) and the German Gene 
Trap Consortium (http://genetrap.de) are the largest libraries of gene–trap ES cells lines 
available to the public. Combined, these resources contain insertions in about 14% of 
genes currently annotated in Ensembl (Branda and Dymecki, 2004). 
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1.6 Objectives 
 
The aim of this work was to dissect functional and structural aspects of the MED25 
Mediator subunit. MED25 was purified in association to the Mediator complex and to the 
viral activator VP16. Since MED25 has been identified in Meisterernst and Naar 
laboratories rather recently, many questions about its function are still open. To address 
those questions three main lines of investigation were chosen in this work. First of all, a 
structure–function analysis of the protein was carried out based on the existence of the 
two functional domains VWA and ACID. With the generation of MED25 deletion 
constructs and MED25 point mutants we aimed to the identification of MED25 critical 
domains and possibly MED25 critical amino acids involved in Mediator and VP16 
interactions.  
In order to clarify whether MED25 has a specific function in relation to other Mediator 
subunits, a second approach was chosen to identify MED25 cellular targets. To follow 
this line of investigation inducible cell lines expressing MED25 derivatives were 
generated and used for microarray analysis.  
Finally, to explore MED25 in vivo function, the generation of a MED25 conditional 
knock–out mouse has been chosen as a third approach for the characterization of 
MED25.  
 
MATERIALS AND METHODS  36 
2 MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Chemicals and biochemicals 
 
Acetic Acid       Roth 
Acrylamide solution 30% (Rotiphorese Gel A)   Roth 
Agarose        Gibco 
Ammonium persulfate (APS)     Merck, Roth 
Ammonium sulphate     Merck 
Ampicillin (Ap)       Roth 
Aprotinin        Sigma 
Bacto Agar        Difco 
Bacto Trypton       Difco 
Bacto Yeast Extract      Difco 
Benzamidin        Sigma 
BES (N,N–bis[2–hydroxyethyl]–2–aminoethanesulfonic Sigma 
acid) 
Bisacrylamide solution 2%     Roth 
Boric Acid        Roth 
Bradford reagent      BioRad 
Bromophenol Blue       Sigma 
BSA (10 mg/ml) (bovine serum albumin)   NEB 
Coomassie brilliant blue R–250     Sigma 
Dimethylsulfoxide       Sigma 
Dithiothreitol (DTT)       Roth 
DMEM medium       Gibco 
dNTPs        MBI, Roche 
Ethanol (EtOH)       Merk 
Ethidium bromide       Sigma 
Ethylendiamintetraacetate disodium salt (EDTA) Merck 
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EGTA        Merck 
Fetal calf serum (FCS)      Gibco 
Gancyclovir        Sigma 
Gelatine        LGC Promochem 
Geneticin G– 418 sulphate     Gibco 
Glucose       Merck 
Glycerol        Roth 
Glycine        Roth 
Hepes        Biomol 
Histogel mounting medium     Linaris 
4– hydroxytamoxifen (OHT)    Sigma 
Hygromicyn       PAA 
Isopropanol        Merck 
Leupeptin        Roche 
LIF, ESGRO        Chemicon International 
Light oil        Sigma 
Magnesiumchloride      Merck 
β–Mercaptoethanol       Sigma 
Methanol        Merck, Roth 
Milk powder        Heirler Cenovis, Roth 
NP40 (IGEPAL CA630)     Sigma 
ONPG       Sigma 
Penicillin–Streptomycin      Invitrogen 
Phenol Clorophorm Isoamil 25/24/1    Roth  
Phenylmethylsulfonfuoride (PMSF)    Biomol, Roth 
Ponceau S        Sigma 
Protein G–Sepharose      Amersham 
Potassium clorid      Sigma 
Potassium hidroxyd      Roth 
RPMI 1640–Medium      Gibco 
Sodium azide       Sigma 
Sodium carbonate       Merck 
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Sodium chloride       Merck, Roth 
Sodium Citrate      Merck 
Sodiumdodecylsulphate (SDS)     Merck, Roth 
Sodium hydroxid       Merck 
Tetramethylethylendiamin (TEMED)    Sigma, Roth 
Top agar       Sigma 
Trishydroxidmethyl–aminomethan (Tris)    Sigma 
Triton X–100       Sigma 
Trypsin–EDTA solution      Gibco 
Xylene cyanole       Fluka 
 
2.1.2 Additional material 
 
Disposable plastic material     Greiner, Nunc, Falcon 
DNA maxi and midi preps kit    Qiagen, NucleoBond 
ECL detection system      Perkin Elmer 
Film X–OMAT, BioMax      Kodak 
GFX Gel Band Purification Kit     Amersham 
Luciferase Assay System Kit    Promega 
Megaprime DNA labelling system Kit   Amersham 
Membrane Hybond–N+     Amersham 
MicroSpin colums G25     Amersham 
Miniprep Kit       Amersham 
Nitrocellulose membrane      BioRad 
Nucleobond AX Plasmid DNA Kit     Macherey & Nagel 
Qiagen RNeasy Kit      Qiagen 
Siliconized Plastic tubes      Sorenson 
SYBR Green PCR Kit     Applied Biosystem 
Steril flter (0.22/0.45 µm)      Roth 
ThermoScript™RT–PCR system Kit   Invitrogen  
TNT Coupled Retyculocite Lysate System Kit  Promega 
Whatman 3MM Paper      Whatman 
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2.1.3 Instruments 
 
Acrylamide gel electrophoresis   Amersham/Hoefer/BioRad 
Agarose gel electrophoresis   BioRad 
Autoradiography cassette    Amersham/Kodak 
Centrifuges      Avanti, Beckman 
Multifuge 3 L–R, Heraeus 
Zentrifuge 5417, 5415R, Eppendorf 
Confocal light microscope    TCS SP2, Leica 
Developing machine    Curix60, Agfa 
Electroblot, semi–dry   BioRad 
Electroporator    Gene Pulser II, BioRad 
Gaiger counter    LB122, Berthold 
Gel drier     GD2000, Hoefer 
Heating block    Eppendorf 
Homogenizer     Douncer, Wheaton 
Incubator      WJ311, Forma Scientific 
Unequip, Unitherm 
B6200, Heraeus 
Instant Imager     Packard 
Light microscope     Axiovert 25, Zeiss 
PCR–Thermocycler    GeneAmp 5700, Applied Biosystem 
pH–Meter      Calimatic 760, Knick 
Photometer      GeneQuant Pro, Amersham 
Rotors      JA10, JA25–50, SW41, SW28, Beckman 
UV–Illuminator     Bachofer (254 nm, 366 nm) 
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2.1.4 General buffers 
 
2x BBS: 
For 100ml use 1.07g BES (N,N–bis[2–hydroxyethyl]–2–aminoethanesulfonic acid), 1.6g 
NaCl, 0.027g Na2HPO4. Adjust to pH 6.96 with NaOH before adding H2O to 100ml. 
Sterilize with 0.22µm filter and store aliquots at –20oC.  
 
BCx buffer: 
20mM Tris–HCl pH 7.3, 0.2mM EDTA, 20% Glycerol, xmM KCl. Before use add freshly 
0.2mM PMSF, 0.2mM DTT, 2µg/µl Aprotinine, 0.1% NP40, 0.1mM Benzamidine. 
 
β–GAL substrate solution: 
1.1mM MgCl2, 1mg/ml ONPG, 82mM Na2HPO4, 18mM NaH2PO4, 50mM β–
Mercaptoethanol.  
 
BL21 lysis buffer: 
20 mM Hepes pH 7.5, 100 mM KCl, 1 mM EDTA, 10% Glycerol, 0.1% NP–40, 5mM β–
Mercaptoethanol. Add protease inhibitors before use. 
 
CaCl2 0.25M: 
For 20ml use 1.1g CaCl2•6H2O. Sterilize with 0.22µm filter and store aliquots at –20oC. 
 
Coomassie Staining solution: 
For 1L use 500ml H2O, 400 ml MeOH, 100ml Glacial acetic acid, 0.25g Coomassie R–
250. For distaining prepare the same solution without Coomassie R–250. 
 
6x DNA loading buffer: 
30% glycerol, 0.25% Bromphenol Blue, 0.25% Xylene Cyanole in TAE buffer. 
 
Dot blot hybridisation solution: 
6X SSC, 0.5%SDS, 5x Denhardt's solution, 100µg/ml tRNA. 
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0.5M EDTA (pH 8.0): 
For 1L use 186.1g EDTA 2 H2O. Adjust to pH 8.0 with about 20g NaOH before adding 
H2O to 1L.  
 
ES cells lysis buffer: 
10mM NaCl, 10mM Tris–Cl pH 7.5, 10mM EDTA, 0.5% Sarcosyl, 0.4mg/ml proteinase K 
freshly added. 
 
GST fusion protein elution buffer: 
25mM Tris–HCl pH 8.2 RT, 100mM KCl, 10% Glycerol, 0.1% NP–40, 30mM reduced 
Glutathione. Add protease inhibitors before use. 
 
HEGN 100:  
25mM Hepes–KOH pH 7.6, 0.2mM EDTA pH 8.0, 100mM KCl, 10% glycerol, 0.1% 
NP40. 
 
LB medium: 
For 1L use 10g Trypton, 5g Yeast extract, 5g NaCl. To prepare LB–agar plates add 15g 
Top agar to 1L LB. Autoclave. 
 
6x SDS loading buffer: 
0.35M Tris–HCl pH 6.8, 0.12mg/ml Bromphenolblue, 10% (w/v) SDS, 30% (v/v) glycerol, 
50mM DTT. 
 
NEX A: 
10mM HEPES pH 7.9, 10mM KCl, 0.1mM EDTA pH 8.0, 0.1mM EGTA pH 8.0. 
Immediately before use add 1.0mM DTT, 0.5mM PMSF, 2µg/µl Aprotinin, 2µg/µl 
Leupeptin. 
 
 
 
MATERIALS AND METHODS  42 
NEX B: 
20mM HEPES pH 7.9, 0.4M NaCl, 1mM EDTA pH 8.0, 1mM EGTA pH 8.0, 10% 
Glycerin. Immediately before use add 1mM DTT, 1mM PMSF, 2µg/µl Aprotinin, 2µg/µl 
Leupeptin. 
 
PBS 20x: 
For 1L solution use 160g NaCl, 4g KCl, 28.8g Na2HPO4, 4.8g KH2PO4 in H2O. 
 
Southern blot transfer buffer: 
0.4M NaOH, 0.6M NaCl. 
 
20x SSC: 
For 2L use 350g NaCl, 176g Sodium Citrate. Adjust to pH 7.0 with NaOH. 
 
50x TAE: 
For 1L use 242g Tris, 57.1ml glacial acetic acid, 100ml 0.5M EDTA pH 8.0. 
 
Tail lysis buffer: 
100mM Tris pH 8.5, 5mM EDTA, 0.2% SDS, 200mM NaCl, 100µg/ml proteinase K 
freshly added. 
 
10x TBE: 
For 5L use 275g Boric Acid, 46.5g EDTA and 540g TRIS. 
 
10x TBS: 
For 1L use 24.2g Tris, 80g NaCl, 2g KCl. Adjust pH to 7.6 with HCl concentrate before 
adding H2O to 1L. 
 
TBS–BG: 
For 1L use 20ml 1M Tris–HCl pH 7.6, 28ml NaCl 5M, 1ml KCl 3M, 1.5ml MgCl2 1M, 5g 
glycine, 5g BSA, 0.5ml TWEEN20, 0.5g Na–Azid. 
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1x TBS–T: 
For 1L use 100ml 10x TBS, 2ml 10% TWEEN20  
 
1x TE: 
10mM Tris–HCl pH7.5 and 1mM EDTA pH 8.0. 
 
10x TGS: 
For 1L use 30.2g Tris, 148g glycine, 10g SDS. 
 
5x Western blot transfer buffer: 
For 1L use 72g glycine, 15g Tris. 
 
1x Western blot transfer buffer: 
For 1L use 200ml 5x buffer, 200ml MeOH, 600ml H2O. 
 
2.1.5 Enzymes 
 
Calf intestine alkaline phosphatase     Fermentas 
DNase        Invitrogen, Qiagen 
Klenow Fragment        Fermentas 
Lysozim        Sigma 
Pfu Polymerase        Fermentas 
Pfu Turbo        Stratagene 
Polynucleotide Kinase (PNK)     MBI 
Proteinase K        Roche 
Restriction enzymes       NEB or Fermentas 
RNase A         Roche 
T4 DNA ligase        Fermentas 
Taq polymerase        Fermentas 
Vent polymerase       NEB 
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2.1.6 Antibodies 
 
Table 3. Primary antibodies used in this work 
 
PRIMARY ANTIBODY ORIGIN PROVIDER DILUTION WB DILUTION IF 
MED7 (3E12–4) rat E. Kremmer 1:5  
MED15 (6C9) rat E. Kremmer 1:5  
MED25 (9C2) rat E. Kremmer 1:5  
Flag M2 (F 3165) mouse Sigma 1:2000  
ER (sc–543) rabbit Santa Cruz 1:500 1:50 
ER (sc–8002) mouse Santa Cruz 1:500  
GAL 4 (sc–577) rabbit Santa Cruz 1:1000  
Myc (9E10) mouse E. Kremmer 1:20  
 
 
Table 4. Secondary antibodies used in this work 
 
SECONDARY ANTIBODY PROVIDER DILUTION WB DILUTION IF 
Anti Rabbit Promega 1:5000  
Anti Mouse  Promega 1:5000  
Anti Rat Jackson ImmunoResearch 1:3000  
Anti Rabbit FITC Promega  1:25 
 
 
2.1.7 List of plasmids 
 
Table 5. Plasmid used in this work. 
 
PLASMID ID PARENTAL PLASMID DESCRIPTION CLONED BY 
pLS1 pBAC MED25 genomic DNA fom 129/Ola mouse strain BAC library 
pLS2 pBAC MED25 genomic DNA fom 129/Ola mouse strain BAC library 
pLS3 pBAC MED25 genomic DNA fom 129/Ola mouse strain BAC library 
pLS4 pBAC MED25 genomic DNA fom 129/Ola mouse strain BAC library 
pLS5 pBAC MED25 genomic DNA fom 129/Ola mouse strain BAC library 
pLS6 pBAC MED25 genomic DNA fom 129/Ola mouse strain BAC library 
pLS7 pBAC MED25 genomic DNA fom 129/Ola mouse strain BAC library 
pLS8 pBAC MED25 genomic DNA fom 129/Ola mouse strain BAC library 
pLS9 pNeohAP contains a FRT/NEO/FRT/LoxP cassette Capecchi 
pLS10 pK°Neo6TK contains a Timidine Kinase cassette Gertraud Stelzer 
pLS11 pK°Neo6TK/pNeohAP pK°Neo6TK (–Neo) + FRT/Neo/FRT/LoxP (pNeohAP) LS 
pLS12 pK°Neo6TK/pNeohAP pLS11 (–AscI/SpeI fragment) LS 
pLS13 pCI (pLB27A) mouse MED25 genomic DNA (exon 3–exon 10) LS 
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pLS14 pK°Neo6TK/pNeohAP pLS12 (+ SmaI fragment HRR3') LS 
pLS17 pK°Neo6TK/pNeohAP pLS14 (+ BglII/BamHI fragment Intron 10) LS 
pLS18 pK°Neo6TK/pNeohAP pLS17 (+ BglII fragment from pLS13) LS 
pLS20 pK°Neo6TK/pNeohAP pLS18 (+ EcorV/LoxP sequence in SpeI) LS 
pLS23 pWWWP–luc p21(–2325/+8)_Luc Kardassis 
pLS24 pGL2basic p21(–215/+8)_Luc Kardassis 
pLS25 pGL2basic p21(–143/+8)_Luc Kardassis 
pLS26 pGL2basic p21(–2325/+8delta–122/–60)_Luc Kardassis 
pLS29 pEP7/EBV vector ER–MED25 LS 
pLS35 pCI_Neo_vector GAL/Myc–MED25(290–754) LS 
pLS36 pCI_Neo_vector GAL/Myc–MED25(290–730) LS 
pLS37 pCI_Neo_vector GAL/Myc–MED25(290–685) LS 
pLS38 pCI_Neo_vector GAL/Myc–MED25(1–685) LS 
pLS39 pCI_Neo_vector Flag–MED25(290–754) LS 
pLS40 pCI_Neo_vector Flag–MED25(290–730) LS 
pLS41 pCI_Neo_vector Flag–MED25(290–685) LS 
pLS42 pCI_Neo_vector Fag–MED25(1–730) LS 
pLS43 pCI_Neo_vector Flag–MED25(1–685) LS 
pLS45 pEP7/EBV vector ER–MED25–NTD LS 
pLS47 pCI_Neo_vector GAL/Myc–MED25(1–393)A335V mut LS 
pLS48 pCI_Neo_vector Flag–NLS–MED25(1–754)A335V mut LS 
pLS49 pCI_Neo_vector Flag–NLS–MED25(1–393)A335V mut LS 
pLS50 pCI_Neo_vector Flag–MED25(1–754)A335V mut w/o NLS LS 
pLS51 pCI_Neo_vector Flag–MED25(1–393)A335V mut w/o NLS LS 
pLS52 pCI_Neo_vector GAL/Myc–MED25(1–754)A335V mut LS 
pLS53 pEP7/EBV vector ER LS 
pLS56 pCI_Neo_vector GAL/Myc–p78 LS 
pLS57 pCI_Neo_vector GAL/Myc–MED25–mut5_FHF473AAA LS 
pLS58 pCI_Neo_vector GAL/Myc–MED25–mut14_WPQK444APQA LS 
pLS59 pCI_Neo_vector GAL/Myc–MED25–mut15_W408A LS 
pLS60 pCI_Neo_vector GAL/Myc–MED25–mut18_KKIF518AAIA LS 
pLS61 pCI_Neo_vector GAL/Myc–MED25–mut9_LRSLL646ARSAA LS 
pLS62 pCI_Neo_vector GAL/Myc–MED25–mut7_HMVL219AMAA LS 
pLS63 pCI_Neo_vector GAL/Myc–MED25–mut19_YR487AA LS 
pLS64 pCI_Neo_vector GAL/Myc–MED25–mut1_Y152A LS 
pLS65 pCI_Neo_vector GAL/Myc–MED25–mut2_Y161A LS 
pLS66 pCI_Neo_vector GAL/Myc–MED25–mut3_F47A LS 
pLS67 pCI_Neo_vector GAL/Myc–MED25–mut4_Y66A LS 
pLS68 pCI_Neo_vector GAL/Myc–MED25–mut10_FR465AA LS 
pLS69 pCI_Neo_vector GAL/Myc–MED25–mut11_Y39A LS 
pLS70 pCI_Neo_vector GAL/Myc–MED25–mut16_RK186AA LS 
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pLS71 pCI_Neo_vector GAL/Myc–MED25–mut6_F125A LS 
pLS72 pCI_Neo_vector GAL/Myc–MED25–mut8_KT443AA LS 
pLS73 pCI_Neo_vector GAL/Myc–MED25–mut13_T138A LS 
pLS74 pCI_Neo_vector GAL/Myc–MED25–mut17_VVFV17LVFL LS 
pLS75 pET21b hHis–MED25(394–543) K411/413A D418A mut Sonja Baumli 
pLS76 pET21b hHis–MED25(394–543) E437/442A K440A mut Sonja Baumli 
pLS77 pET21b hHis–MED25(394–543) K478A mut Sonja Baumli 
pLS78 pET21b hHis–MED25(394–543) K518/519/520A mut Sonja Baumli 
pLS79 pCI_Neo_vector GAL/Myc–MED25–mut20_Q137A LS 
pLS80 pCI_Neo_vector GAL/Myc–MED25–mut21_T138D LS 
pLS81 pCI_Neo_vector GAL/Myc–MED25–mut22_NS147/148AA LS 
pLS82 pCI_Neo_vector GAL/Myc–MED25–mut23_Y151F LS 
pLS83 pCI_Neo_vector GAL/Myc–MED25–mut24_E157R LS 
pLS84 pCI_Neo_vector GAL/Myc–MED25–mut25_Y161F LS 
pLS85 pCI_Neo_vector GAL/Myc–MED25–mut26_E167A LS 
pLS86 pCI_Neo_vector GAL/Myc–MED25–mut27_ER175/176AA LS 
GAL–MED25(1–754) pCI_Neo_vector Gal/Myc–MED25(1–754) TH 
pTH24 pCI_Neo_vector Gal/Myc–PTOV1_A TH 
pTH25 pCI_Neo_vector Gal/Myc–PTOV1_B TH 
SB93 pET24b dHis–MED25(514–656) Sonja Baumli 
SB94 pET24b dHis–MED25(514–663) Sonja Baumli 
SB105 pET21b hHis–MED25(394–543)  Sonja Baumli 
pLB52 pBACe 3.6 mouse genomic DNA Acc. N. AC069498 LB 
pLB58   human cDNA MED25 Acc. N. AL136746 LB 
pLB60 pCI_Neo_vector Flag–MED25(1–715) w/o NLS LB 
pLB67 pCI_Neo_vector Gal/Myc–MED25(1–183) LB 
pLB68 pCI_Neo_vector Gal/Myc–MED25(389–543) LB 
pLB77 pCI_Neo_vector Gal/Myc–MED25(1–290) LB 
pLB78 pCI_Neo_vector Gal/Myc–MED25(1–393) LB 
pLB79 pCI_Neo_vector Gal/Myc–MED25(1–543) LB 
pLB80 pCI_Neo_vector Gal/Myc–MED25(183–393) LB 
pLB85 pCI_Neo_vector Gal/Myc–MED25(1–226) LB 
pLB86 pCI_Neo_vector Gal/Myc–MED25(1–200) LB 
pLB90 pCI_Neo_vector Gal/Myc–MED25(393–754) LB 
pLB92 pCI_Neo_vector Flag–MED25(1–754) w/ NLS LB 
pLB105 pCI_Neo_vector Gal/Myc–MED25(1–715) LB 
pLB113 pCI_Neo_vector Gal/Myc–MED25(1–570) LB 
pLB114 pCI_Neo_vector Gal/Myc–MED25(1–613) LB 
pLB115 pCI_Neo_vector Gal/Myc–MED25(1–667) LB 
pLB116 pCI_Neo_vector Gal/Myc–MED25(543–715) LB 
pLB117 pCI_Neo_vector Gal/Myc–MED25(393–715) LB 
MATERIALS AND METHODS  47 
pTS1   Flag–MED25(144–715) TS 
pTS2   Flag–MED25(290–715)  TS 
pTS3   Flag–MED25(541–715)  TS 
pGEX–VP16H1  pGEX  GST–VP16–H1 TS 
pGEX–VP16H1mut  pGEX  GST–VP16H1mut TS 
 
 
2.1.8 List of oligonucleotides 
 
Table 6. Oligonucleotides used in this work 
 
OLIGO ID SEQUENCE 5´–> 3´ GENERAL USE 
PC6exon1up ATGGTCCCCGGATCCGAAGGCC screening mouse 
MED25 BACs library 
for targeting vector 
generation 
PC6exon1down ACTCTATGGCAGGCAGCAGGTA screening mouse 
MED25 BACs library 
for targeting vector 
generation. ProbeA 
for southern blot on 
the 5' side 
PC6exon9up TCTCACCCATCAACCCTCTCCA screening mouse 
MED25 BACs library 
for targeting vector 
generation 
PC6exon9down CCAGAGACGGCGCCCCAGGCTG screening mouse 
MED25 BACs library 
for targeting vector 
generation 
PC6PreExon1 ACTGCTTCGCTTCCAAGTCCCG screening mouse 
MED25 BACs library 
for targeting vector 
generation 
PC6Exon3up TATGGTGGAACCCAGTACAGCC screening mouse 
MED25 BACs library 
for targeting vector 
generation 
PC6postExon3 CTTCATCTCCTCGTTGACACGT screening mouse 
MED25 BACs library 
for targeting vector 
generation 
PC6Exon14down CCCGCGCTGTTGCTCCAGCTTC screening mouse 
MED25 BACs library 
for targeting vector 
generation 
PC6prepreExon1 AACGGAGCCAAGCGCTTCAGCG screening mouse 
MED25 BACs library 
for targeting vector 
generation. ProbeA 
for southern blot on 
the 5' side  
pLS12TKup GGCGTCTGTGGCTGCCAAACAC sequencing of 
pLS12 
PC6HRR3´down CCCGGGGCCCTCACCAAGTTGG Homology recomb 
region 3' for 
targeting vector 
PC6HRR3´up CCCGGGCTATACAGAGAAACTC Homology recomb 
region 3' for 
targeting vector 
MATERIALS AND METHODS  48 
PC6probe3´down CCCTCAGACTCTCAGGGGACTG probeB for ES 
southern blot on the 
3' side w/ oligo 
PC6probeBup 
pLS16loxPseqdown CGCCTGACACGCCACGCTGAAG sequencing of 
pLS16(loxP site 
orientation) 
PC6loxPdownEcoRV CTAGTGATATCATAACTTCGTATAGCATACATTATACGAAGTTATA loxP site of targeting 
vector 
PC6loxPupEcoRV CTAGTATAACTTCGTATAATGTATGCTATACGAAGTTATGATATCA loxP site of targeting 
vector 
PC6intron10down CGAGATCTGATGCCCACTTCTGGA reconstitution of the 
missing part of intron 
10 in the targeting 
vector 
PC6intron10up CGGGATCCCTGTCCTGGAACTCACTTTGTAGACC reconstitution of the 
missing part of intron 
10 in the targeting 
vector 
B–actinFw TGCGTTGTTACAGGAAGTCCC human RT–PCR 
B–actinRev CTATCACCTCCCCTGTGTGGA human RT–PCR 
p21–FW CATGTGTCCTGGTTCCCGTT human RT–PCR 
p21–Rev TCAGCATTGTGGGAGGAGC human RT–PCR 
PC6probeBup CCCAGGCAGAGTACTGTTGGTC probeB for ES 
southern blot on the 
3' side w/ oligo 
PC6probe3´down 
pLS19intron10seqdown GCACCCGACTGCTCTTCCGAAG sequencing of 
pLS19 (intron 10) 
PC6loxPEcoRVup TGGGGCCCTAAAATGGCCAGGA genotyping clone 5A 
of MED25 inducible 
KO by PCR w/oligo 
pLS16loxPseqdown 
PC6NeoFRTup CGTGCTTTACGGTATCGCCGCT genotyping clone 5A 
of MED25 inducible 
KO by PCR w/oligo 
PC6HRR3'down 
PC6intron8up CTGTGGGAGAAACCAGCGTGAG genotyping clone 5A 
of MED25 inducible 
KO by PCR w/oligo 
PC6loxPdownEcoRV 
PC6intron8down TGGGCCCACGCTGTGAGTTCTA genotyping clone 5A 
of MED25 inducible 
KO by PCR w/oligo 
Neo down 
Neo down GCGATAGAAGGCGATGCGCTGC genotyping clone 5A 
of MED25 inducible 
KO by PCR w/oligo 
PC6intron8down 
PC6NeoFRTloxPdown GTGAGGTTGTTCAGACTACAATCTG sequencing of PCR 
products from clone 
5A of MED25 
inducible KO  
ER–Acid1up CGCGGCTAGCTTAAAAAGGAACTTTATTGGGTGT cloning of pLS29 
ER–Acid1down ATAGTCGACGATGGTCCCCGGGTCCGAG cloning of 
pLS29,pLS45 
hVacid2190stop–XbaI CGTCTAGATCAGCAGGCCCGGCTGGGGGAA cloning of 
pLS36,pLS40,pLS42 
and pLS44 
hVacid2055stop–XbaI CGTCTAGATCACTGGCAGTCCAGCCCGAGGGG cloning of pLS37, 
pLS38,pLS41 and 
pS43 
ER–hAcid1NTDup–stop TACTGCTAGCTCACTCCACTGCATTCTGCGC cloning of pLS45 
hAcid1A335Vup CAGGTGGTGGCTTGGGGACGCCAGGGGGTCCTGG cloning of 
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pLS47,pLS48,pLS49 
hAcid1A335Vdown CCAGGACCCCCTGGCGTCCCCAAGCCACCACCTG cloning of 
pLS47,pLS48,pLS49 
JunRev GACCCTCTCCCCTTGCAAC mouse RT–PCR (c–
Jun) 
JunFW ATACTCTCTCCCCCGGCAAC mouse RT–PCR (c–
Jun) 
FosBrev AATGTTCCATGCAGCACGG mouse RT–PCR 
(FosB) 
FosBfw CTCCAGCTTTCACCTCGTGAG mouse RT–PCR 
(FosB) 
hAcid1Y39Adown GGGCTCCGCAAGCACGCCCTGCTCCCGGCCATC cloning of pLS69 
hAcid1Y39Aup GATGGCCGGGAGCAGGGCGTGCTTGCGGAGCCC cloning of pLS69 
hAcid1Y66Adown CTATGGGGGGACCCAGGCCAGCCTCGTGGTGTTC cloning of pLS67 
hAcid1Y66Aup GAACACCACGAGGCTGGCCTGGGTCCCCCCATAG  cloning of pLS67 
hAcid1Y152Adown CTGCAACTCACCCCCAGCCTTGTTGCCTGCTGTTG cloning of pLS64 
hAcid1Y152Aup CAACAGCAGGCAACAAGGCTGGGGGTGAGTTGCAG cloning of pLS64 
hAcid1Y161Adown GTTGAGAGCACCACGGCCTCTGGATGCACAACTG cloning of pLB65 
hAcid1Y161Aup CAGTTGTGCATCCAGAGGCCGTGGTGCTCTCAAC cloning of pLB65 
hAcid1F47Adown CCGGCCATCGAGTATGCTAATGGTGGTCCTCCTG cloning of pLB66 
hAcid1F47Aup CAGGAGGACCACCATTAGCATACTCGATGGCCGG cloning of pLB66 
hAcid1F125Adownnew CACAGCCTTGCAGCTGGCTGATGACTTCAAGAAG cloning of pLS71 
hAcid1F125Aup CTTCTTGAAGTCATCAGCCAGCTGCAAGGCTGTG cloning of pLS71 
hAcid1HMVL219AMAAdown GAGCCAGGACCCGAGGGCCATGGCGGCGGTTCGGGGACTCGTG cloning of pLS62 
hAcid1HMVL219AMAAup CACGAGTCCCCGAACCGCCGCCATGGCCCTCGGGTCCTGGCTC cloning of pLS62 
hAcid1VVFV17LVFLdown GAGCGTGGTGGCCGACCTGGTGTTTCTGATTGAGGGTACGGCC  cloning of pLS74 
hAcid1VVFV17LVFLup GGCCGTACCCTCAATCAGAAACACCAGGTCGGCCACCACGCTC cloning of pLS74 
hAcid1RK186AAdown CTCCATTGTGTCTCCCGCGGCGCTGCCTGCGCTTCGG  cloning of pLS70 
hAcid1RK186AAup CCGAAGCGCAGGCAGCGCCGCGGGAGACACAATGGAG cloning of pLS70 
hAcid1T138Adown GAGCAGATTGGCCAGGCGCACCGGGTCTGCCTC  cloning of pLS73 
hAcid1T138Aup GAGGCAGACCCGGTGCGCCTGGCCAATCTGCTC cloning of pLS73 
hAcid1W408Adown GAGCGGGGTCCTGGAGGCGCAAGAGAAACCCAAAC cloning of pLS59 
hAcid1W408Aup GTTTGGGTTTCTCTTGCGCCTCCAGGACCCCGCTC cloning of pLS59 
hAcid1WPQK444APQAdown CTGAAGACGGAGCAGGCGCCCCAGGCGCTGATCATGCAGCTC cloning of pLS58 
hAcid1WPQK444APQAup GAGCTGCATGATCAGCGCCTGGGGCGCCTGCTCCGTCTTCAG cloning of pLS58 
hAcid1KKIF518AAIAdown CTGTACTCGTCCAAGGCGGCGATCGCCATGGGCCTCATCCCC cloning of pLS60 
hAcid1KKIF518AAIAup GGGGATGAGGCCCATGGCGATCGCCGCCTTGGACGAGTACAG cloning of pLS60 
hAcid1YR487AAdown GTCTCTCAAAGGCCTCGCCGCCATCATGGGCAACGGC cloning of pLS63 
hAcid1YR487AAup GCCGTTGCCCATGATGGCGGCGAGGCCTTTGAGAGAC cloning of pLS63 
hAcid1FHF473AAAdown CTCAAGGATGGTCCAGGCCGCTGCCACCAACAAGGACCTG cloning of pLS57 
hAcid1FHF473AAAup CAGGTCCTTGTTGGTGGCAGCGGCCTGGACCATCCTTGAG cloning of pLS57 
hAcid1KT443AAdown CATGGCGAGAACCTGGCGGCGGAGCAGTGGCCCCAG cloning of pLS72 
hAcid1KT443AAup CTGGGGCCACTGCTCCGCCGCCAGGTTCTCGCCATG  cloning of pLS72 
hAcid1FR465AAdown CACCCTGGGCCCTTTGGCCGCGAACTCAAGGATGGTC cloning of pLS68 
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hAcid1FR465AAup GACCATCCTTGAGTTCGCGGCCAAAGGGCCCAGGGTG cloning of pLS68 
hAcid1LRSLL646ARSAAdown GGGGCCAACCCTCAGGCGCGAAGCGCCGCCCTCAACCCACCACCG cloning of pLS61 
hAcid1LRSLL646ARSAAup CGGTGGTGGGTTGAGGGCGGCGCTTCGCGCCTGAGGGTTGGCCCC cloning of pLS61 
newhcJunFW GAGAGGAAGCGCATGAGGA human RTPCR(cJun) 
hcJunrev210705 CCACCTGTTCCCTGAGCAT  human RTPCR(fosB) 
newFosB last 2 exons FW TCACCCCAGAGGAAGAGGAGA human RTPCR 
hfosbrev210705 TCCGACTCCAGCTCTGCTTT human RTPCR 
Med25Q137Afw CGCGAGCAGATTGGCGCGACGCACCGGGTCTGC cloning of pLS79 
Med25Q137Arew GCAGACCCGGTGCGTCGCGCCAATCTGCTCGCG cloning of pLS79 
Med25T138Dfw GAGCAGATTGGCCAGGACCACCGGGTCTGCCTC cloning of pLS80 
Med25T138Drev GAGGCAGACCCGGTGGTCCTGGCCAATCTGCTC cloning of pLS80 
Med25NS147/148AAfw GCCTCCTCATCTGCGCCGCACCCCCATACTTGTTG cloning of pLS81 
Med25NS147/148AArev CAACAAGTATGGGGGTGCGGCGCAGATGAGGAGGC cloning of pLS81 
Med25Y151Ffw GCAACTCACCCCCATTCTTGTTGCCTGCTGT cloning of pLS82 
Med25Y151Frev ACAGCAGGCAACAAGAATGGGGGTGAGTTGC cloning of pLS82 
Med25E157Rfw CTTGTTGCCTGCTGTTCGGAGCACCACGTACTCTG cloning of pLS83 
Med25E157Rrev CAGAGTACGTGGTGCTCCGAACAGCAGGCAACAAG cloning of pLS83 
Med25Y161Ffw GTTGAGAGCACCACGTTCTCTGGATGCACAACTG cloning of pLS84 
Med25Y161Frev CAGTTGTGCATCCAGAGAACGTGGTGCTCTCAAC cloning of pLS84 
Med25E167Afw ACTCTGGATGCACAACTGCGAATCTTGTGCAGCAG cloning of pLS85 
Med25E167Arev CTGCTGCACAAGATTCGCAGTTGTGCATCCAGAGT cloning of pLS85 
Med25ER175/176AAfw GTGCAGCAGATTGGGGCGGCGGGGATCCACTTCTCC cloning of pLS86 
Med25ER175/176AArev GGAGAAGTGGATCCCCGCCGCCCCAATCTGCTGCAC cloning of pLS86 
BCL2_RT_fw TCGCCCTGTGGATGACTG human RTPCR (BCL2) 
BCL2_RT_rev GGCAGGCATGTTGACTTCAC human RTPCR (BCL2) 
hVacidEcorI   GGAATTCGAGGCTGCCAAGAACCAGAAG cloning of pLS35, pLS36, pLS37 
hVacid ende XbaI CGTCTAGATTAAAAAGGAACTTTATTGGG cloning of pLS35, pLS39 
hPC6–ATG–EcorI GGAATTCATGGTCCCCGGGTCCGA cloning of pLS38 
hVacid NLS XhoI  CCGCTCGAGCCCAAGAAGAAGCGGAAGGTGGAGGCTGCCAAGAACCAGAAG cloning of pLS39, pLS40, pLS41 
hPC6ATGNLSXhoI TCGAGCCCAAGAAGAAGCGGAAGGTGATGGTCCCCGGGTCCGAGGGC cloning of pLS42, pLS43 
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2.2 Molecular biology 
 
2.2.1 Cloning  
 
For each cloning step described, standard protocols were employed for restriction 
digestion, dephosphorylation, ligation and transformation of bacteria. In general, DNA 
digestions were carried out from a minimum of 2 hours to overnight at 37°C using 2 units 
of enzyme (Fermentas MBI or New Englan Biolab) per µg of DNA. In the case of 
vectors, phosphate groups were removed by adding Calf Intestine Alkaline Phosphatase 
(CIAP, Fermentas MBI) to the digest solution for an additional hour. Before ligation DNA 
vectors or fragments were purified with PCI (Phenol Clorophorm Isoamil 25/24/1, Roth) 
and precipitated with EtOH 100% or purified over an agarose gel and recovered using 
the Gel Band Purification Kit (Amersham, Cat. N. 27–9602–01). Vector backbone and 
insert were ligated overnight at 16°C usually in a 1:3 ratio in a total volume of 30µl using 
2 µl of T4 DNA ligase (Fermentas MBI, Cat. N. EL0015). Transformation of competent 
cells was performed mixing 15µl of ligation solution with 50µl of bacteria (usually DH5α) 
and leaving them in ice for 10–15 minutes. After heat shock, which was taking place at 
42°C for 45 seconds followed by 1–2 minutes in ice, cells were diluted in 1 ml LB 
medium and shacked at 37°C for 1 hour. Bacteria were finally centrifuged at full speed 
for 30 seconds at RT, resuspended in 100µl of left over LB and plated in LB–agar plates 
containing 100µg/ml Ampicillin (or any other suitable antibiotic) where they were growing 
overnight at 37°C. Single colonies were used to inoculate 3ml of LB medium and left 
overnight at 37°C shaking. The following day DNA was extracted from the bacteria 
cultures via mini preps, performed using the miniprep kit (Amersham) according to the 
manufacturer's instructions. Positive clones were verified by restriction digest and re–
transformed to be able to inoculate bigger amounts of culture (100–200ml) which were 
processed for DNA extraction using midi or maxiprep kits (NucleoBond or Qiagen). 
 
MED25 conditional knock–out targeting vector (pLS20): the back–bone of the 
targeting construct (pLS11, 7666bp) was made by fusing two plasmids, pLS9 (kindly 
provided by Capecchi and described by (Moon and Capecchi, 2000)) and pLS10. A 
SpeI/ClaI fragment containing a Neomycin cassette was removed from pLS10 and 
replaced with a 3421bp SpeI/ClaI fragment cut from pLS9 and containing a FRT–flanked 
MATERIALS AND METHODS  52 
Neomycin cassette followed by a loxP site. Methylation of ClaI site in DH5 alpha 
bacterial strain makes the restriction of this DNA sequence not possible. Therefore, in 
order to be able to perform this cloning step, both plasmids were expressed in a Dam 
negative bacterial strain called GM2163. Beside this step, the rest of the cloning was 
carried out using DH5α bacteria. A 300bp AscI/SpeI fragment was removed from pLS11, 
blunt ends generated by feeling in the overhanging sequences with Klenoow, and finally 
the plasmid re–ligated to create the vector pLS12 (7300bp). An 8000bp BglII fragment 
containing the genomic sequence of MED25 from exon 1 to exon 10 was cut from pLS2 
(BAC clone selected form a 129/Ola mouse cosmid library via Dot blot analysis) and 
inserted in a pCI vector (pLB27A) generating pLS13. In the mean time, the homologous 
recombinant region 3' was synthesized by PCR using PC6HRR3'down and 
PC6HRR3'up primers and pLS2 as template. The fragment was cut with SmaI and 
inserted through the same restriction site in pLS12, generating pLS14. A missing DNA 
sequence of 200bp belonging to the intron 10 was also synthesized by PCR, using 
PC6intron10down and PC6intron10up primers on pLS2 DNA template and cut with 
BamHI and BglII in order to clone it into pLS14 through the BglII site. Ligation (creating 
pLS17) was possible due to the fact that BamHI and BglII are isoschizomer. At this point 
the 8000bp BglII genomic fragment coming from pLS13 was inserted in pLS17 with the 
generation of pLS18. The targeting vector pLS20 was resulting from last step of cloning 
where the annealed oligos PC6loxPdownEcoRV and PC6loxPupEcoRV were cloned in 
the SpeI site of pLS17, therefore introducing a second loxP site, and an additional 
EcoRV restriction site necessary to discriminate in between homologous recombinant 
and wild type during the southern Blot analysis of the selected ES clones. 
 
pLS29, pLS45 and pLS53: A SalI/NheI DNA fragment was removed from pEP7 (gb233, 
expressing ER–Notch) and replaced with PCR fragments coding either for MED25 full 
length (pLS29) or for NTD (pLS45). Alternatively the plasmid was re–ligated to generate 
pLS53 expressing only for the ER–LBD. PCRs were performed using pLB58 (human 
MED25 cDNA, clone DKFZp434K0512Q2, Gene Bank Acc. N. AL136746) as template 
and the following primer pairs for the synthesis of pLS29 and pLS45 respectively: 
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ER–Acid1down (5' ATAGTCGACGATGGTCCCCGGGTCCGAG 3') 
ER–Acid1up (5' CGCGGCTAGCTTAAAAAGGAACTTTATTGGGTGT 3') 
ER–Acid1down (5' ATAGTCGACGATGGTCCCCGGGTCCGAG 3') 
ER–hAcid1NTDup–stop (5' TACTGCTAGCTCACTCCACTGCATTCTGCGC 3') 
 
The following amounts of each component were used in the PCR reaction:  
 
DNA template (100ng/µl)  1µl 
dNTPs(25mM)   0.6µl 
10x Buffer Pfu (–MgSO4, MBI) 5µl 
MgSO4    4µl 
Pfu (MBI)    0.5µl 
Primer 1 (100pmol/µl)  0.25µl 
Primer 2 (100pmol/µl)  0.25µl 
DMSO 50%    5µl 
H2O     33.4µl 
 
PCR program: 
 
   1. 95oC   3 minutes 
   2. 95oC   1 minute 
   3. 60oC   1 minute 
   4. 72oC   3 minutes 2x4 
   5. 95oC   1 minute 
   6. 66oC   1 minute 
   7. 72oC   3 minutes 5x21 
8. 72oC   5 minutes 
9. 4oC   ∞ 
 
pLS35, pLS36, pLS37, pLS38: DNA fragments coding for MED25290–754, MED25290–730, 
MED25290–685, MED251–685, respectively, were synthesized by PCR using pLB58 as 
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template (human MED25 cDNA, clone DKFZp434K0512Q2, Gene Bank Acc. N. 
AL136746) and the following primer pairs: 
 
pLS35: hVacidEcoRI 
hVacidendeXbaI 
pLS36: hVacidEcoRI 
  hVacid2190stopXbaI 
pLS37: hVacidEcoRI 
  hVacid2055stopXbaI 
pLS38: hPC6ATGEcoRI 
  hVacid2055stopXbaI 
 
The following amounts of each component were used in the PCR reaction:  
 
DNA template (100ng/µl)  1µl 
dNTPs(25mM)   0.6µl 
10x Termobuffer (NEB)  5µl 
Vent Polymerase (NEB)  0.2µl 
Taq Polymerase (MBI)  0.4µl 
Primer 1 (100pmol/µl)  0.25µl 
Primer 2 (100pmol/µl)  0.25µl 
DMSO 50%    5µl 
H2O     37.3µl 
 
The employed PCR program was the same as the one previously described for pLS29 
and pLS45, except for the annealing temperatures which were 45oC at step number 3 
and 60oC at step 6 respectively. Each PCR fragment was cut with EcorI/XbaI and 
inserted in a plasmid named pLS65, in frame with its GAL/Myc–tag on the 5' site. 
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2.2.2 Site directed mutagenesis 
 
Med25 point mutants were generated following the principle of QickChange Site–
Directed Mutagenesis Kit (Stratagene). GAL4–MED25 expressing vector was used as a 
template for all MED25 mutants. Oligonucleotide primers containing the desired 
mutation and complementary to opposite strands of the vector were designed according 
to the manufacturers instructions. The primers used for the synthesis of each MED25 
mutant are listed in table 6. Extension of the primers was performed during temperature 
cycling by Pfu Turbo DNA polymerase (Stratagene). Incorporation of the oligonucleotide 
primers generated a mutated plasmid containing staggered nicks. Amounts of each 
component in the PCR reaction were used as follows: 
 
DNA template (1ng/µl) 10µl 
dNTPs(25mM)    1µl 
10x Buffer     5µl 
Pfu Turbo (2.5U/µl)    1µl 
Primer mix (1pmol/µl) 20µl 
H2O    13µl 
 
PCR program: 
 
    1. 95oC   30 seconds 
    2. 95oC   30 seconds 
    3. 55oC   1 minutes 
    4. 68oC   16 minutes 2x16 
    5. 68oC   10 minutes 
    6.   4oC   ∞ 
 
The product of PCR reaction was treated for a minimum of 2 hours with 1µl of DpnI 
endonuclease (NEB) which, being specific for methylated and hemymethylated DNA, is 
used to digest the parental DNA template and to select for mutation–containing 
synthesized DNA. The selected mutated plasmid was then transformed into XL2–Blue 
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supercompetent cells (Stratagene), or into high efficiency GC5 competent cells 
(Ampliqon IIII) following the manufacturers instructions.  
 
2.2.3 RT–PCR 
 
RNA was extracted from NIH–ER and NIH–ER–MED25 cell lines using the Qiagen 
RNeasy Mini, Midi or Maxi kit (Qiagen) according to the manufacture's instructions and 
depending on the cell's number. To eliminate residual amounts of genomic DNA, 
samples were treated with DNase either on the columns during the RNA extraction 
process using RNase–Free DNase Set (Qiagen, Cat. N. 79254), or using DNase I 
(Invitrogen, Cat N. 18068–015) after extraction and determination of RNA concentration. 
In this second case 5µg of isolated RNA were mixed with 1µl of DNase, 1µl of 10x buffer 
in a total volume of 10µl and incubated for 15 minutes at RT. Reaction was stopped by 
adding 1µl of 25mM EDTA and by heat inactivation at 65oC for 10 minutes. All the 
reagents were upscaled when the amount of RNA to be treated was higher. At this point 
about 1–2µg of DNase treated RNA were subjected to reverse transcription according to 
the protocol reported by the ThermoScript™ RT–PCR System (Invitrogen, Cat. 
N. 11146–024). The oligo dT provided by the kit was used to synthesize the first strand. 
The reaction was carried out at 50oC for 1 hour followed by a denaturation step at 85oC 
for 5 minutes. cDNA was stored at –20oC or immediately used for quantitative Real–
Time PCR to reveal differences in the amount of transcripts coming from OHT 
stimulated samples. For this purpose the SYBR Green PCR reagents (Applied 
Biosystems, Cat. N. 4306736) and gene specific primers were employed as follows: 
 
SYBR Green buffer     2.5µl 
MgCl2 (25mM)     2.5µl 
dNTP mix      2.0µl 
AmpliTaq Gold DNA polymerase (5U/µl)  0.2µl 
AmpErase UNG (1U/µl)    0.2µl 
H2O       13.6µl 
cDNA       2.0µl 
primer mix (5pmol/µl each)    2.0µl 
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Primers were designed with a melting temperature (Tm) of 58oC. β–Actin primers were 
always included as a reference control. Samples obtained from reverse transcription 
reactions carried out without reverse transcriptase were used as negative control. PCR 
reactions were performed in a Applied Biosystem GeneAmp 5700 instrument setting the 
program to 40–45 cycles.  
 
2.2.4 Microarrays 
 
NIH–ER–MED25 Microarrays: About 2x107 cells/sample were collected 3 hours and 10 
hours after stimulation with 1mM OHT. Since the time corse experiment was performed 
in two different moments, a sample of nonstimulated cells (NS) was collected for each 
time point, with a total amount of 4 samples (NS3 hours, 3 hours, NS10 hours, 10 hours). 
RNA was extracted from the cells using the Qiagen RNeasy Midikit (Qiagen) according 
to the manufacturer's instructions. RNA, without DNase treatment, was sent to the lab of 
dr. Johannes Beckers (IEG, GSF, Neuerberg) where a microarray analysis was carried 
out as follows. 
Chip design  
A glass–surface DNA–chip containing ≈ 21000 probes was used. About 20200 of these 
probes are from the commercial Lion mouse array–TAG clone set, which is mostly 
derived from 3’UTRs. All Lion probes have been sequenced. The remaining probes 
were isolated in a subtractive screen for differentially expressed genes in the mesoderm 
of Delta/Notch pathway deficient mouse embryos. Mouse array–TAG clones have the 
general ID MG–VW–XYZ and the Delta/Notch specific probes are named rda–X.  
DNA microarrays  
PCR products with 5’–aminogroup were amplified from the mouse array TAG library 
from Lion Bioscience comprising approximately 20200 clones (Heidelberg, Germany). 
PCR products were dissolved in 3–fold SSC buffer and spotted on aldehyde–coated 
slides (Telechem, USA) using a Microgrid TAS II spotter (Biorobotics) with 48 Stealth 
TM SMP3 pins (Telechem). Spotted slides were rehydrated overnight in a humid 
chamber containing 50–70% aqueous solution of glycerol. Rehydrated slides were 
immersed in blocking solution (0,1M sodium borohydride in 0,75 fold PBS with 25% 
ethanol) for 5 minutes, boiled in water for 2 minutes, briefly immersed in 100% ethanol 
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and air–dried. Slides were pre–hybridised for 1 hour in pre–hybridisation buffer (6–fold 
SSC, 1%BSA, 0,5%SDS) rinsed in water, dried and hybridised the same day.  
Reverse Transcription and Fluorescent Labelling  
For labelling 20µg of total RNA were used for reverse transcription and indirectly 
labelled with Cy3 or Cy5 fluorescent dye according the TIGR protocol 
(http://pga.tigr.org/sop/M004_1a.pdf). Labelled cDNA was dissolved in 30µl hybridisation 
buffer (6x SSC, 0,5% SDS, 5 fold Denhardt’s solution and 50% formamide) and mixed 
with 30µl of reference cDNA solution labelled with the second dye. This hybridisation 
mixture was placed on a pre–hybridised microarray, under a cover slip, placed into a 
hybridisation chamber (Genetix) and immersed in a thermostatic bath at 42°C for at 
least 16 hours. After hybridisation slides were washed in 40ml of 3x SSC, 40ml of 1x 
SSC and 40ml of 0.25x SSC at room temperature. For drying slides were placed in an 
empty 50ml Falcon tube (Becton Dickinson, USA) and centrifuged at 4000 m/s2. Dried 
slides were scanned with a GenePix 4000A microarray scanner and the images were 
analysed using the GenePix Pro3.0 image processing software (Axon Instruments, 
USA). All data were normalised by adjusting the median of log–ratios of Cy5 to Cy3 
intensities to 0. For data analysis in–house produced LabView based software was 
used.  
 
721–ER–MED25–NTD Affymetrix arrays: About 1x 107 cells/sample were collected 1 
hour, 10 hours and 24 hours after stimulation with 1mM OHT. One sample of 
nonstimulated cells (NS) was also included as a reference sample. RNA was extracted 
from 4 samples (NS, 1 hour, 10 hours, 24 hours) using the Qiagen RNeasy Minikit 
(Qiagen) according to the manufacturer's instructions. During the extraction process, 
RNA was treated with the RNase–Free DNase Set (Qiagen, Cat. N. 79254). RNA 
concentration was determined using a spectrophotometer and about 1µg/sample was 
sent to the company KFB, Regensburg, where affimetrix arrays were performed. For this 
analysis an Affymetrix Human Genome U133 Plus 2.0 Array GeneChip was employed. 
This chip is characterized by a complete coverage of the human genome and it is 
suitable for an analysis of over 47000 transcripts. It includes a total number of 54675 
probe sets the sequences of which are derived from GenBank®, dbEST and RefSeq. 
The company in charged for the analysis sent to us a list of genes up and down–
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regulated at each time point which was obtained comparing each experimental sample 
(derived from cells stimulated with OHT) to the baseline sample (derived from non 
stimulated cells). In order to reduce the number of false positives and consider only 
statistically relevant genes the mentioned list was additionally sorted following the 
instructions suggested by the GeneChip® Expression Analysis manual.  
 
To determine robust increases: 
- Probe sets in the experimental sample called "Absent" were eliminated 
- Probe sets called "Increase" were selected 
-  
To determine robust decreases: 
- Probe sets in the baseline sample called "Absent" were eliminated 
- Probe sets called "Decrease" were selected 
 
Additionally, the genes indicated with MI (marginal increase) and MD (marginal 
decrease) were eliminated.  
 
2.2.5 Dot blot 
 
Before starting to generate the MED25 conditional knock– out targeting vector an 
analysis of the eight pBAC clones (from library N. 121, 129/Ola mouse cosmid) received 
from the rzpd screening service was made to identify which of them was containing a 
large portion of MED25 genomic locus. These clones were selected from the center 
using a probe that was synthetized by PCR using the primers PC6PreExon1 and 
PC6exon1down on a DNA template named pLB52 (GeneBank Acc. N. AC069498, mus 
Musculus chromosome 7 in pBACe 3.6 vector). DNA was prepared from each clone via 
minipreps and from the first three clones also via maxipreps. 3µl of each sample were 
mixed with 0.3µl EDTA 200mM, 0.8µl of NaOH 1M and heated at 100oC for 10 minutes. 
After cooling down in ice for 5 minutes, samples were briefly span down before use. 22 
squares were drown on a membrane which was pre–equilibrated in water, quickly dried 
and spotted with the DNA in duplets as described in the following table: 
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Table 7. Distribution of the cosmid clones on the filter 
 
SQUARE'S NUMBER  CLONE'S NAME  
1–2 pLS1  
3–4 pLS2 
5–6 pLS3 
7–8 pLS4 
9–10 pLS5 
11–12 pLS6 
13–14 pLS7 
15–16 pLS8 
17–18 pLS1 (maxi prep) 
19–20 pLS2 (maxi prep) 
21–22 pLS3 (maxi prep) 
 
Membrane was incubated in a rotating cylinder with 10ml of dot– blot pre– hybridisation 
solution for 3–4 hours at a temperature equal to the Tm of the used oligoprobe 
subtracted of 20 degrees (i.e. 54oC for Tm=74oC). The oligos used as probes for this 
analysis are listed below: 
PC6prepreExon1 
PC6exon1up 
PC6Exon3up 
PC6exon9up 
PC6Exon14down 
Oligoprobes were synthetized mixing together the following components and incubating 
them for 20 minutes at 37oC: 
 
5 pmol oligo 
1x  PNK buffer (MBI) 
50µCi  [γ32P] ATP 
1.5µl  PNK (MBI) 
to 20µl  H2O 
 
An additional amount of 0.5µl of PNK was added to the mixture and incubated for 
another 20 minutes. Finally the radio–labelled probe was added to the pre–hybridization 
solution and incubated overnight. The following day, the membrane was washed at RT 
in 6x SSC solution for 15 minutes. After an inspection of the counts with a Geiger–
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counter, an additional wash was performed at 40oC for 15 minutes. Once the counts 
were reaching about 200cpm, the filter was sealed in a plastic bag and exposed to X–
ray film (Kodak BioMax MS) at –80oC for 2 days. 
 
2.2.6 Genomic DNA extraction  
 
From 96 well plates: Genomic DNA was extracted from 96 well plates where TBV2 ES 
cells were let overgrow. Once removed from the incubator cells were washed twice with 
100µl PBS and left in 50µl ES cells lysis buffer overnight at 56oC, after sealing the plates 
with parafilm and placing them in a humid chamber. The following day plates were 
removed from the incubator and left at RT for about one hour. 100µl of EtOH 100% were 
added to each well for another hour to provoke DNA precipitation. After precipitation to 
the bottom of the wells, DNA was washed 3 times with EtOH 70% turning gently the 
plate up side down. To get ready for the Southern blot analysis DNA was finally 
resuspended in 34µl of the following solution: 
 
1mM   Spermidine 
1mM   DTT 
100µg/ml  BSA (NEB) 
50µg/ml  RNase 
1X   Buffer (NEB) 
20U   BglII (50U/µl, NEB) or EcoRV (100U/µl) 
 
Digestion was carried out overnight at 37oC. The following day 7µl of 6X DNA loading 
buffer were added to each well and the plate sealed with parafilm and stored at – 20oC.  
 
From expanded clone 5A cells: Genomic DNA was extracted from expanded MED25 
homologous recombinant ES cells to confirm the genotype of the positive clone 5A. 
Cells were let grow onto gelatin in 1 well of a 6 well plate until confluent and then 
trypsinized, pelleted, washed with PBS, resuspended in 500µl of ES cells lysis buffer 
and incubated overnight at 56oC. To eliminate the protein content, lysate was divided in 
two aliquots of 250µl, and each aliquot mixed with 800µl Phenol/Clorophorm/Isoamil 
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(PCI, Roth). After centrifugation at full speed, the water fraction was collected and DNA 
precipitated by adding 40µl of a 3M Sodium Acetate solution and 800µl of EtOH 100%. 
DNA was then pelleted, washed with EtOH 70% and resuspended in TE buffer. 
 
From mouse tails: Genomic DNA was extracted from mouse tails collected from the 
offspring of MED25 conditional knockout chimeras. 5–10mm of tail were cut and placed 
in an Eppendorf tube and left overnight at 56oC in 500µl of tail lysis buffer moderately 
shaking. Hair and cell debris were pelleted centrifuging the samples at full speed for 5 
minutes. The supernatant was transferred into a new Eppendorf tube and mixed with 
500µl of isopropanol to allow DNA precipitation. After full speed centrifugation for 15 
minutes, supernatant was discarded and the pelleted DNA was washed twice with 250µl 
of EtOH 75%, and let dry at RT. Genomic DNA was finally resuspended in 100µl TE 
buffer and gently shacked for 1–2 hours at 37oC. From this preparation 15µl were used 
for Southern blot analysis. 
 
2.2.7 Southern blot 
 
The identification of the homologous recombinant ES cell clone for MED25 conditional 
knock–out was accomplished analysing genomic DNA extracted from double selected 
ES cell clones via Southern blot the surviving the double selection. 0.8% agarose gels 
were made in big chambers containing 75 pockets, and loaded with 40µl/well of genomic 
DNA collected in the 96 well plates (see paragraph 2.2.6). Gels were running in TAE 
buffer overnight at RT and at 27 Volts. After about 16 hours gels were photographed 
under UV light. To favour the transfer of fragments which are bigger than 10kb, 
depurination was promoted leaving gels in 0.25N HCl solution for 15–20 minutes on a 
shaker at a very low speed. Gels were then briefly washed with water and equilibrated 
for 45 minutes in alkaline transfer solution. The transferring of the DNA fragments onto a 
charged nylon membrane (Hybond–N+, Amersham, Cat.N. RPN 203B) was carried out 
for a minimum of 3 hours downward as follows. A 3–4 cm layer of paper towel was used 
as a base on top of which from bottom to top were placed as listed: 
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4 sheets of dry Watman paper 
1 sheet of Watman paper soaked in transfer buffer 
1 gel sized nylon membrane pre–equilibrated with buffer 
the agarose gel 
4 sheets of Watman paper soaked in transfer buffer 
 
The last sheet of Watman paper was reaching a box containing transfer buffer, placed at 
a higher level to direct the buffer floss and the transfer of the DNA from top to bottom. 
On top of everything were placed a plate of glass and a thick book. After blotting, the 
membrane was rinsed and neutralized with 2x SSC buffer, sandwiched in between 2 
sheets of Watman paper and baked for 30–60 minutes at 80oC to fix the DNA. 
Prehybridization was carried out at 65oC for a minimum of 15 minutes placing the 
membrane into a rotating cylinder with 15 ml of Rapid Hyb Buffer (Amersham, Cat. N. 
RPN 1635). Once synthetized, 38µl of the 32P radio labeled probe were added to the 
prehybridization solution and incubated again for a minimum of 2 hours. For the 
synthesis of the probes 25ng of DNA were radioactively labelled with 50 µCi of 
[α32P]dATP using the Megaprime DNA labelling system Kit (Amersham, protocol 1606) 
according to the manufacturer's instructions. Unincorporated radiolabelled nucleotides 
were removed with MicroSpin columns G25 (Amersham) to reduce background during 
hybridization. The probe was denatured at 95°C for 5 min, before it was added to the 
hybridisation solution. Probe Neo was a 383bp fragment obtained by PstI/NcoI 
restriction of a Neomycin cDNA contained in a pBluescript vector provided by Nathalie 
Uyttersprot. The following primers were used for the synthesis of the probes A and B' by 
PCR on the genomic DNA template pLS2: 
 
probe A (660bp) PC6PreExon1 (5' ACTGCTTCGCTTCCAAGTCCCG 3') 
   PC6exon1down (5' ACTCTATGGCAGGCAGCAGGTA 3') 
probe B' (540bp) PC6probeBup (5' CCCAGGCAGAGTACTGTTGGTC 3') 
   PC6probe3'down (5' CCCTCAGACTCTCAGGGGACTG 3') 
 
After hybridisation, the membrane was washed at 65oC for 20 minutes with 2x 
SSC/0.1% SDS solution, for 15 minutes with 1x SSC/0.1% SDS solution and for 15 
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minutes with 0.1x SSC/0.1% SDS solution. Finally the filter was monitored with a Geiger 
counter and the washes were stopped when specific signals reached 30 to 60 cps. 
Then, the filter was sealed in a plastic bag and exposed to X–ray film (Kodak BioMAX 
MS) at –80oC for a minimum of 16 hours. 
 
2.3 Cell biology 
 
2.3.1 Cell lines 
 
Jurkat  Human T lymphoblastoid cell line, grow in suspension 
HEK293T Human embryonic kidney cell line, adherent 
HeLa  Human epithelial cell line, cervical carcinoma, adherent 
721B  Human B lymphoblastoid cell line, grow in suspension 
HepG2 Human hepatoma cell line, adherent 
NIH3T3 Murine fibroblast cell line, adherent 
 
2.3.2 Growth conditions 
 
Adherent cells were grown in Dulbecco's modified Eagle medium (DMEM plus 4500 
mg/ml glucose, L–Glutamine, without pyruvate. Gibco Invitrogen, Cat. No. 11971–025) 
supplemented with 10% fetal bovine serum (FCS; Gibco Invitrogen, Cat. No. 10270–
106) and 1% Penicillin–Streptomycin (Gibco Invitrogen, Cat. No. 15140–122) in culture 
dishes ranging from 15 and 10 cm down to 6 and 12 well plates (Nunc, Cat. No. 157150, 
150350, 140675, 150628) in a tissue culture incubator under 5% CO2 and at 37oC. 
Confluent cells were detached from the plates using 0.25% trypsin and 0.2% EDTA 
(Gibco Invitrogen, Cat. No. 25050–014) diluted 1:4and seeded to a new plate. 
Suspension cells were grown in RPMI 1640 medium, L–Glutamine (Gibco Invitrogen, 
Cat. No. 21875–034), supplemented with 10% FCS and 1% Penicillin–Streptomycin. 
The suspension cells were growth in 25 to 175 cm2 cell culture flasks. When the cells 
reached a density of 0.8–1x106 cells/ml, they were diluted to a new concentration of 0.2–
0.4 x106 cells/ml. Cell lines transfected with EBV vectors expressing ER–tagged 
constructs were initially selected with 200µg/ml Hygromycin containing medium which 
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was replaced every 3 days for about 2 weeks. Once stable the cell line was cultured in 
maintenance conditions with 100µg/ml Hygromycin containing medium. To induce 
translocation of ER–tagged proteins into the nucleus, cells were feed at a given time 
with 4– hydroxytamoxifen (OHT) at a final concentration of 1µM. 
 
2.3.3 Freezing and thawing conditions 
 
Trypsinized adherent cells grown to a 90% confluence in 10 or 15 cm dishes or 1x107 
suspension cells, were pelleted and resuspended in 0.5–1ml of a cold solution 
containing 90% serum and 10% dimethyl–sulfoxide (DMSO, Sigma), aliquoted in 
cryovials (Nunc) and left for 24 hours at –80oC before been stored in liquid nitrogen. For 
thawing, frozen aliquots were quickly hand wormed, resuspended in 10ml of their own 
medium, pelleted to remove residual amount of DMSO and resuspended in fresh 
growing medium. Adherent cells were then seeded in a dish the same size of the one 
they were frozen from, and suspension cells resuspended in 10ml medium and placed in 
a 25cm2 flask at least for 24 hours and then diluted with fresh medium. 
 
2.3.4 Transfection of the cells 
 
Calcium phosphate transfection: HEK293T, NIH3T3 and HepG2 cells were 
transfected following a so called alternative protocol developed by Okayama and 
colleagues and described by (Sambrook, 1989), which is a modification of the classical 
calcium phosphate transfection method. In brief, the day before transfection cells were 
seeded in a 10cm plate, in 10ml growth medium, at 20% confluence in order reach 30–
50% confluence at the moment of transfection. 16 to 24 hours later, a total amount of 
20µg DNA at a concentration of 1µg/µl in 0.1xTE was mixed with 0.5ml of a 0.25M CaCl2 
solution followed by addition of 0.5ml 2xBES–buffered–saline (BBS) solution, mixed and 
incubated for 10–20 minutes at room temperature. Before using them, the two solutions 
were also pre–equilibrated to a temperature of 20–25°C. The DNA–CaCl2– BBS mixture 
was then added drop wise to the dish of cells which was gently swirled to favorite 
distribution of the transfecting solution. After placing the cells in a humidified incubator in 
an atmosphere of 3.4% CO2 for 18–24 hours at 37°C, the old medium was substituted 
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with fresh one and normal growing conditions of 5% CO2 re–established for another 24 
hours. After about 48 hours cells were rinsed with PBS and harvested after leaving them 
for a minimum of 30 minutes in 3ml of cold PBS/EDTA 0.5mM solution. When using 
dishes or plates of a different size, cell density, DNA amount and reagent volumes were 
scaled accordingly. 
In the specific case of HEK293T cells transfected with titrated amounts of MED25 
mutants to analyze proteins expression in relation to the transcription activity, cells were 
plated in 6 well plates and transfected with 600ng of pGLMRG5, 60ng of β–Gal plasmid 
and 3 different concentrations (60, 300, 600ng) of MED25 derivative expression vectors 
(GAL–MED251–754, pLS64, pLS70). pLB28 was used to complement the total amount of 
DNA to 1.2µg, 100µl of each transfecting solution was added to the DNA and distributed 
to the cells according to the protocol. After 48 hours cells were harvested with 3ml 
PBS/EDTA 0.5mM per well, of which 2 ml were processed to prepare nuclear extract 
and 1ml pelleted and resuspended in 100µl of reporter lysis buffer. 40µl of this cell lysate 
were used to perform the luciferase assay while 20µl were used for the β–GAL assay. 
 
PolyFect transfection: HeLa cells were transfected using PolyFect reagent (Qiagen, 
Cat. N. 301105) according to the manufacturers protocol. In short, the day before 
transfection 2x105 cells were seeded in a 6cm dish in 5ml of appropriate medium. The 
day of transfection cells were washed once with PBS and leaved in 3ml of fresh growth 
medium while 3µg DNA were diluted in 150 µl of DMEM without FCS or other additives 
and added to 25µl of PolyFect reagent. The Polyfect–DNA complexes were diluted with 
1ml of complete medium and distributed to the cells. Because of the toxicity of the 
PolyFect reagent, cells were harvested after 24 hours using cold PBS/EDTA 0.5mM. 
When using dishes or plates of a different size, cell density, DNA amount and reagent 
volumes were scaled accordingly. 
 
Electroporation: Jurkat cells were employed to test the transcription activity of GAL–
 fused MED25 deletion constructs or point mutants on a promoter carrying 5 GAL4 
binding sites and fused to a luciferase reporter (pGLRMG5). Once reached a confluence 
of about 0.5 x106 cells/ml cells were pelleted and washed once with PBS. Cells were 
resuspended in growth medium without serum in a dilution of 0.8–1.2x107 cells per 
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400µl medium per sample. The cell suspension was then distributed in electroporation 
cuvettes (Gene Pulser Cuvette, BioRad Cat. N. 165–2088) where it was mixed together 
with a total amount of 20µg DNA and left at RT for about 10–20 minutes. Beside the 
GAL4–fused lucifearse reporter (pGLRMG5) and a GAL– MED25 derivative expression 
vector, an empty plasmid (pLB28) and a β–GAL plasmid were included to reach a total 
amount of 20µg DNA and to monitor the transfection efficiency, respectively. Per 
sample, the following amount of each plasmid was used: 
 
pGLMRG5  10µg 
β–GAL  1µg 
MED25 derivative 5µg 
pLB28   5µg 
 
For the electroporation each cuvette was connected to a Gene Pulser electroporator 
(BioRad) and the conditions set to a capacitance of 975µF and a voltage of 250V. After 
the electric shock, cells were resuspended in 10ml medium per sample, transferred in 
25cm2 flasks and incubated at 37°C and 5% CO2. 36–48 hours later, cells were 
harvested for Luciferase or β–Gal assay. 
 
Stable transfection: NIH3T3 cells were stably transfected with pLS29 expressing ER–
 MED25 or pLS53 expressing ER(LBD) randomly integrated in their genome. After 
failing to select NIH3T3 transfected with circular plasmid, 35µg of pLS29 or 24µg of 
pLS53 were linearized with NheI and with SalI respectively and 2x106 cells per each 
construct were transfected under 1000µF and 230V electroporating conditions. A mock 
control of cells electroporated without DNA was included in the experiment as a negative 
control. Transfected cells were resuspended in fresh growth medium and seeded in 6cm 
or 10cm plates. Selection with 200µg/ml Hygromycine was started after 24hours and 
was lasting for about two weeks. Only one surviving clone was selected from the cell 
line transfected with pLS29 while 5 clones were selected, expanded and frozen from 
cells carrying pLS53. The expression of ER(LBD) protein was checked by Western blot 
on the nuclear extract of each clone after induction by OHT. A single clone showing the 
expressed protein was used for further experiments. 721 B cells were stably transfected 
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with pLS45 episomally maintained and expressing ER–MED25– NTD. 15µg of circular 
pLS45 were mixed together with 5µg of pGFP plasmid (pML4) to control the transfection 
efficiency and with a cell suspension of 5x106 cells in 400µl of medium without serum. 
Several conditions of electroporation were tested: 950µF/250V, 950µF/230V, 
1000µF/250V, 1000µF/230V. Cells transfected at 230V were showing a higher 
transfection efficiency and were growing faster then the others. After about two weeks of 
selection in 200µg/ml Hygromycine the batch of cells transfected at 1000µF/230V were 
frozen in aliquots.  
 
2.3.5 Luciferase assay and β–GAL assay 
 
Jurkat cells were harvested 36–48 hours after transfection, pelleted, washed once with 
PBS and resuspended in 200µl of 1x Reporter Lysis Buffer (Promega, Passive Lysis 
Buffer 5x, Cat. No. E194A). The lysate was collected in a Eppendorf tube and 
centrifuged at full speed for 10 minutes to clear the lysate. 40 µl were used for the 
luciferase assay (Promega, Luciferase Assay System, Cat. No. E1501). In the β–GAL 
assay, 40µl of the cell lysate were incubated together with 200µl of β–GAL substrate 
solution overnight at 37°C. After incubation time, the absorption at 420nm was 
measured in a 96 well plate reader (BIO–TEK INSTRUMENTS INC., EL800 Universal 
Microplate Reader) and the values used to normalize the luciferase counts to the 
transfection efficiency. 
 
2.3.6 Immunofluorescence 
 
NIH– ER– MED25 or NIH3T3 cells were seeded at 20% confluence in 15cm plates on 
top of 4 microscope–slides previously bathed in EtOH 100% and dried. The following 
day OHT at a final concentration of 1µM was added to the medium. 4 hours later the 
medium was removed from the plates, and the cells washed with PBS and fixed on the 
slides for 5 minutes by addition of MeOH (–20oC) for 5 minutes to fix them on the slides. 
The slides were dried for about 30 minutes. At this point slides were either stored at –
20oC or permeabilized with 1% Triton X–100/PBS for 10 minutes and soaked in 
sufficient volume of TBS–BG solution for a minimum of 15 minutes. Cells were removed 
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from the TBS–GB solution and the primary antibody (α–ER sc543, Santa Cruz) diluted 
1:50 in PBS was placed on top of them and leaved for about 1–2 hours in a humid 
chamber. Slides were washed 3 times for 5 minutes and then incubated for at least 30 
minutes with a secondary antibody conjugated to the fluorescent dye and diluted 1:25 in 
a solution containing 0,5µg/ml DAPI (SIGMA Cat. No.–D9564) which stains the DNA 
and therefore makes the nucleus visible. This second incubation was carried out in a 
darkened humid chamber to prevent the dye from bleaching. After repeating the 
washing procedure described above, the slides were quickly dried and a drop of 
HistoGel mounting medium (Linaris) covered by a coverslip was placed right onto the 
cells. Before the microscope analysis slides were left at 4oC in the darkness overnight. 
The analysis of the samples was done with a Leica TCS SP2 confocal microscope.  
 
2.3.7 Embryonic stem cell culture 
 
TBV2 ES cells, the embryonic stem (ES) cells used in this work, are 129/Ola strain 
derived cells, created in the IEG department of GSF, Neuerberg. To maintain their 
pluripotency, ES cells were cultured in medium containing leukaemia inhibiting factor, 
(LIF, ESGRO, Chemicon International, Cat. N. ESG1107) on a layer of mitotically 
inactivated embryonic feeder cells (EMFI). The ES cell medium (DMEM, high glucose, 
sodium pyruvate, 15 % FCS, 2mM L–glutamine, 1000U/ml LIF, 0.1mM 2–β–
mercaptoethanol) contained FCS, which had been previously tested to promote ES cell 
growth and to prevent in vitro differentiation (PAA laboratories, Cat. N. A15041). ES and 
EF cells were grown in tissue culture dishes (Falcon) and kept at 37°C under humid 
atmosphere with 10% CO2. In normal conditions ES cell medium was changed in daily 
bases and cells diluted 1:4 every second day. EF cells were cultured in DMEM, high 
glucose, sodium pyruvate supplemented with 10% FCS, 2mM L–glutamine, 1x non 
essential amino acids and were never passaged more than three times. EF cells were 
mitotically inactivated by mitomycin–C treatment (10µg/ml for 2 h) before being cultured 
with ES cells. ES cell colony growth was stopped before they became confluent. 
Colonies were washed once with PBS and then treated shortly with trypsin (0.05 % 
trypsin, 0.02 % EDTA in PBS; Gibco) at 37°C, until the cells were detached from the 
dish. The cell suspension was then used for passaging, transfection, or freezing. ES 
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cells were frozen in 90% FCS, 10 % DMSO at –80°C and later transferred into liquid 
nitrogen for long–term storage. For the transfection of the MED25 targeting construct, an 
aliquot of TBV2 ES cells at the 10th passage was thawed and plated on a 6cm plate. 
Cells were passaged in total 2 times before collecting enough cells for the 
electroporation. Two days before transfecting 3x106 cells were distributed equally in 3 
plates. 50µg of two preparations of the same MED25 targeting construct were linearized 
with NotI and resuspended in 50µl of PBS. The cells grown in the 3 plates were 
trypsinized, pooled together, and counted. Among them, 2 aliquots of 107cells each were 
pelleted and resuspended in 750µl of transfection buffer (RPMI w/o phenol red, Gibco) 
and mixed together with 50µl of each preparation of linearized DNA. Cell were 
transfected under electroporating conditions of 500µF and 230V using a Gene Pulser II 
(BioRad) electroporator and left at RT for 10 minutes. Transfected cells were 
resuspended in 10ml of which 9ml were equally distributed onto embryonic feeder layer 
in 3 plates of 10cm. The remaining 1ml containing 106 cells was resuspended in 20ml 
and divided in 2 plates of 10cm and used as control plates. 5x105 cells of non 
transfected cells plated in one 10cm were also used as control. 48 hours later (at day 
three after transfection) cells were placed under G418 (Geneticin G– 418 sulphate, 200 
µg/ml, 71% active, Gibco, Cat. N. 11811–023). Selection against HSV–tk containing 
random integrants started at day six after transfection by supplementing the medium 
with 2µM gancyclovir (Sigma, Cat. N. G2536). One of the control plates containing 
transfected cells was also treated as just described, while the other two (one with 
tranfected cells and one with non transfected cells) were exclusively G418 selected. The 
comparison of these last two control plates allows monitoring of selection specificity, and 
helps to understand when it is time to start to pick colonies. The ratio of double selected 
colonies versus G418 selected colonies is defined as Ganciclovir enrichment, i.e. the 
theoretical enrichment of homologous recombinant versus random integrants while 
using Ganciclovir. In this experiment the number of colonies survived after G418 
selection were 60 while the double resistant colonies were 20. This means that 
Ganciclovir killed 30% of the colonies that would have undergone G418 selection. 
Between day 9 and day 11 after transfection, about 500 double resistant colonies were 
picked, tripsinized in 5 round–bottom 96 well plates and split into 15 EMFI–containing 
96–well tissue culture plates for expansion. In this way each clone was present in 3 
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different plates, one of which was kept in culture for longer time and finally divided in two 
96 well plates treated with 0.1% gelatine (LGC Promochem, Cat. N. 440454B). Cells 
were kept in culture until overgrown, processed for DNA extraction and enzymatic 
restriction with BglII and EcoRV and analysed by Southern blot. The other two plates 
were frozen at day 5 and day 7, respectively, after picking. To freeze the cells in the 96 
well plates, cells were washed twice with 100µl/well PBS and left for 10 minutes in 
50µl/well of trypsin containing 2% Chicken Serum. 50µl of 2x freezing medium (20% 
DMSO, 80%FCS) were added to each well, mixed and covered by 100µl of light oil 
(Sigma, Cat. N. M8410). Quickly, plates were closed and sealed with parafilm, 
embedded in several layers of cellulose paper sheets and stored at –80oC until the end 
of the Southern blot analysis. A schematic view of the steps followed from the 
electroporation of MED25 targeting construct to the end of the selection process is given 
in figure 8). 
 
 
Figure 8. Schematic view of the steps followed to generate ES cell line containing a MED25 conditional 
allele. 
 
Once finished the Southern blot analysis, the random integrant ES cell clone 5A 
identified was thawed from the plate which was frozen 5 days after picking. Therefore, 
the plate was partially immersed in few milliliters of water at 40°C, and the 100µl of 
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suspension cells removed from the well (avoiding to aspirate the mineral oil as well) and 
transferred in a 24 well plate. The cells were divided 1:2 every second day for four times 
and then partially processed for DNA extraction for confirmation of the genotype and 
partially frozen for stock storage (4 aliquots from 6cm plate each). For blastocyst 
injection one of these vials was thawed and plated in a 6cm dish containing feeders and 
2 days later splitted 1:3 in gelatine plates, in order to be injected the following day. The 
injection process was carried out in the IEG department of GSF, Neuerberg. 
 
2.4 Biochemistry 
 
2.4.1 Isolation of nuclear extract from HEK 293T and 721B cells  
 
48 hours after transfection (in the case of HEK 293T cells) or at a given time after OHT 
induction (in the case of 721– ER–MED25– NTD cell line), cells were harvested and 
washed with cold 1X PBS. Pelleted cells were then resuspended in cold NEX A buffer 
and left in ice for 10 minutes and permeabilized with a 0,2% final concentration of NP40 
for 5 minutes. Nuclear membranes were broken mechanically using a douncer and 
cytoplasm was removed after centrifugation of the homogenized cells at about 200–
1000g. Pellet was resuspended in NEX B buffer to a final salt concentration of 0.27M 
and rocked at 4°C for a minimum time of 30 minutes. Finally, samples were centrifuged 
at 16000g and protein concentration of supernatants was determined using Bradford 
reagent (BioRad). 
 
2.4.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) 
 
Protein were separated on an SDS–PAGE using either a maxi–gel system from Hoefer 
or the mini–gel system from Bio–Rad. Depending of the size of the protein, 
either 12–15% 170:1 acrylamide/bisacrylamide gels or 17% 85:1 
acrylamide/bisacrylamide gels were used. For electrophoresis, proteins were mixed 1:6 
with 6x loading buffer, heat denatured at 95°C and loaded onto the gel. Proteins were 
separated applying a current of 25mA for the mini–gels and 35mA for the maxi–gels. In 
both cases the running buffer was 1x TGS. The maxi–gels were connected to a cooling 
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system. For molecular weight determination, unstained marker was run in parallel (Bio–
Rad, SDS–PAGE standards Low Range, Cat. No. 161–0304; Bio–Rad, SDS–PAGE 
standards High Range, Cat. No. 161–0303). Following electrophoresis, proteins were 
stained with Coomassie Brilliant blue G250 or subjected to Western blotting. 
 
Table 8. Components for different percentages of SDS PAGE 
 
 12% 15% 17% stacking gel 
GelA (Roth, Cat.N.3037.1) 4ml 5ml 5.7ml 1.7ml 
GelB (Roth, Cat.N.3039.1) 0.35ml 0.44ml 1ml 0.7ml 
1.5M Tris–HCl (pH 8.8 RT) 2.5ml 2.5ml 2.5ml  
1M Tris–HCl (pH 6.8 RT)    1.25ml 
H2O 3ml 2ml 0.8ml 6.2ml 
10% SDS 0.1ml 0.1ml 0.430 0.1ml 
30% APS 23µl 23µl 23µl 35µl 
TEMED 6µl 6µl 6µl 16µl 
 
2.4.3 Western blot  
 
Protein extracts were separated on a polyacrylamide gel (12–15%; Laemmli, 1970) and, 
by the use of a Semi–Dry Transfer Cell (Bio–Rad, Trans–Blot SD), transferred for 1hour 
at 15 Volts to a nitrocellulose membrane (Bio–Rad, Cat. No. 162–0115) which was then 
stained with red ponceau solution to confirm the transferring of the proteins to the 
membrane and to evidence the bands of the protein marker (High range or Low range, 
Bio–Rad). The membrane was blocked with 6% milk/TBS for a minimum of 90 minutes 
and probed using MED7 or MED25 rat monoclonal or ER rabbit policlonal primary 
antibodies in 1%milk/TBS–T (Tween 0.02%) for a minimum of 1 hour. The membrane 
was then washed 3 times for 10 minutes with TBS–T buffer and incubated for 30 
minutes with anti–rat or anti–rabbit IgG–horseradish peroxidase (HRP) conjugates 
(Promega) as secondary antibodies. After washing the membrane with TBS–T as 
mentioned above, the membrane was quickly rinsed with TBS and with water. To detect 
protein bands the membrane was treated with an enhanced chemiluminescence 
detection system (Perkin Elmer, Western Lightning Cat. No. NEL105) according to the 
manufacturer's instructions and exposed to a BioMax MR film (Kodak, Cat. No. 873 
6936).  
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2.4.4 Immunoprecipitation of MED25 derivatives with MED15 antibody 
 
MED25 deletion constructs or mutants were in vitro expressed and labelled with [S35]–
Methionine (10 or 15mCi/ml, Amersham) using the TNT Coupled Retyculocite Lysate 
System kit (Promega, Cat. No. L4611), according to the manufacturer's instructions. 3–
5µl of each synthetized construct were resolved in a SDS PAGE gel where the protein 
were fixed by Coomassie staining for a minimum of 1 hour followed by distaining. To get 
dried, gels were alternatively framed in between cellophane films at RT overnight or 
further incubated in water containing 10% glycerol, placed on top of a wheat piece of 
thick Whatman paper and dried on a gel drier for 90 minutes at 80°C. Expression of the 
radioactive proteins was checked by phosphoimaging or autoradiography. For the 
preparation of the chromatography column MED15 rat monoclonal antibody was 
immobilized on protein G–Sepharose (Amersham, Protein G Sepharose Fast Flow, Cat. 
No. 17–0618–03) at a concentration of about 1µg/µl as follows. In a 50ml falcon tube 
300µl of protein G were washed two times with water and two times with PBS. 50ml of 
the hybridoma supernatant were added to the beads and left on the roller at room 
temperature from a minimum of 4 hours to overnight. After removing the antibody, the 
beads were again washed with PBS for 3 times and left in PBS containing 0.01% 
Sodium Azide for storage at 4°C. For the IP, beads were pre–washed with PBS and 
then equilibrated with BC buffer 150. 10µl of MED15 coupled beats were then incubated 
overnight at 4°C with normalized amount of each deletion construct or with 5µl of each 
mutant together with 100µl of HeLa nuclear extracts (about 800µg), at 0.15M salt, with 
addition of phosphatase inhibitors. Full–length wild type MED25 construct incubated with 
an Isotype antibody was used as control to show the specificity of the method, and HeLa 
nuclear extract alone was used as positive control for the presence of Mediator. Beads 
were then precipitated, washed four times at 0.45M salt (with BC buffer 450) and once 
at 0.15M salt (with BC buffer 150). Proteins were then eluted with 20µl of 2x SDS 
sample buffer, resolved by SDS PAGE and finally transferred into a nitrocellulose 
membrane which was then analysed either by western blot or by autoradiography while 
exposing it to a BioMax film for about 3 days at –80°C. For ER–MED25 and ER–
MED25–NTD coimmunoprecipitation, 500µg of 0.15M nuclear extract isolated from 
transiently transfected HEK293T cells and 721– ER– MED25–NTD cells respectively 
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were incubated overnight at 4°C with 10µl of MED15 antibody coupled beads. After five 
washes with BC buffer 150, beads were boiled in 20µl of 2x SDS sample buffer and the 
samples loaded into a gel and analysed by western blot. 
 
2.4.5 Immunoprecipitation of flag–MED25(A335V) with FLAG–M2 antibody 
 
Flag M2 mouse monoclonal antibody (SIGMA) was immobilized on protein G–
Sepharose at a concentration of 2µg/µl, as described in the paragraph 2.4.4 for MED15 
antibody. 500µg of nuclear extract prepared from transiently transfected HEK293T 
overexpressing flag–MED25 (A335V) mutant were diluted to 150mM salt and incubated 
overnight at 4°C with 10µl of Flag antibody coupled beads also previously equilibrated 
with BC buffer 150. Nontransfected cells derived nuclear extract and naked beads were 
used as negative controls. After washing the beads five times with BC buffer 150, 
proteins were eluted with 20µl of 2x SDS sample buffer, resolved by SDS PAGE and 
analysed by Western blot.  
 
2.4.6 Expression and purification of GST–VP16 derivative proteins 
 
Recombinant GST–VP16H1 and GST–VP16H1mut were expressed in BL21 E.coli 
expression strain using expression plasmids encoding the desired protein. An overnight 
starter culture was diluted to an OD600 of 0.1 into 200 ml LB medium and grown at 
37°C. At an OD600 corresponding to 0.6–0.8 the expression of the protein was induced 
by addition of 0.5mM IPTG. To prevent the formation of inclusion bodies the E.coli 
culture was shifted to 30°C for 2–6 hours. Cells were harvested by centrifugation for 15 
minutes at 3.500 rpm (4°C). All the following purification steps were carried out at 4°C. 
Cells were resuspended in 10ml of lysis buffer and lysed by incubation with 10mg of 
Lysozyme for 10 minutes. Samples were then placed in an ice–water bath and sonified 
using the microtip and an output amplitude of 30% for a total time of 2 minutes with a 
repetitive cycle of 10 seconds On–time and 50 seconds Off–time. The lysate was 
cleared by centrifugation for 10 minutes at 10.000 g (4°C). In the mean time, 200µl of 
Glutathione–Sepharose 4B (Amersham, Cat. No. 17–0756–01) were washed and 
equilibrated in Lysis–buffer. The lysate was incubated together with the beads for 90 
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minutes at 4°C on a rotating wheel to allow binding of the fusion protein to the matrix. 
The supernatant was removed and the remaining beads were subsequentially washed 
with 100 volumes of BC2000 and BC150 buffer. The immobilized fusion proteins were 
eluted upon incubation with 500µl of elution buffer for 10 minutes at 4°C. For quality 
control, an aliquot was analyzed in a Coomassie stained SDS–PAGE gel. 
 
2.4.7 GST–VP16 pull down 
 
As previously described (2.4.4) MED25 mutants were S35 labelled and expressed in vitro 
using the TNT Coupled Retyculocite Lysate System kit. After having controlled the 
protein expression via autoradiography on a dried SDS PAGE gel, 5µl of each mutant 
were diluted in 210µl of HEGN 100 buffer with the addition of 1mM DTT and 0,2mM 
PMSF and incubated overnight at 4°C together with 10µl of GST– VP16H1 or GST–
 VP16H1mut (as a negative control) beads, previously equilibrated with HEGN 100 
buffer. Beads were then precipitated, washed five times with the same incubation buffer, 
boiled in 20µl of 2x SDS sample buffer and analysed by SDS PAGE. Gels were then 
Coomassie stained, distained and incubated with a 10% glycerol solution for 30 minutes, 
placed on top of a wheat piece of thick Whatman paper and dried on a gel drier for 90 
minutes at 80°C. Protein bands were revealed by exposing the gels to BioMax films for 
about 3 days at –80°C. 
 
2.5 Mouse keeping 
 
Mice were kept in the mouse facilities of GSF, Neuerberg. Chimeras generated after 
blastocyst injection of MED25 homologous recombinant ES cells were mated with 
C57BL/6 wild type mice in order to produce germ line transmitted offspring. 
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3. RESULTS 
 
3.1 Structure–function analysis of MED25 
 
MED25 is a 103kD protein composed of 754 amino acids. It was originally identified as a 
cofactor activity necessary for transcriptional activation by the prototypic acidic herpes 
simplex activator VP16 in a purified RNA polymerase II transcription system. Using the 
activation domain of VP16 immobilized on a column the protein was purified to 
homogeneity by affinity chromatography and sequenced by N–terminal Edman 
degradation (Mittler et al., 2003). The analysis of the primary sequence of MED25 
revealed the existence of two evolutionary conserved domains (figure 9A).  
 
The VWA domain, resembles the "A" domain of the Willebrand factor. The predicted 
secondary structure of the MED25 VWA domain (indicated in figure 9A with stretches of 
"h" and "e") is related to the corresponding fold of the VWA domain of integrin CD11a; 
its X–ray structure is shown in figure 9B. The second conserved domain, the so–called 
ACID (activator interaction domain), shows sequence homology to a functional domain 
of the gene product of the prostate cancer overexpressed gene (PTOV–1), which 
contains two copies of the ACID domain. (Mittler et al., 2003). Figure 9C represents a 
schematic view of the domain organization of MED25. The VWA domain is localized in 
the N–terminal part of the protein, from amino acid 17 up to amino acid 226. The amino 
acids 389–543 encode the ACID domain of MED25. 
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Figure 9. MED25 contains two functional domains, the VWA domain and the ACID domain. (A) Alignment 
of human, mouse, Fugu, Drosophila, and Ciona MED25 blocks of conserved sequences. Identities are 
indicated in blue, conserved changes in red and yellow. (B, p.79) X–ray structure of the VWA domain of 
integrin CD11a. On the surface are located the two specific regions (SR1 and SR2). (C, p.79) Schematic 
representation of MED25. The VWA domain includes amino acids 17–226, ACID domain includes amino 
acids 389–543. 
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3.1.1 Mapping of a minimal Mediator–interaction domain 
 
After the identification of ACID as the VP16–interaction domain (Mittler et al., 2003), the 
structural study of MED25 was continued in an effort to find the minimal portion of 
MED25 capable of binding Mediator. Therefore, [35S]–methionine–labelled MED25 
deletion constructs were expressed in reticulocytes, complemented with HeLa nuclear 
extracts as a source for the limiting human Mediator and immunoprecipitated with an 
anti–MED15 monoclonal antibody (6C9), which recognizes the Mediator subunit MED15 
with high specificity. Incorporation of MED25 derivatives into Mediator was monitored by 
autoradiography. As shown in figure 10, MED251–226 coprecipitated efficiently with 
Mediator (lane 4). Using C–terminally extended MED25 deletion constructs, MED251–290, 
MED251–393, MED251–543 and MED251–715, a similar result was obtained (lanes 5–7 and 
12). In contrast, MED25 derivatives missing partially (lanes 2, 3, 8, 11) or completely (1, 
9, 10) the VWA domain did not coprecipitate with Mediator. These data suggest that an 
intact VWA domain is required and sufficient for interaction of MED25 with Mediator. 
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1 226 389 543 75417
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Figure 10. The MED25 VWA domain is the minimal domain required for Mediator–interaction. (A) MED25 
deletion constructs used in this experiment. (B) Upper panel, autoradiography of the immunoprecipitation 
assay. MED25 deletion constructs were translated in reticulocytes, radiolabelled with 35S, incubated with 
HeLa nuclear extract and immunoprecipitated with MED15 antibody. HeLa nucelar extract alone and an 
isotype antibody were used as control (lanes 13 and 14). As a positive control MED25 (1–715) was used 
(lane 12). Only the constructs carrying an intact VWA domain were coprecipitated (lanes 4–7). Bottom 
panel, western blot analysis of the same membrane, probed against the Mediator core subunit MED7 to 
monitor levels of coprecipitated Mediator.  
 
 
3.1.2 Transcription activation analysis of MED25 deletion constructs 
 
Since MED25 was shown to physically interact with both Mediator and VP16, which are 
involved in transcriptional activation, the question was addressed whether MED25 
harbours an intrinsic transcription activation domain. Towards this end, MED25 deletion 
mutants fused to a GAL4 DNA binding domain were cloned and their expression was 
confirmed by Western blot analysis of nuclear extracts isolated from transiently 
transfected 293T cells (data not shown). The same constructs were then expressed in 
Jurkat cells by transient transfection including the luciferase reporter pGLRMG5 which 
carries five GAL4 binding sites (figure 11B). 48 hours post–transfection cells were 
harvested and cell lysates were subjected to a luciferase assay. The measured relative 
luciferase units of the reporter alone control was used as a reference to calculate fold 
activation rate of the MED25 mutants.  
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Figure 11. MED25 contains an activation domain. (A) Functional assay to investigate MED25 intrinsic 
transcription activation capability. MED25 deletion constucts fused to a GAL4–DNA–binding domain 
(GAL4–DNA–BD) were transfected in Jurkat cells together with a luciferase reporter fused to a promoter 
carrying 5 GAL4 binding sites. On the left site, the MED25 deletion construct used in this assay are 
depicted. On the right site, the fold activation of each construct was calculated normalizing luciferase 
levels to the β–gal activity, and setting the reporter alone control (pGLRMG5) to 1. (B) Schematic view of 
the pGLRMG5 reporter used in this assay. (C) Schematic view of MED25 and the identified functional 
domains, the VWA domain interacting with Mediator, the ACID domain interacting with VP16 and a 
presumptive intrinsic transcription activation (TA) activity included in between amino acids 290 and 715. 
 
As depicted in figure 11A, the construct MED1–290 (lane 3), carrying only the Mediator 
interaction domain, activates transcription very likely through the binding and recruitment 
of Mediator to the promoter. The fold activation levels induced by the other VWA–
containing constructs show that the potential for transcriptional activation of MED25 is 
partially dependent on the C–terminal amino acids 290–715 since the gradual extension 
of the MED25 C–terminus results in a modest but robust increase in reporter activity 
(lanes 4–6). Surprisingly, transcriptional activation was still present even after removal of 
the Mediator binding domain (lanes 8–12) pointing towards a possibly alternative 
Mediator–independent transcription activation mechanism. In these constructs deletion 
of amino acids 290–393 of MED25 results in a decrease of transcriptional activation 
(lanes 11–12) and the additional removal of the ACID domain leaves only a residual 
transcriptional activation capacity to the MED543–715 construct (lane 13). Rather 
unexpected was the observation that the transactivation capacity of the MED1–715 
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construct is significantly stronger than the one of the full–length construct MED1–754 
(lanes 6–7). A possible explanation for this phenomenon is that the last 39 amino acids 
are subject to a modification which negatively regulates the protein.  
In conclusion the data presented here provide evidence for an intrinsic capacity of 
MED25 to activate transcription. The region responsible for this activity is located in 
between amino acids 290 and 715. Whether this region is additionally organized in sub 
domains (amino acids 290–393, ACID domain, amino acids 543–715) that act 
independently from each other or cooperate with each other to activate transcription is 
still not yet clear and needs to be further investigated.  
 
3.1.3 Site–directed mutagenesis of MED25 ACID and VWA domain 
 
To identify critical residues involved in the interaction of MED25 with its binding partners, 
a series of 19 different GAL4–fused MED25 variants containing point mutations were 
generated. Ten of them are localized within the VWA domain, eight in the ACID domain 
and one at the C–terminus of the protein (figure 12A). In figure 12B the relative position 
of the point mutations within the primary sequence of MED25 is indicated.  
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Site–directed mutagenesis of two MED25 functional domains VWA and ACID. (A) The 
introduced point mutations are listed on top of the domain in which they are located. (B, p.83) Distribution 
of the mutations relative to the primary sequence and and its conservation through evolution. Black dots 
indicate the amino acids targeted for point mutations.  
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In general, regarding the VWA domain, amino acids that were conserved throughout 
evolution and therefore possibly relevant for the function of the protein were targeted. Of 
particular interest are the amino acids localized in the corresponding specific region 2 
(SR2) of the VWA domain represented in the X–Ray structure of CD11a (figure 9B). 
This region is characterized by a loop, which was shown to share little homology within 
the group of other VWA proteins but which is highly conserved through evolution. This 
indicates a possible involvement of the SR2 region in a critical function of MED25, which 
could be the interaction with Mediator or an unknown function (Mittler et al., 2003).  
In order to study the interaction of the ACID domain with VP16 the following facts were 
considered for the selection of the amino acids to be mutated. First, the ACID domain 
binds to a highly acidic viral activator probably through positively charged residues. 
Second, it has been reported that aromatic residues within the activation domain of 
VP16 are critical for activation of transcription and for binding to its targets. Based on 
this knowledge particular attention was paid to amino acids that are positively charged 
or aromatic. More detailed information regarding mutagenesis design is found in table 9. 
 
Table 9. Amino acid residues mutated in the VWA domain and in the ACID domain of the human MED25 
protein. 
 
NAME CRITERIA FOR MUTATION DOMAIN 
VVFV18/21LVFL changed to the corresponding CD11a sequence VWA 
Y39A conserved through evolution VWA 
F47A conserved through evolution VWA 
Y66A conserved through evolution VWA 
F125A conserved through evolution VWA 
T138A conserved through evolution VWA 
Y151A conserved through evolution, located in the SR2 region, 
predicted phosphorylation site 
VWA 
Y161A conserved through evolution and located in the SR2 
region 
VWA 
RK186/187AA conserved through evolution  VWA 
HMVL219/221/222AMAA conserved through evolution VWA 
W408A conserved through evolution and aromatic ACID 
KT440/441AA positively charged and hydrophilic/neutral ACID 
WPQK444/447APQA aromatic and positively charged ACID 
FR465/466AA aromatic and positively charged ACID 
FHF473/474/475AAA aromatic and positively charged ACID 
YR487/488AA aromatic and positively charged ACID 
KKIF519/520/522AAIA positively charged and aromatic ACID 
LRSLL646/649/650ARSAA nuclear–receptor box motif (LXXLL) confers binding to 
nuclear receptors 
C–terminal 
region 
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3.1.3.1 Dissection of the Mediator–interaction domain of MED25 using VWA point 
mutants 
 
In order to identify critical amino acid residues involved in Mediator–binding, MED25 
derivatives carrying mutations in the VWA domain were tested for their potential to 
physically interact with Mediator. For this purpose an immunoprecipitation assay was 
performed. These data were combined with a functional study in an effort to understand 
if and how changes of the physical interaction between MED25 and Mediator would 
influence the transcription activation potential of MED25. 
 
Figure 13. Investigation of MED25 residues critical for the  Mediator–interaction. (A) Autoradiography 
(AR) and Western blot analysis (WB) of the immunoprecipitation assay. MED25 point mutants were 
translated in reticulocytes, radiolabelled with 35S, incubated with HeLa nuclear extract and 
immunoprecipitated with MED15 antibody. HeLa nucelar extract alone (lane 22), an isotype antibody 
(lanes 10 and 23) and MED25290–754 construct (lane 24) were used as controls. As a positive control 
MED25 wild–type was used (lanes 9 and 21). To monitor levels of coprecipitated Mediator the membrane 
was probed with an antibody, which recognizes the Mediator core subunit MED7. (B) Input of the MED25 
point mutants used in the immunoprecipitation assay. (C) Transcription activation analysis to test whether 
the mutations interfere with MED25 intrinsic transcription activation capability. MED25 point mutants were 
fused to a GAL4–DNA–binding domain (GAL4–DNA–BD) and transfected in Jurkat cells together with 
pGLRMG5 luciferase reporter. The fold activation rate of each mutant was calculated normalizing 
luciferase levels to the β–gal activity, and using the wild–type control as a reference. 
B
0
1
2
3
4
5
6
7
GA
L4
-S
p1
FH
F4
73
AA
A
W
PQ
K4
44
AP
QA
W
40
8A
KK
IF5
19
AA
IA
LR
SL
L6
46
AR
SA
A
YR
48
7A
A
FR
46
5A
A
KT
44
0A
A
W
T
HM
VL
21
9A
MA
A
Y1
51
A
Y1
61
A
F4
7A
Y6
6A
Y3
9A
RK
18
6A
A
F1
25
A
T1
38
A
VV
FV
18
LV
FL W
T
fo
ld
 a
ct
iv
at
io
n 
re
la
tiv
e 
to
 W
T
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21
ACID domain VWA domain
MED7 (WB)
MED25 (AR)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
FH
F4
73
AA
A
W
PQ
K4
44
AP
QA
W
40
8A
KK
IF5
19
AA
IA
LR
SL
L6
46
AR
SA
A
YR
48
7A
A
FR
46
5A
A
KT
44
0A
A
W
T HM
VL
21
9A
MA
A
Y1
51
A
Y1
61
A
F4
7A
Y6
6A
Y3
9A
RK
18
6A
A
F1
25
A
T1
38
A
VV
FV
18
LV
FL
W
T CO
NT
RO
LS
CO
NT
RO
L
A
C
1 2 3 4 5 6 7 8 9
11 12 13 14 15 16 17 18 19 20 21 22
RESULTS  86 
Physical interaction analysis 
In analogy to the initial MED25–deletion analysis (see 3.1.1), VWA–domain–MED25 
point mutants were in vitro translated in reticulocyte lysates, radiolabelled with 35S, 
incubated with HeLa nuclear extract and tested for binding to Mediator via 
immunoprecipitation using the anti–MED15 monoclonal antibody 6C9. In this assay the 
ACID–domain–MED25 point mutants designed for the VP16–interaction study (see 
3.1.3.3) were employed as a positive control. In fact, since the ACID domain is not 
involved in the binding of MED25 with Mediator (figure 10) these mutants should 
efficiently coprecipitate with Mediator. After immunoprecipitation, proteins were resolved 
in a SDS gel and transferred into a nitrocellulose membrane. To confirm that Mediator 
was successfully immunoprecipitated the lower part of the membrane was probed 
against an antibody, which specifically recognizes another subunit of Mediator, MED7. 
The rest of the membrane was analysed by autoradiography. In figure 13A the upper 
bands (MED25 AR) correspond to MED25 mutants which were coprecipitated with 
Mediator and are therefore detected by autoradiography. Underneath, the bands of 
MED7 visualized by western blot (MED7 WB) monitor levels of coprecipitated Mediator.  
Among the mutations made in the VWA domain only two, Y151A and T138A, seem not 
to affect Mediator interaction (lanes 12 and 19). Moreover, the mutant Y151A rather 
shows a stronger incorporation in Mediator as compared to the WT construct (lane 12 
versus 21). As expected, the mutations in the ACID domain were not influencing 
Mediator interaction (lanes 1–9). As a negative control the construct 290–754 lacking 
the VWA domain (lane 22) and an isotype antibody (lanes 10 and 23) were used. In 
figure 13B the input signals of the MED25 derivatives used in this experiment are 
shown.  
 
Transcription activation analysis 
To be able to correlate structural and functional aspects of the VWA domain, the MED25 
mutants used in the chromatoghraphy assay described above were also employed in a 
transcriptional activation assay. Therefore, MED25 point mutants fused to a GAL4 DNA 
binding domain were transiently transfected in Jurkat cells and tested on a luciferase 
reporter carrying five GAL4 binding sites as previously described (paragraph 3.1.2). 
Nuclear extract was isolated from part of the transfected cells and analyzed by Western 
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blot to confirm the expression of the MED25 mutants (data not shown). Figure 13C 
shows the fold activation rate of each point mutant calculated relatively to the MED25 
wild type construct. Except for the mutants Y151A and T138A the fold activation rate of 
all the other VWA–domain point mutants was reduced to basal levels (lanes 11, 13–
18, 20). While the fold activation of T138A was only slightly reduced (lane 19) the 
mutant Y151A showed a striking increase of activity (lane 12). Since Y151 is a predicted 
phosphorylation site, the assumption was made that phosphorylation of the tyrosine may 
negatively regulate the interaction of MED25 with Mediator. Alternatively, the 
substitution of a bulky residue (tyrosine) with a smaller one (alanine) may simply favor 
binding. Replacement of the same tyrosine with a phenylalanine could help to clarify this 
unresolved issue. 
The ACID–domain mutants previously employed in the binding assay were used in this 
transcription activation study as well. Among them, YR487AA, FR465AA and KT440AA 
were performing similar to wild–type (lanes 6–8), while the mutants FHF473AAA, 
WPQK444APQA, W408A and KKIF519AAIA showed impaired capability to activate 
transcription with fold activation rates 40 to 50% reduced as compared to the wild type 
construct (lanes 1–4).  
 
For most of the VWA–domain point mutants the data collected so far showed that 
impaired Mediator–interaction was associated with dramatic loss of transcription 
activation potential. The results of our previous functional study using MED25 deletion 
constructs, however, indicate that a residual intrinsic activation capacity is retained even 
after complete loss of Mediator interaction (figure 11, lanes 8–12). Very likely in several 
instances these effects result from a collapsed structure. This is suggested by the 
location of some of the targeted residues in predicted structured regions (figure 12B). 
Assuming that the structure of the VWA domain collapses upon changes of its 
conserved residues could help to explain the unexpected effects observed for the VWA–
domain mutants in our functional assay. One hypothesis would be that the unstructured 
VWA domain becomes highly flexible therefore affecting the capability of the intrinsic 
transcriptional activation domain (290–715) to interact with other factors. However this 
hypothesis still needs to be validated. 
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Hence, additional amino acid residues located in the non–structured SR2 region and in 
the surrounding area were targeted. Altogether, seven additional VWA–domain–MED25 
point mutants were designed that are located in this region. Depicted in figure 14 is a 
detail of the primary sequence of the VWA domain which includes the specific region 2 
(SR2). Black dots indicate the amino acid residues targeted for the generation of a 
second series of VWA–domain–MED25 point mutants.  
 
 
 
 
 
 
 
 
 
 
Figure 14. Generation of a second series of VWA–domain–MED25 point mutants. For the identification of 
amino acids critical in the Mediator–interaction new mutants were designed that are located in the SR2 
region or in its proximity. 
 
E157, E167 and E175 were chosen because glutamate is commonly found on the 
protein surface and involved in protein–protein interaction. Q137 is highly conserved 
throughout evolution in MED25 homologs but not at all among different VWA proteins 
(supplementary figure 1). Therefore it may represent an amino acid which has a 
MED25–specific function rather than a function associated to VWA–domain–containing 
proteins. T138, Y151 and Y161 mutated to alanine in a first approach (see above), this 
time were replaced by aspartate and phenylalanine respectively, which are 
characterized by similar sterical properties as compared to the wild–type amino acids. In 
particular, the substitution of the hydroxylated aromatic ring of Y151 with a 
phenylalanine was meant to elucidate whether phosphorylation or alternatively the 
sterical characteristics of the amino acid may affect the binding of MED25 with Mediator. 
In analogy with the study done with the first series of point mutants, the same assays 
were employed for the analysis of the new MED25 derivatives. 
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Figure 15. Investigation of MED25 residues critical in the Mediator–interaction using MED25 derivatives 
mutated in the SR2 region of VWA domain. (A) Autoradiography (AR) and Western blot analysis (WB) of 
the immunoprecipitation assay. MED25 point mutants were translated in reticulocytes, radiolabelled with 
35S, incubated with HeLa nuclear extract and immunoprecipitated with MED15 antibody. HeLa nucelar 
extract alone (lane 10), an isotype antibody (lane 9) and MED25290–754 construct (lane 11) were used as 
controls. As a positive control MED25 wild–type was used (lane 8). To monitor levels of coprecipitated 
Mediator the membrane was probed to an antibody which recognizes the Mediator core subunit MED7. 
(B) Input of the MED25 point mutants used in the immunoprecipitation assay. (C) Transcription activation 
analysis to test whether the mutations interfere with MED25 intrinsic transcription activation capability. 
MED25 point mutants were fused to a GAL4–DNA–binding domain (GAL4–DNA–BD) and transfected in 
Jurkat cells together with pGLRMG5 luciferase reporter. The fold activation of each mutant was calculated 
normalizing luciferase levels to the β–gal activity using the wild–type control as a reference. 
 
Physical interaction analysis 
MED25 point mutants were expressed and radioactively labelled in retyculocites as 
previously described. Figure 15B shows the input signals of the in vitro expressed 
proteins used for the immunoprecipitation assay. These constructs were loaded on an 
anti–MED15 associated chromathography column to test their Mediator–interaction 
capability and finally analyzed by autoradiography (figure 15A). As a negative control the 
construct 290–754 lacking the VWA domain (lane 11) and an isotype antibody (lane 9) 
were used. Beside E157R (lane 4), all the other constructs were coprecipitated, even 
though the coprecipitation of mutants T138D and Y161F seemed to be dramatically 
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affected (lanes 2, 5). Of interest, the replacement of T138 with an alanine was basically 
not affecting the binding (figure 13B, lane 19). This may underline the importance of an 
hydrophobic residue in this position for the binding with Mediator. The amino acid Y161 
could be additionally critical for VWA domain structure. Its replacement with alanine 
provoked a complete loss of Mediator binding (figure 13B, lane 13) while mutation into 
another aromatic residue still shows binding, although very weak. Stronger bands were 
observed for Q137A and Y151F. However, while the effect displayed by the mutant 
Y151A may be due to an excessive load compared to the other coprecipitated mutants, 
this is not the case for the mutant Q137A (figure 15B). 
 
Transcription activation analysis 
As previously described for other MED25 derivatives, the newly generated VWA–
domain–MED25 point mutants were also transiently transfected in Jurkat cells together 
with the GAL4–luciferase reporter pGLRMG5 to test their capability to activate 
transcription. The transcriptional assay provided evidence for reduction of fold activation 
at least for some of the mutants that showed impaired binding to Mediator (lanes 2 and 
5). Interestingly, E157R mutant only showed a slightly reduced transactivation capacity, 
despite its complete loss of binding to Mediator (lane 4). These observations, in 
accordance with the fact that a MED25 deletion construct missing the first 290 amino 
acids remains active (figure 11A, lanes 8–10), argue for a critical role for amino acids 
T138, Y161 and in particular E157 in Mediator complex formation. The transcriptional 
activation capabilities of the mutants E167A and ER175/176AA were almost not affected 
(lanes 6 and 7). The change of Y151A into Y151F (lane 3) reduced the activation rate to 
wild–type level reinforcing the hypothesis that the gain of function observed in the case 
of Y151A (figure 13, lane 12) was probably the consequence of a more efficient 
Mediator–interaction capability associated with a smaller residue. The two fold increase 
of transcriptional activation observed for the mutant Q137A may also be explained with 
the substitution of a bulky residue by a smaller one, which apparently causes also a 
more efficient coprecipitation of the mutant together with Mediator (lane 1). 
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In summary, from the data presented here we can conclude the following: 
i) Among the VWA–MED25 mutants HMVL219AMAAA, Y161A, F47A, Y66A, Y39A, 
RK186AA, F125A and VVFV18LVFL have completely lost the capability to physically 
interact with Mediator and the capability to activate transcription as compared to the wild 
type construct. However, whether this effect is specific for Mediator–interaction or only 
the consequence of the collapse of VWA domain structure still needs to be clarified.  
ii) In the SR2 region, mutants T138D, Y161F and E157R show impaired or no Mediator 
complex formation while they still have a capability to activate transcription probably 
associated to the 290–715 region. E167A and ER175/176AA mutants are only slightly 
affected in both binding and transcriptional assays as compared to the wild type. Mutant 
Y151A displays a stronger Mediator–interaction which associates with a significant 
increase of the transactivating function. A similar phenomenon was observed for the 
mutant Q137A. The loss of function in the case of Y151F argues for improvement of the 
physical interaction when the tyrosine is replaced by alanine and indicates that Y151 
and probably also Q137 may negatively regulate the association with Mediator .  
iii) Concerning the ACID–MED25 mutants, all show binding to Mediator as expected. 
While the mutants YR487AA, FR465AA and KT440AA are comparable to the wild type 
in the transcriptional assay, mutants FHF473AAA, WPQK444APQA, W408A and 
KKIF519AAIA show impaired transactivation capacity. This observation supports the 
data previously presented (figure 11) where contribution of the ACID domain to the 
intrinsic transcription activation domain of MED25 is hypothesized. 
 
3.1.3.2 Study of the transcriptional activation function of MED25 point mutants 
with respect to their expression levels 
 
To rule out the possibility that the fluctuations of activation rates observed in the 
transcriptional assay are due to different expression levels of the constructs, some of the 
VWA–domain MED25 point mutants were chosen as representative examples for 
normal (WT), very high (Y151A) and very low (RK186A) transcriptional activation 
potential. Therefore HEK293T cells were transiently transfected with titrated amounts of 
these constructs along with the luciferase reporter pGLRMG5. Cells were processed 
partially for luciferase assays (figure 16B) and partially for isolation of the nuclear 
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extract, in which the expression levels of the proteins were analyzed by Western blot 
using an antibody against MED25 (figure 16A).  
 
 
Figure 16. Intrinsic transcription activation capability of MED25 mutants with respect to their expression 
levels. Titrated amounts (60ng, 300ng and 600ng) of each GAL4–tagged MED25 point mutant and 
MED25 wild–type were transfected in HEK293T cells together with pGLRMG5 luciferase reporter (A) 
Western blot analysis of nuclear extracts using monoclonal antibodies against MED25 and against the 
Mediator core subunit MED7. (B) The activation rate of each MED25 construct was calculated normalizing 
luciferase levels to the β–gal activity, using the reporter alone (pGLMRG5) as a reference. 
 
An antibody against another subunit of Mediator, MED7, was used as internal control for 
protein expression levels. Lanes 3, 6, and 9, which correspond to transfected amounts 
of GAL4–construct versus luciferase–reporter in the same ratio as used previously 
(figure 13C), show the activation rates of Y151A and RK186AA relative to WT are 
reproduced as compared to figure 13. The Western blot analysis (figure 16A) shows 
efficient nuclear transport for each of the constructs (the weaker signals corresponding 
to the lanes 8–10 seem to be rather due to a lower amount of nuclear extract that were 
loaded).  
These data demonstrate that the different activation levels of different MED25 mutants 
are not related to different protein expression levels or variations in nuclear transport 
efficiency.  
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3.1.3.3 Dissection of the VP16–interaction domain of MED25 using ACID–domain–
MED25 point mutants 
 
To monitor the physical interaction of MED25 with VP16, MED25 full–length constructs 
mutated in the ACID domain were translated and labelled by [35S]–methionine in 
reticulocyte lysates and subjected to chromatograpy on a GST–VP16–H1 column. H1 
represents one of the two subdomains within the VP16 activation domain. Both, the H1 
and the H2 subdomains of the VP16 activation domain have been shown to bind the 
ACID domain of MED25 (Mittler et al., 2003). However, only H1 has been used in this 
study. The corresponding VP16–H1–mut derivative carrying a point mutation (F442P) 
within the H1 subdomain was used as negative control (figure 17A, bottom panel). As an 
additional control a MED25 deletion construct was used lacking the ACID domain 
(MED251–290), which showed no binding to the VP16 activation domain (figure 17A, lane 
10 and figure 17B, lane 11) (Mittler et al., 2003). In addition to the ACID–domain–
MED25 mutants designed according to the primary sequence (table 9), another series of 
mutants were used to test the VP16 interaction, which were originally designed and 
generated in Cramer's laboratory by S. Baumli. These mutants, KKD411AAA, 
EKE437AAA, K478A, KKK518AAA and WT are expressing human ACID domain point 
mutants and wild type, respectively (lanes 12–16). Moreover, the ACID2.1 and ACID2.2 
domains of the PTOV1 protein (lanes 17 and 18) were included in this study. Figure 17A 
shows the autoradiography of the pull down experiment carried out with the MED25 full–
length point mutants. Figure 17B shows the results obtained using wild type and point 
mutants of the MED25 ACID domain only. The position of the targeted amino acid 
residues is shown in figure 17C relative to the conservation of the ACID domain 
troughout evolution and in different proteins (MED25 and PTOV1).  
Regarding the full–length MED25 derivatives (figure 17A), the mutations YR487AA, 
FR465AA and KT440AA (lanes 6–8) located in the ACID domain and the 
LRSLL646ARSAA (lane 5) located in the C–terminus, do not seem to affect the binding 
to VP16. In contrast to these, the mutants FHF473AAA and WPQK444APQA (lanes 1 
and 2) have lost their potential to interact with the VP16–H1 domain while the mutant 
W408A (lane 3) shows a dramatic reduction in binding to VP16. However, since these 
residues are highly conserved throughout evolution and part of predicted secondary 
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structures (figure 17D), an impact on the structure of ACID cannot be excluded after the 
conversion of aromatic/hydrophobic amino acids to alanine. The KKIF519AAIA mutation, 
positioned in a predicted non–structured part of the protein, characterized by positively 
charged and aromatic residues and also showing impaired binding to VP16 (lane 4), is 
more likely directly influencing the VP16–MED25 interaction. This hypothesis is 
supported by the fact that among the human ACID domain mutants of MED25 tested 
(figure 17B, lanes 12–16), the KKK518AAA mutant is the only one that fails to be 
precipitated by GST–VP16–H1 (figure 17B, lane 15). These results point towards a 
possible involvement of lysines 518, 519 and 520 in the binding to VP16 activation 
domain. To further investigate the contribution of these lysines in VP16 complex 
formation the ACID domains derived from another gene (PTOV1/ACID2) and therefore 
providing for natural variants in this specific region were employed (figure 17C). As 
shown in figure 17B, lysine 518 substituted by a negatively charged residue (glutamate) 
in PTOV1_B/ACID2.2, completely prevents binding to VP16 (lane 18) in contrast to 
PTOV1_A/ACID2.1 (lane 17). This observation stongly argues for a critical role for lysine 
518 in the interaction of MED25 with VP16. Since K518 is not targeted in the mutant 
KKIF519AAIA, the low effciency with which it is precipitated by VP16H1 indicates that 
the amino acid F522 very likely participates in the binding reaction, and leaves open the 
possibility that also K519, K520 may contribute. In conclusion these data indicate that 
targeting of amino acids in mutants FHF473AAA, WPQK444APQA, W408A, 
KKIF518AAIA and KKK518AAA eliminate or strongly affect the binding of the ACID 
domain to VP16H1 in vitro. These residues seem also to be relevant for intermolecular 
interactions involving the ACID domain of MED25 in vivo. In fact, constructs carrying the 
same mutations have previously displayed partial loss of transactivation capacity (figure 
13, lanes 1–4). 
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Figure 17. Investigation of MED25 residues critical for VP16–interaction using ACID–domain point 
mutants (in the context both of MED25 full–length and the ACID domain only of MED25) and single ACID 
domains of the PTOV1 protein. MED25 point mutants were translated in reticulocytes, radiolabelled with 
35S and loaded into a VP16H1 or VP16H1mut columns. MED251–290 construct was used as control. (A) 
Upper panel, autoradiography of the VP16H1 pull–down carried out using full–length MED25 point 
mutants. Bottom panel, VP16H1mut pull–down was used as negative control. (B) Autoradiography of 
VP16H1 pull–down carried out using ACID only constructs. Point mutants of the human MED25 ACID 
domain (lanes 12–16) and the two ACID domains of human PTOV1 (lanes 16–17) were used. (C) Input of 
MED25 point mutants and ACID–domain constructs of PTOV1 used in this GST–VP16H1 pull–down 
assay. (D, p.96) Distribution of the ACID mutations relative to the conservation of the ACID domain 
throughout evolution and in different proteins. Black dots indicate the residues targeted in the full–length 
protein while green triangles indicate those, which have been targeted in the ACID–domain–only 
constructs. Predicted strand and helices are shown underneath the sequence as arrows and lines, 
respectively. 
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3.2 MED25 mutation and human pathogenesis: Charcot–Marie–Tooth disease 
 
Recently, an A335V amino acid exchange in MED25 has been linked to an autosomal 
recessive variant of Charcot–Marie–Tooth disease, which represents a family of genetic 
peripheral neuropathies. Alanine 335 is located within a proline–rich region of MED25 
between the VWA domain and the ACID domain. In an unpublished study a SH3–
recognition motif of the Abelson type tyrosine kinases family was predicted in the 
corresponding region. In humans the motif is characterized by the following sequence: 
PAPQLPPGPPGAPKPPPASQPS, where the mutated alanine is underlined. In vitro 
binding experiments have been carried out using peptides with or without the mutation. 
The conclusion from these experiments is that while the wild–type peptide displays 
binding specificity for the Abl kinase, the A335V mutant shows the same binding affinity 
for the SH3 domain of both, the Abl kinase and the Src–family kinase Lck. Beause of the 
loss of binding specificity for SH3 domain proteins, the A335V mutation seems to be the 
responsible for the CMT2B2 variant of CMT disease. Here we investigate whether the 
presence of the A335V mutation would somehow affect major functional properties of 
MED25, namely transcriptional activation and Mediator–interaction capabilities, 
therefore providing alternative or additional mechanisms to explain the disease.  
 
3.2.1 Study of transcriptional activation potential and Mediator– binding capacity 
of MED25 (A335V) mutant 
 
Transcriptional activation analysis.  
In order to investigate whether the CMT mutation would result in impaired MED25 
transcription activation function, the A335V mutation was introduced into full–length 
MED25 fused to the GAL4 DNA–binding domain. The transcriptional activation potential 
of this MED25 mutant was tested in a reporter assay in Jurkat cells using the pGLRMG5 
reporter, containing five GAL4 binding sites in front of luciferase. In the reporter assay 
shown in figure 18B, increasing amount of wild–type and mutant MED25 were used. 
Luciferase values were determined and activation rates were calculated using the 
reporter alone as a reference. In order to monitor the expression levels of the wild–type 
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and mutant MED25, nuclear extracts where prepared and subjected to an immunoblot 
analysis using an anti–GAL4 DNA–binding domain antibody.  
 
Figure 18. A335V mutation does not affect the intrinsic transcription activation capability of MED25. 
Titrated amounts (0.5µg, 5µg and 10µg) of GAL4–tagged MED25(A335V) point mutant and MED25 wild–
type were transfected in Jurkat cells together with pGLRMG5 luciferase reporter (A) Western blot analysis 
of isolated nuclear extracts using an α–GAL4 antibody (B). The fold activation of MED25 constructs was 
calculated normalizing luciferase levels to the β–gal activity, using the reporter alone (pGLMRG5) as a 
reference. 
 
As shown in figure 18B, the fold activation values observed for the wild–type MED25 
were increasing from 0.5µg to 10µg of transfected expression vector (lanes 5 and 7), 
reaching a plateau already at 5µg of transfected construct (lane 6). A direct correlation 
between the amount of construct transfected and the expression levels of the 
corresponding protein in the cells was confirmed by the increasing signals in Western 
blot analysis (figure 18A, lanes 5–7). For the same amounts of transfected MED25 
(A335V) mutant expression vector, almost identical activation rates were obtained as 
compared to the wild type (figure 18B, lanes 2–4). Expression levels of the MED25 
(A335V) mutant in Jurkat cells were also in accordance to the amount of construct 
transfected (figure 18A, lanes 2–4) and comparable to the wild–type. 
1 2 3 4 5 6 7
pG
LM
R
G
5
M
E
D
25
 (A
33
5V
)
M
E
D
25
 (A
33
5V
)
M
E
D
25
 (A
33
5V
)
M
E
D
25
 W
T
M
E
D
25
 W
T
M
E
D
25
 W
T
!-GAL4
GAL4-MED25 -
0
2
4
6
8
10
12
14
16
fo
ld
 a
c
ti
v
a
ti
o
n
A
B
RESULTS  99 
Physical interaction analysis 
The MED25 (A335V) mutant does not show impaired transcriptional activation 
compared to the wild–type construct, and since the transcriptional activity of MED25 
wild–type is also related to its capability to bind Mediator, the question was raised 
wether the potential of A335V mutant MED25 to interact with Mediator was unaffected 
as well. To adress this question an immunoprecipitation assay was performed. A Flag–
antibody–coupled column was loaded with nuclear extract from HEK–293T cells 
overexpressing a Flag tagged version of the MED25 (A335V) mutant. Non–transfected 
nuclear extract and naked beads were used as negative controls (lanes 3 and 5). The 
Western blot analysis revealed that Mediator could efficiently coprecipitate with the 
Flag–tagged MED25 (A335V) mutant (figure 19, lane 4).  
 
 
3.3 Identification of MED25 target genes 
 
The in vivo function of MED25  is still an open question. Certainly, the fact that MED25 
Mediator subunit is an exclusive prerogative of higher eukaryotes can be interpreted as 
a hallmark of a specialized function rather than a general one. This hypothesis is in line 
with data recently published by Kim et al., (Kim et al., 2004), showing a specific role for 
MED25 in the transcriptional activation of the Drosophila genes Attacin A and Hsp26 in 
contrast to other Mediator subunits. The identification of genes that are specifically 
regulated by MED25 in mammals would help to understand MED25 function. MED25 
has been reported to interact with VP16 in vitro (Mittler et al., 2003). Transfection 
experiments revealed a dominant negative function for the Mediator–interaction domain 
INPUT Flag IP NO AB
 IP
1 2 3 4 5
α-MED25
α-MED7
Flag-MED25 (V335A)       -         +         -         +         + Figure 19. A335V mutation does not impair 
Mediator–interaction capability of MED25. Nuclear 
extracts isolated from 293T cells overexpressing 
Flag–tagged MED25 (A335V) mutant were 
immunoprecipitated with α–Flag antibody. 
Monoclonal antibodies against MED25 to monitor 
MED25 (A335) mutant or against the Mediator core 
subunit MED7 to monitor levels of coprecipitated 
Mediator were employed in the Western blot 
analysis. Beads only were used as a control (lane 
5).  
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(MED25–NTD). Overexpression of this domain impaired dramatically transactivation by 
another viral factor, EBNA2 (Laux, personal communication). Together these results 
indicate a possible involvement of MED25 in immune response and raise the question 
whether MED25 regulates genes that are critical in this process. 
Microarray analysis is a powerful tool to identify genes that are directly or indirectly 
regulated by a certain protein. In an attempt to learn more about the biological function 
of MED25, this approach was chosen to identify genes that were affected on a genome–
wide level. Two strategies were combined: 
i) the overexpression of MED25 in a murine cell system (NIH3T3 cells)  
ii) the overexpression of a dominant negative mutant of MED25 (MED25–NTD) 
in a human B cell line constitutively expressing the viral activator EBNA2 
(721–B–cells).  
In the first approach we set out to identify the population of genes which are regulated 
by MED25 in a normal cellular background. In this system the regulation of MED25 
target genes was expected to be enhanced by the overexpression of the ER–fusion 
protein. In the second approach we aimed more specifically to the identification of 
MED25 target genes affected in front of the background of viral infection. The use of a 
dominant negative mutant was supposed to interfere with genes regulated by MED25–
bound Mediator and with genes exploited by the viral activator EBNA2 in order to 
support the viral life cycle.  
In both cases the overexpressed proteins were fused to Estrogen Receptor Ligand 
Binding Domain (ER–LBD) in order to control the overexpression of the proteins in the 
nucleus (inducible system). This type of system offers the advantage of monitoring 
genes differentially expressed upon induction of the fusion protein at different time 
points compared to the non–induced situation (reference). Genes regulated at an early 
time point are likely to be direct target genes while genes regulated at a late time point 
are possibly indirect target genes. 
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3.3.1 Generation of an inducible cell line expressing MED25 
 
A murine cell line (NIH3T3 mouse fibroblasts) was stably transfected and selected using 
hygromycine for stable replication of an EBV vector carrying wild–type full–length 
MED25 fused to the Estrogen Receptor Ligand Binding Domain (ER–LBD) at the N–
terminal part of the protein. This LBD carries mutations that abolish the activation by 
endogenous ligands while responding activation by synthetic derivatives (Feil et al., 
1997). In this system the fusion protein is constitutively expressed but kept in the 
cytoplasm in an inactive state due to the binding of the ER–LBD to the heat shock 
protein HSP90. As soon as the cells are treated with the synthetic estrogen antagonist 
4–hydroxy–tamoxifen (OHT), ER–MED25 dissociates from HSP90 protein and 
translocates into the nucleus (figure 20A). A cell line overexpressing only ER–LBD was 
created as a negative control even though it has been reported that the transactivation 
function in the LBD is silenced by the binding to OHT (MacGregor Schafer et al., 2000). 
To monitor the translocation into the nucleus of ER–MED25 and of ER–LBD proteins, 
nuclear extracts from NIH–ER–MED25 and NIH–ER–LBD stable cell lines were 
collected before and three hours after induction with OHT and analyzed for MED25 
expression in the nucleus via Western blot analysis using a monoclonal antibody against 
MED25 (figure 20B, upper panel) or against ER (figure 20B, lower panel). These data 
were confirmed by immunofluorescence analysis using the NIH–ER–MED25 cell line 
and an antibody against the ER–LBD tag (figure 20C). While the α–ER antibody could 
visualize the translocation of ER–MED25 from the cytoplasm to the nucleus 3 hours 
after OHT induction in the NIH–ER–MED25 cell line, no signal could be detected in the 
NIH3T3 wild–type cell line, confirming the specificity of the antibody. Since the 35kDa 
ER–LBD fused to the N–terminus of MED25 may interfere with the potential of MED25 
to interact with Mediator, the following control experiment was confirmed. ER–MED25 
was transiently over–expressed in HEK–293T cells, which were harvested 48 hours later 
to isolate nuclear extract. In parallel, a Flag–tagged MED25 construct, known to bind 
Mediator, was used as a positive control. Nuclear extracts containing over–expressed 
either ER–MED25 or Flag–MED25 proteins were loaded on an α–MED15 
chromatography column and analyzed by Western blot. Two monoclonal antibodies 
against MED25 and MED7 were used to recognize the tagged MED25 proteins and 
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Mediator, respectively. As shown in figure 20D, ER–MED25 and Flag–MED25 were 
efficiently coimmunoprecipitated with Mediator (lanes 5 and 3) providing evidence that 
ER–LBD fused MED25 interacts with Mediator and is, therefore, suitable for this study. 
 
 
Figure 20. Generation of an inducible cell line expressing MED25. (A) ER–LBD tagged MED25 was stably 
transfected in NIH3T3 cells. HSP90 retains the protein into the cytoplasm in an inactive state. Tamoxifen 
binds to ER–LBD releasing the protein from the binding and allowing its translocation into the nucleus. (B) 
Western blot analysis of nuclear extracts collected from NIH–ER–MED25 (upper panel) and NIH–ER cells 
lines 0 and 3 hours after OHT induction. Antibodies against MED25 and against ER–LBD were used, 
respectively. (C) Immunofluorescence in NIH–ER–MED25 cell line and in wild type NIH3T3 cells 
performed using an antibody against ER–LBD. (D) Nuclear extracts isolated from 293T cells 
overexpressing ER–tagged MED25 and Flag–tagged MED25 were immunoprecipitated with MED15 
antibody (lanes 3 and 5). Monoclonal antibodies against MED25 to monitor tagged and wild–type MED25 
or against the Mediator core subunit MED7 to monitor the level of coprecipitated Mediator were used in 
the Western blot analysis. An isotype antibody was used as control (lanes 4 and 6) 
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3.3.2 RNA expression profiling of NIH–ER–MED25 cell line and RT–PCR analysis 
 
With the previously described inducible NIH–MED25 cell line, a microarray analysis was 
performed in collaboration with Dr. J. Beckers and Dr. M. Horsch (IEG, GSF, 
Neuerberg). A glass–surface DNA–chip containing about 21000 probes was used. 
These probes are from the commercial Lion mouse array–TAG clone set, which is 
mostly derived from 3'UTRs. Translocation to the nucleus of ER–MED25 was observed 
as early as 3 hours after OHT induction offering the opportunity to look at genes to look 
at genes affected early and late. Towards this end, a time course experiment was 
carried out and RNA was collected from non–induced cells and from cells induced for 3 
and 10 hours with Tamoxifen. RNA was used for reverse transcription and indirectly 
labelled with Cy3 or Cy5 fluorescent dye. Labelled cDNA from each time point was 
mixed with the reference cDNA solution labelled with a second dye and used to 
hybridise microarrays. Four chip hybridisations were performed with RNA from each 
time of measurement. Each chip hybridisation was performed against RNA of non–
treated cells (reference RNA). For each time of measurement the chip experiments 
included two colour–flip experiments. After hybridisation, chips were scanned and the 
images analysed using an image processing software. For data analysis an in–house 
produced LabView based software was used. The analysis of the data revealed a very 
low number of genes differentially regulated upon induction. 3 hours after induction 5 
genes were down–regulated (table 10); 10 hours after induction 8 genes were 
upregulated and 2 genes were down–regulated (table 11).  
Quantitative real–time PCR was used to validate arrays for some of the listed genes 
(data not shown). Array data were confirmed via RT–PCR comparing RNA from the 
same cell line with samples from a control cell line for two down–regulated genes, cJun 
and FosB. While the amount of cJun and FosB transcripts detected on the NIH–ER–
MED25 cell line was decreasing after OHT induction (figure 21A), it remained 
unchanged in the control cell line NIH–ER (figure 21B), which indicates that cJun and 
FosB are specifically regulated by ER–MED25. 
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Table 10. Differentially regulated genes in NIH–ER–MED25 cell line 3 hours after OHT induction. 
Downregulated genes 
GENE NAME FOLD REPRESSION 
Pax5 3.8 
Dio1 3.9 
Ldhd 3.4 
Scn1b 2.7 
Angptl2 3.0 
 
Table 11. Differentially regulated genes in NIH–ER–MED25 cell line 10 hours after OHT induction. 
Upregulated genes 
GENE NAME FOLD INDUCTION 
Sc4mol 1.7 
Cyp51 1.8 
Sqle 1.7 
Rps29 1.5 
Dbi 1.5 
Rps23 1.5 
Rsp21 1.5 
Rpl44 1.5 
Downregulated genes 
GENE NAME FOLD REPRESSION 
FosB 1.8 
cJun 1.3 
 
Figure 21. Validation of array data via RT–PCR on cJun and FosB genes. RT–PCR analysis was 
performed using RNA isolated from NIH–ER–MED25 cell line (A) and NIH–ER cell line control (B) 0, 3 and 
10 hours after OHT induction. Fold repression at 3 and 10 hours time points was calculated relatively to 
the 0 time point reference sample. 
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3.3.3 Generation of an inducible cell line expressing a dominant negative mutant 
of MED25 
 
The N–terminal 290 amino acids (NTD), comprising the VWA domain that binds 
Mediator, were shown to repress transcription activation by GAL–VP16–H1 on a GAL4–
luciferase reporter (Mittler et al., 2003). The aberrant MED25–NTD integrates into 
Mediator (figure 10, lane 5) in competition with wild type MED25 (Mittler et al., 2003). As 
a consequence, transcription activation by VP16 is impaired. The same phenomenon 
was observed when VP16 was substituted by another viral transcription activator, 
e.g. the Epstein–Barr virus (EBV) Nuclear Antigen 2 (EBNA2) (Gerhard Laux, personal 
communication). Moreover, EBNA2 and VP16 activation domains have been reported to 
share analogies in their function and structure (Cohen, 1992; Cohen and Kieff, 1991), 
which renders EBNA2 a candidate target for MED25. EBNA2 is essential for initiation 
and maintenance of B–cell immortalisation (Cohen et al., 1989; Hammerschmidt and 
Sugden, 1989; Kempkes et al., 1995). The 721–B–cell line is derived from primary B 
cells that were infected in vitro and therefore converted to an immortalized 
lymphoblastoid cell line constitutively expressing EBNA2. In order to analyze the effect 
of a dominant negative mutant of MED25 in a background of constitutive EBNA2 
expression, a 721–B–cell line was generated stably expressing MED25–NTD. This 
approach could provide for an insight into mechanisms of gene control by EBNA2 and a 
useful tool to elucidate a possible role for MED25 in immunological processes. The 
stable 721–ER–MED25–NTD human cell line was used for the identification of 
differentially expressed genes upon overexpression of the MED25 dominant negative 
mutant at different time points. A MED25–NTD construct N–terminally fused to the ER–
LBD was cloned into an episomal vector (figure 11A). Cells were stably transfected, 
hygromycine selected and checked for expression levels of the fusion protein 
translocated to the nucleus 1 hour, 10 hours and 24 hours after Tamoxifen induction. 
Nuclear extracts collected at different time points after induction of the cells with OHT 
were analysed by Western blot using antibodies against MED25 (to visualize 
endogenous MED25 and ER–MED25–NTD fusion protein). Additionally, an antibody 
against the Mediator subunit MED7 was used to visualize expression levels of a core 
Mediator subunit in relation to the expression levels of induced ER–MED25–NTD 
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protein. As shown in figure 22B, ER–MED25–NTD seems to be present in small amount 
in the nucleus even before induction (lane 1), which, however, might be the 
consequence of cytoplasmic contamination of the nuclear extract. Tamoxifen induction 
for 10 and 24 hours, respectively, results in translocation of the ER–MED25–NTD fusion 
protein into the nucleus (lanes 3 and 4) which was less evident 1 hour after induction 
(lane 2). At the same time, the overexpression of the dominant negative construct ER–
MED25–NTD in the nucleus upon 24 hours induction results in a diminished amount of 
endogenous MED25 in the nucleus (lane 4). By contrast, the signals corresponding to 
MED7, shown as loading control, are unchanged at all times (lanes 1–4, lower bands). 
To demonstrate the integration of ER–MED25–NTD construct into the Mediator complex 
an immunoprecipitation assay was performed. For this purpose, an anti MED15 antibody 
column was used. The eluate obtained after immunoprecipitation was analysed by 
Western blot using the monoclonal antibody (VC1) against MED25 to visualize ER–
MED25–NTD. Another antibody against the core Mediator subunit MED7 was employed 
as a control. Figure 22C shows that Mediator, represented by MED7 bands, was 
efficiently immunoprecipitated from nuclear extracts at all times (lanes 1–4). The 
coimmunoprecipitation of ER–MED25–NTD from nuclear extracts collected 1, 10 and 24 
hours after Tamoxifen induction (lanes 2–4) confirmed that ER–MED25–NTD fusion 
protein retains Mediator–binding capacity. The amount of ER–MED25–NTD fusion 
protein incorporated in the complex seems to gradually increase over the time course 
experiment (lanes 2–4). 
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Figure 22. Generation of an inducible cell line expressing MED25–NTD. (A) ER–LBD tagged MED25–
NTD was stably transfected in 721–B–cells. In the generated cell line HSP90 retains the protein into the 
cytoplasm in an inactive state. Tamoxifen binds to ER–LBD releasing the protein from the binding and 
allowing its translocation into the nucleus. (B) Expression levels of ER–MED25–NTD protein visualized by 
Western blot analysis of nuclear extracts collected from 721–ER–MED25–NTD cells line 0, 1, 10, and 24 
hours after OHT induction. Antibodies against MED25 and against MED7 were used. (C) Nuclear extracts 
isolated from 721–ER–MED25–NTD cells 0, 1, 10, and 24 hours after OHT induction were 
immunoprecipitated with MED15 antibody. Monoclonal antibodies against MED25 and MED7 were used 
in Western blot analysis for detection of MED25 and MED7, respectively (lane 5). 
 
3.3.4 Genome–wide analysis of transcriptional regulation by ER–MED25–NTD 
 
The Tamoxifen inducible 721–ER–MED25–NTD cell line was used in a time course 
experiment in order to identify genes differentially regulated by MED25–NTD. RNA 
samples were isolated from cells 1 hour, 10 hours and 24 hours after Tamoxifen. RNA 
derived from non–induced cells was also collected and used as a reference. Each 
sample was therefore used to analyze the gene expression profiles using Affymetrix 
arrays. Affymetrix arrays analysis was performed by KFB, Regensburg. For this analysis 
an Affymetrix Human Genome U133 Plus 2.0 Array GeneChip was employed, which 
covers the human genome completely. The data received from the company were 
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analyzed according to their instructions (see 2.2.4). The total number of genes 
differentially regulated at the three time points are summarized in table 12.  
 
Table 12. Total number of genes differentially regulated upon Tamoxifen treatment of 721–ER–MED25–
NTD cell line at different time points. Genes up or down regulated less than 1.2 fold are not included.  
 
TIME POINT TOTAL UPREGULATED GENES 
TOTAL 
DOWNREGULATED GENES 
1 h 411 541 
10 h 221 78 
24 h 290 142 
 
Because of its dominant negative effect the assumption was made that ER–MED25–
NTD protein may impair the regulation of EBNA2 target genes. In order to identify 
EBNA2 target genes that may be downregulated by ER–MED25–NTD, genes 
downregulated in this microarray analysis (table 12) were compared with known EBNA2 
target genes. From this analysis 13 presumptive common target genes were found.  
 
Table 13. Genes downregulated by ER–MED25–NTD, which are as well reported as EBNA2–target 
genes. Indicated are fold repression rates. 
 
GENES 1h down  10h down  24h down 
Bcl2 2.8   
CCL4 2.8   
MAFF 2.6   
CCL3 2.5   
SNX9 2.1   
RGS1 1.9   
TRIO 1.9   
ATP1B1 1.5   
CCL5 1.3   
CD300A 1.3  1.4 
CMKOR1 1.3 1.2 1.3 
GADD45ß 1.3  1.3 
RBBP6 1.3   
 
These data support the hypothesis of MED25–bound Mediator involvement in both, 
EBNA2 transcriptional activation mechanism and immune response. 
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3.3.5 Activation of p21 promoter by MED25 
 
In an attempt to understand the mechanism of MED25 recruitment to its target gene 
promoters we looked for cellular activators containing an acidic domain resembling that 
of the viral activator VP16. One of them, p53, was tested on a p21 luciferase reporter 
containing the p21 promoter region –2325/+8. Transient overexpression of MED25 led 
to five–fold increase of reporter activity (data not shown). Co–transfection of MED25 
together with p53, however did not lead to significantly increased activation rates. These 
findings indicated the activation of the p21 promoter by MED25 in a p53 independent 
manner. Hence the question was addressed whether MED25 might activate p21 
promoter through an alternative pathway. The proximal region (–122 and –64) of the p21 
promoter is GC–rich and contains six binding sites for the ubiquitous transcription factor 
Sp1 (Moustakas and Kardassis, 1998). One of these Sp1 sites was shown to be 
required for the stimulation of the p21 promoter by TGF-β and its downstream targets, 
the Smad protein  family. It has been reported that another Mediator subunit, MED15, is 
involved in this pathway via interaction with the Smad transcription activators (Kato et 
al., 2002). To elucidate whether the activation of the p21 promoter by MED25 functions 
also through this pathway, HeLa cells were transiently cotransfected with a p21 
promoter variant (–143/+8, figure 23A) containing the Sp1 site mentioned above 
together with expression vectors for MED25, Sp1 and Smad3 (figure 23B). Luciferase 
measurements showed that each of the proteins contribute to activation of the p21 
promoter. However, no synergistic effect could be observed when using combinations of 
these proteins. Hence MED25 does not seem to use the TGF-β pathway to activate p21. 
These data were confirmed in HepG2 cells, a tumor-derived cell line of hepatic origin 
frequently used as a model to study the transcriptional regulation of the p21 gene 
(Moustakas and Kardassis, 1998) (data not shown). 
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Furthermore the activation of p21 promoter by MED25 was tested in the NIH–ER–
MED25 cell line stably expressing inducible ER–MED25. Cells were transiently 
transfected with titrated amounts of p21 reporter (-2325/+8) 24 hours before induction. 
3 hours after addition of 1mM Tamoxifen, cells were collected and luciferase levels were 
determined.  
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Figure 24. ER–MED25 induces a 
p21 reporter in NIH–ER–MED25 
stable cell line. NIH–ER–MED25 cells 
were transiently transfected with 
titrated amounts of p21 (-2325/+8)  
luciferase reporter. Cells were 
collected 3 hours after Tamoxifen 
induction and luciferase activity was 
measured. 
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Figure 23. MED25 activates 
a p21 reporter in transiently 
transfected cells.  
(A) Schematic view of the 
p21 reporter construct used 
in transient transfections. 
The six Sp1 sites are  
depicted. (B) .Flag–tagged 
Med25, Sp1 and Smad3 
constucts were transiently 
transfected in HeLa cells 
together with the p21 
reporter. 
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As shown in figure 24, the luciferase acivity was increased more than two fold upon ER–
MED25 translocation into the nucleus confirming the results of the transient analysis. 
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3.4 Towards the generation of a MED25 conditional knock–out mouse 
 
In order to identify and characterize MED25 in vivo functions a conditional knock–out 
mouse approach was followed by gene targeting in mouse embryonic stem cells.  
 
3.4.1 Organization of MED25 genomic locus  
 
In the mouse, the 13kb MED25 genomic locus (figure 25) is located on the seventh 
chromosome and it is characterized by 17 introns and 18 exons encoding for a 760 
amino acids protein. In the MED25 locus, exons are alternated by introns of a relatively 
small size, except for the third intron which causes a distance of 5.5kb between the third 
and the fourth exon. The functional domains of MED25 with respect to the genomic 
organization of its locus are distributed as follows: the VWA domain is encoded by 
exons 1–6 while the ACID domain is encoded by exons 10–14 (figure 25). Table 14 
shows the exon distribution in the MED25 cDNA murine sequence (gb BC031138.1) and 
the length of the corresponding introns in the MED25 genomic locus (gb NT039420). 
 
Table 14. Distribution of MED25 exons in the mouse cDNA sequence and length of the corresponding 
introns in the mouse MED25 genome locus.  
 
Exon cDNA division in exons (bp) Intron Intron length (bp) 
1 1–181 1 85 
2 182–225 2 192 
3 226–350 3 5511 
4 351–449 4 268 
5 450–568 5 281 
6 569–732 6 128 
7 733–864 7 155 
8 865–952 8 77 
9 953–1146 9 310 
10 1147–1274 10 933 
11 1275–1361 11 73 
12 1362–1418 12 101 
13 1419–1527 13 1647 
14 1528–1715 14 284 
15 1716–1788 15 97 
16 1789–2006 16 147 
17 2007–2185 17 407 
18 2186–2314 –  
 
RESULTS  113 
 
Figure 25. Schematic view of MED25 genomic locus. The exons are numbered from 1 to 18. VWA 
domain amino acids are encoded by exons 1–6 and ACID domain amino acids are encoded by exons 10–
14. PC6preExon1 probe was used to screen the 129/Ola derived genomic library. Letters indicate the 
oligoprobes used to select the 129/Ola derived BAC clone containing the MED25 genomic locus 
(a=PC6prepreExon1, b=PC6Exon1up, c=PC6Exon3up, d=PC6Exon9up, e=PC6Exon14down) 
 
3.4.2 Targeting strategy for the generation of a conditional null allele 
 
At the starting point of the MED25 transgenic mouse project, the only information 
available about MED25 function was related to its two functional domains. Therefore the 
assumption was made that disruption of the Mediator–interaction domain would very 
likely result in a phenotype that would provide insights into MED25 in vivo function. 
Towards this end a targeting vector was designed with respect to some general rules, 
which are  to be mentioned briefly: 
1. As starting material, a genomic clone of sufficient length must be obtained from a 
mouse library, the strain of which should be the same as the ES cells employed. 
2. The length of the homologous recombination arms is recommended to be at least 
4kb of uninterrupted sequence on one side with 1–2kb on the other one. 
3. For the selection of the positive ES cell clone, a neomycin (neo) cassette should 
be included; the additional employment of a thymidine kinase gene (TK) at the 
distal end of the genomic DNA construct ideally increases the number of 
homologous recombinants among the clones surviving selection. 
4. In the case of a conditional knock–out, a site–specific DNA recombinase system 
is required, commonly represented by two loxP sites flanking the targeted portion 
of DNA. The use of a CRE recombinase able to selectively recognize loxP 
sequences, allows a spatially and/or temporally controlled deletion of the gene of 
interest. The employment of an additional recombinase system, the Flp/FRT, 
allows the removal of the neomycin cassette in an independent step.  
VWA ACID
5 6 7 8 9 10 11121341 2 3 15161714 18
a b c d e
PC6preExon1
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5. A screening strategy should be designed that will provide for clear discrimination 
between wild type and different parental types of deletions during Southern blot 
analysis. 
Figure 26 shows a schematic view of the MED25 targeting vector of which a detailed 
description is provided. A 3kb MED25 genomic region included in between exons 4–10 
is followed by a neomycin cassette (positive selection marker) which is flanked by two 
FRT sites. Two loxP sites are located before the fourth exon (almost at the end of the 
third intron) and after the second FRT site, respectively. The 5' homologous 
recombination region, upstream of the first loxP site, is composed of the third exon and 
most of the third intron and includes about 5kb of the MED25 genomic locus. Upstream 
of the 5' homologous recombination region is located the thymidine kinase (TK) cassette 
encoding for the negative selection marker. Downstream of the second loxP site, the 3' 
homologous recombination includes a 1.2 kb genomic region spanning between the 
tenth and the thirteenth intron, which comprises the exons 11, 12 and 13. Several 
approaches are possible after replacement of the endogenous allele with the conditional 
null allele. Avoiding to use site specific recombination (with Cre of Flp) in the cells and, 
therefore, using the original targeting vector for the blastocyst injection, allows the 
generation of a mouse in which the MED25 allele is "interrupted" by a neomycin 
cassette. This cassette may interfere with the regulation of MED25 expression 
(hypomorphic allele), therefore providing a strong or mild phenotype. Mating this original 
line of MED25 conditional knock–out mice with Flp recombinase expressing mice allows 
removal of the neomycin cassette, creating a second MED25 conditional knock–out line 
which is comparable to a wild type mouse. Mating this second line of MED25 conditional 
knock–out mice with Cre recombinase expressing mice (ubiquitously or tissue–
specifically) leads to the generation of a MED25 knock–out mouse where the portion of 
MED25 genome locus containing the exons 4–10 (encoding for amino acids 117–424) is 
deleted. In this MED25 knock–out mouse a chimeric MED25 protein will be translated, 
which contains the amino acids 1–116  fused to the amino acids 425–760. As previously 
shown with the structure–function analysis of MED25 protein (figure 10), an intact VWA 
domain (amino acids 17–226) is necessary to bind Mediator. Therefore, the designed 
targeting vector is suitable for the generation of a MED25 knock–out mouse, in which 
the Mediator–interaction capability of MED25 is impaired. 
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Figure 26. Schematic view of MED25 targeting strategy. A targeting vector was generated containing the 
region to be deleted (exons 4–10) floxed by two loxP sites, a neomycin cassette flanked by two FRT sites, 
a negative selection marker (TK) and a unique site of restriction (NotI) for linearization of the vector. For 
the screening by Southern blot of the ES cells clones survived after double selection, probe A (blue) and 
probe B (red) were used. Probe Neo (green) was used to exclude that random integration was occurring 
in the homologous recombinant clone.  
 
3.4.3 Screening strategy by Southern blot analysis 
 
A screening strategy was designed to distinguish wild–type from homologous 
recombinant ES cells and from different parental types of deletions, during southern blot 
analysis. Probes that recognize regions surrounding the portion of DNA replaced by the 
targeting vector, allow for discrimination of homologous recombinants from random 
integrants. Therefore, two external probes, one targeting upstream and the other one 
downstream of the target locus were designed. The upstream probe, probe A 
(represented in blue in figure 26), spans a 660bp region, which starts 420bp upstream of 
the transcriptional start site of MED25 genomic locus and finishes at the end of the first 
exon at the same locus. Digesting genomic DNA with EcoRV restriction enzyme allows 
to distinguish the MED25 wild–type pattern characterized by a single 12.8kb band for 
both alleles from the homologous recombinants, which will lead to detection of an 
additional 7kb band. At the 3' end, probe B' (represented in red in figure 26) is located in 
the thirteenth intron and spans a 540bp region which starts about 360bp downstream of 
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the thirteenth exon. Upon DNA restriction digestion with BglII, wild–type–derived 
genomic DNA displays a single 6.1kb band in contrast to the homologous–recombinant–
derived genomic DNA which is characterized by an additional 2.7kb band. To rule out 
the possibility that random integration was occurring in the ES cell clones positive for 
homologous recombination, a 380bp Neo probe (indicated in green in figure 26) 
recognizing the neomycin cassette was used. Upon BglII or EcorV restriction digest of 
the homologous recombinant genomic DNA, a single band of 6.1kb or 11.2kb 
respectively should be detected. 
 
3.4.4 Selection of a genomic clone from a 129/Ola mouse library 
 
A 129/Ola derived ES cell line called TBV2 was provided by the Wurst laboratory (IEG, 
GSF, Neuherberg). In order to use isogenic DNA for the targeting construct, a 660bp 
probe spanning the ATG starting site and called PC6preExon1/probeA (indicated in 
figure 26) was obtained by PCR using pLB52 DNA BAC clone as template and sent to 
the rzpd screening service in Heidelberg. From a 129/Ola BAC library eight clones 
positive for the probe PC6preExon1/probeA were obtained. In order to identify a full–
length BAC clone a dot blot analysis was performed. DNA was derived from each clone 
via miniprep. Five hybridisation membranes were organized in 22 squares and spotted 
with duplets of DNA coming from each of the eight clones (figure 27, from spot number 1 
to spot number 16). The first three clones appear in 12 squares in total (1–6 and 17–22) 
since the membranes were spotted with DNA coming from additional maxi preps (from 
17 to 22). Five oligo–probes were designed, which are spanning the entire MED25 gene 
locus, and are indicated by a one–letter code in figure 25 (PC6prepreExon1=a, 
PC6Exon1up=b, PC6Exon3up=c, PC6Exon9up=d, PC6Exon14down=e). Each 
membrane was hybridised with a different 32P radioactively labelled oligo–probe and 
exposed to a film for autoradiography.  
The signals at positions number 19 and 20 were stronger on every probed membrane. 
The clone number 2 was chosen because it contains the portion of MED25 genomic 
DNA necessary for the cloning of the MED25 targeting vector. 
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3.4.5 Generation of a MED25 conditional null allele 
 
A 8kb BglII fragment including the DNA from the third to the tenth exon was obtained 
from the 129/Ola derived BAC genomic library mentioned above and inserted in 
between a TK cassette and a FRT flanked Neo cassette fused to a distal loxP site. A 
1.2kb PCR fragment corresponding to the exons 11–13 was cloned on the 3' side to 
function as the 3' homologous recombinant region. The 5' homologous recombinant 
region was created by inserting an EcorV/loxP site in a SpeI unique restriction site 
located in the third intron and 5kb downstream of the first BglII site. For the 
electroporation of the MED25 targeting vector in ES cells, a NotI unique restriction site 
included in the multiple cloning site of the backbone plasmid and positioned immediately 
downstream of the thirteenth exon can be used to linearize the targeting vector. 
22212019
181716151413
121110987
654321
PC6Exon3up PC6Exon14down
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Figure 27. Screening of a 129/Ola 
genomic library to select a clone 
containing the entire MED25 genomic 
locus. Eight clones were selected from a 
pre–screening carried out using 
PC6preExon1 probe (see also figure 
25). Using 5 oligo–probes spanning the 
entire MED25 genomic locus, a dot–blot 
analysis was performed to select a BAC 
clone suitable for the cloning of the 
MED25 conditional null allele. 
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3.4.6 Transfection of ES cells and determination of a homologous recombinant 
 
Once created, the targeting vector was linearized with NotI and electroporated in TBV2 
ES cells. After ES cell clone selection (see 2.3.7) genomic ES cell DNA was digested 
with EcoRV to test for homologous recombination at the 5' end and with BglII to test for 
homologous recombination at the 3' end.  Restricted DNA was separated on an agarose 
gel, blotted and screened with probe A and probe B' respectively. Among about 500 
clones picked, only one (clone 5A) turned out to have undergone homologous 
recombination on both sides of the allele (figure 28A). In addition to the wild–type bands, 
the mutant allele results in the formation of an additional band of 7kb when using EcorV 
and of 6.1kb when using BglII. To rule out a random integration event in addition to the 
homologous recombination event on clone 5A, the membrane previously tested with 
probe A was stripped and subsequently hybridised to the Neo probe. The single band 
detected after hybridisation confirmed the presence of a unique neomycin cassette 
therefore excluding the additional random integration of the targeting vector in this clone 
(figure 28B).  
 
Figure 28. Identification of a ES cell clone carrying MED25 conditional null allele. (A) Southern blot 
analysis was carried out on the genomic DNA of viable clones after double selection. Genomic DNA was 
digested with EcoRV and probed with probe A to confirm homologous recombination on the 5' end or 
digested with BglII and probed with probe B' to confirm homologous recombination on the 3' end. The 
presence of a double band in both cases indicates that homologous recombination was occourring on 
clone 5A. Clone 6A shows a typical wild–type pattern. (B) The same membrane was probed with the Neo 
probe to exclude random integration in addition to homologous recombination. (C) Clone 5A was 
expanded and its genotype confirmed again via Southern blot analysis.  
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The positive clone 5A was thawed from one of the originally frozen 96 well plates, 
cultured and expanded. To guarantee a high quality of the cells a particular care was 
taken to keep the number of passages low and to proceed immediately after reaching 
the number of cells required for blastocyst injection and for a minimum of clone storage. 
During this period, aliquots of the cells were processed for DNA extraction in order to 
confirm the identity of the expanded clone via Southern blot analysis. Figure 28C shows 
the typical double bands of the homologous recombinant in the lane of the expanded 
clone 5A (right lane) compared to the single band characteristic for the wild type DNA 
obtained from a 129/Ola strain mouse tail (left lane). 
 
3.4.7 Injection of homologous recombinant ES cells in mouse blastocysts and 
generation of MED25 chimeras 
 
In order to establish a MED25 mutant mouse line, a series of steps had to be carried 
out, which are schematically represented in figure 29. Injections of the ES cell clone 5A 
into host blastocysts were carried out in the IEG department of GSF, Neuherberg. 
Injected viable blastocysts were subsequently re–implanted in pseudopregnant female 
recipient mice for the generation of coat–colour chimeras. In a first attempt, nine foster 
female mice recipients were implanted with injected blastocysts. In table 15 the number 
of wild–type versus chimeric mice obtained are given. 
 
Table 15. Number of chimeras in relation to the number of clone 5A–injected blastocysts and to the 
number of blastocyst transfers into foster female mice. 
 
Transfer number Blastocysts re–implanted Wild type pups Male chimeras Female chimeras 
1 20 4 – 1 
2 20 – – – 
3 20 8 1 1 
4 16 4 – – 
5 16 6 – – 
6 16 4 – – 
7 23 5 2 – 
8 24 0 – – 
9 24 0 – – 
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Together with the observation that these chimeras were characterized by a very low 
percentage of chimerism (from 10 to 20 %) they were never been able to produce 
offspring and therefore considered sterile. In a second round of blastocyst injection 
attempt a total amount of seven chimeric mice were generated and mated to wild–type 
female mice for F1 generation. Among them, the C57/BL6 coat–colour chimeras (figure 
30, left panel) revealed to be sterile, as well as the CD1 coat–colour chimeras showing 
higher percentage of chimerism (figure 30, central panel). Two remaining CD1 coat–
colour chimeras produced offspring (figure 30, right panel).  
 
 
Figure 30. MED25 coat–colour chimeras. Right panel: C57/BL6 derived chimera. Central panel: CD1 
derived chimera. Left panel: only CD1 derived chimeras were generating offspring. 
 
Because CD1 derived blastocysts were chosen for the injection of the TBV2–derived 
clone 5A, it was not possible to distinguish between wild type and heterozygous litter 
mates by the colour of their coat. Therefore it became necessary to genotype the 
offspring mice using tail–derived DNA, in order to identify possible MED25 conditional 
Figure 29. Scheme for the 
generation of a transgenic mouse. 
After blastocyst injection with the ES 
cell clone carrying the mutated allele, 
blastocysts are re–inplanted into 
foster pseudopregnant female mice, 
which are going to generate coat–
colour chimeras. Chimeras are 
mated to wild type mice to allow 
germ line transmission. ES–cell–
derived offspring are recognized by 
the coat colour. 
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knock–out heterozygous mice. Genomic DNA derived from 36 agouti offspring mice was 
digested with BglII and transferred to a membrane, which was hybridised to probe B'. 
Figure 31 shows the result of the Southern blot analysis.  
 
Figure 31. Genotype of the MED25 chimeras derived offspring.The presence of a unique band visualized 
by Southern blot analysis indicates that germline transmission of the MED25 conditional null allele was not 
occurring. 
 
The presence of a unique band of 2.7kb in all genotyped mice revealed that the MED25 
mutant allele was not germ line transmitted, and therefore that no MED25 conditional 
knock–out heterozygous mouse had been generated. 
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4. DISCUSSION 
 
4.1 Identification and characterization of the Mediator–interacting module of 
MED25  
 
The analysis of the primary sequence of MED25 in combination with a screen for 
homologous sequences in the data base, allowed to identify two regions, named VWA 
and ACID domains, which are highly conserved throughout evolution and therefore 
considered to be critical for the function of the protein. MED25 was isolated via VP16 
affinity chromatography and shown to coprecipitate with the Mediator complex (Mittler et 
al., 2003). However which parts of the protein were involved in these binding reactions 
remained unclear and therefore a structure–function analysis of MED25 was chosen to 
address this question. A number of deletion mutants of MED25 were designed with 
respect to the domain organization as determined in silico. Pull down experiments using 
these constructs and a GST–VP16 column (Mittler et al., 2003; Yang et al., 2004) 
demonstrated that the region identified as ACID domain was necessary and sufficient for 
MED25 interaction with the viral activator. In analogy to this study a biochemical screen 
of MED25 deletion constructs using a Mediator specific column was carried out, which  
allowed the identification of the VWA domain as the minimal Mediator–interacting region 
(figure 10). 
 
Even though the structure of MED25 and of its functional domains have not yet been 
resolved, a prediction of the secondary structure is available. Of particular interest is the 
high homology between the MED25 Mediator–binding module and VWA–domain 
containing proteins. The A region of von Willebrand factor establishes contacts with 
collagen while the corresponding domain the integrins CD11a/b mediates CD18 ligand 
interactions. VWA domains have typical features of a protein–protein interaction module. 
They consist of a rigid scaffold composed of helices grouped around a core that is 
formed by β–sheets. These are connected through loops that are less conserved in 
structure and, therefore, could be used for individual protein–protein interactions. The 
alignment of MED25 with other VWA domains (supplementary figure 1) revealed two 
specific regions, SR1 (amino acids 51–63) and SR2 (amino acids 145–167) that show 
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no or little conservation. In particular, SR2 shows little homology within the other VWA 
proteins but is highly conserved throughout evolution in MED25. Therefore the SR2 
region may play a critical role for the function of the protein, namely the Mediator 
interaction. 
 
To identify MED25 amino acids which are involved in Mediator–complex formation a site 
directed mutagenesis analysis was performed. The physical interaction and transcription 
activation analyses revealed the presence of critical amino acid residues in the SR2 
region (figure 15). While observing the behaviour of each single mutant in the two 
assays, a model can be proposed concerning their contribution in complex formation. 
The negatively charged residue E157 shows a complete loss of physical interaction with 
Mediator upon replacement with a positively charged amino acid. This indicates that 
E157 may play a critical role in the initial electrostatic contact between MED25 and 
Mediator, which can be completely abolished by the change of charge. During this 
process, other negatively charged amino acids, which are located in proximity of the 
SR2 region may reinforce the ionic binding. E167 and E175 may contribute to the 
binding reaction. Mutations of these residues, however, did not lead to the dramatic 
effects observed with the E157 mutant. Once the first contact is established, MED25 
and Mediator probably stabilize the interaction by the formation of hydrophobic bonds, in 
which amino acids T138 and Y161 are thought to be important. Finally the binding may 
be negatively modulated by residues like Y151 and Q137, which have displayed 
stronger effects in both assays when replaced by the smaller amino acid alanine. These 
data bring evidence for a major role played by the SR2 region in Mediator complex 
formation. For the future, the generation of a peptide with SR2 sequence used in 
binding–competition experiments would help to confirm these data. 
 
Other amino acid residues (VVFV18, Y39, F47, Y66, F125, HMVL219) targeted in the 
VWA domain led to complete loss of transcriptional activation (figure 13). However, it is 
possible that these residues contribute to the stability of the structure and therefore that 
their mutation into alanine provokes collapse of the protein structure. To clarify this 
point, a limited proteolysis experiment should be performed to dicriminate unstructured 
regions from correctly folded domains. Moreover, mutating these residues into amino 
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acids sharing similar sterical properties like the ones in the wild type should also be 
considered.  
 
4.2 Characterization of the VP16–interacting module of MED25 
 
The function of VP16 activator has been extensively investigated over the last two 
decades, leading to the identification of several cellular targets of VP16. Among them a 
number of components of the transcription machinery like TFIID, TFIIB, TFIIF, TFIIH and 
cofactors like PC4 and Mediator are included. Moreover VP16 has been shown to bind 
chromatin–related activities such as SAGA, Nu4, Swi/SNF and CBP/p300 (see 1.2.6.1). 
Dispite all these cellular targets, MED25 is the only protein, which turned out to be 
necessary to drive activated transcription from VP16 in vitro. Its importance in VP16 
transcription activation has also been demonstrated in vivo by the use of dominant 
negative mutants (Mittler et al., 2003; Yang et al., 2004).  
The two transcription activation domains of VP16 are located in the carboxy–terminal 
region (residues 410–490) and are highly acidic. Both subdomains (VP16 H1 412–453 
and VP16 H2 454–490) have been studied by mutational analysis, indicating key roles 
for specific hydrophobic and acidic residues (Cress and Triezenberg, 1991; Regier et al., 
1993; Sullivan et al., 1998; Walker et al., 1993). The transcriptional activation domains 
of transcription factors often lack a folded structure under physiological conditions 
(Triezenberg, 1995; Wright and Dyson, 1999). These and other native highly flexible 
random–coil proteins are identified as intrinsically unstructured proteins (IUPs). Lack of 
folded structure has many advantages for the ability of the protein to bind to its targets 
(Dunker et al., 2002; Dunker et al., 2001; Tompa, 2002). The substantial backbone and 
side–chain flexibility enables the protein to overcome steric restrictions and 
consequently enhances binding to various targets and larger interaction surfaces. 
Previous structural studies of VP16 activation domain showed that there is little 
evidence of secondary structure for the free protein (O'Hare and Goding, 1988; Uesugi 
et al., 1997). However, upon binding of a VP16 peptide (469–485) to the hTAFII31 (1–
181), the 472–483 region becomes α–helical (Uesugi et al., 1997). In a recent study, the 
binding of VP16 to PC4 and TFIIB has been investigated in detail using NMR and 
biochemical experiments (Jonker et al., 2005; Jonker et al., 2006). The authors of this 
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study suggest that the two transcription activation subdomains of VP16 adopt an α–
helical conformation around the 429–450 and 465–488 regions upon interaction with 
PC4 and TFIIB. Multiple exchangeable contacts are observed between negatively 
charged VP16 residues and positively charged residues from the target proteins. This 
finding is in agreement with the previous observation that transcription was only 
impaired when multiple patches of negatively charged residues in VP16 H1 were 
mutated, suggesting that the overall acidity of the protein is important for its activity 
(Cress and Triezenberg, 1991). One specific residue in the VP16 H2 subdomain (E476) 
which significantly contributes to transcriptional activation (Sullivan et al., 1998), 
establishes a hydrogen bond to R85 of the structured C–terminous of PC4. The large 
number of charged residues increases the rate of interaction between activator and 
target through long–range electrostatic forces. This is demonstated by the fact that D443 
and D445 of VP16 establish hydrogen bonds to K100 and K77/K79 of PC4, residues 
that are important for the interaction. 
It is suggested that initial binding occurs by electrostatic interactions, resulting in an 
unstable complex, which is slowly stabilized by specific hydrophobic bonds between the 
activation domain and its target (Hermann et al., 2001). Interestingly, hydrophobic 
residues of VP16 that have been shown to be critical for transcription (L439, F442, 
L444, F475, F473, and F479) have been localized in the center of the induced α–helix. 
A model is proposed by Jonker and coworkers (Jonker et al., 2005) in which the VP16 
α–helices are involved in many electrostatic and some idrophobic contacts to residues in 
the β–channel regions of PC4. Obviously many contacts can be replaced by adjacent 
VP16 residues, since complete loss of binding is not observed upon mutation of single 
polar and hydrophobic residues.  
 
In this work the binding of MED25 to activation domain of VP16 has been investigated. 
MED25 point mutants have been generated in which charged and hydrophobic amino 
acids residues of the ACID domain were targeted. A pull down assay has been 
performed using a GST–VP16H1 column. This subdomain has been reported to bind 
MED25 better than VP16H2 (Mittler et al., 2003; Yang et al., 2004). In figure 32 the 
region of VP16H1 containing critical residues for the binding to other factors and for 
transcriptional activation is depicted. 
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Figure 32. Schematic view of the 438–451 region of the VP16H1 subdomain. Hydrophobic residues are 
indicated in blue; negatively charged residues are framed. Some of these residues (L439, F442, L444, 
D443, D445) have been shown to be important for transcription and interaction of VP16 with its targets. 
 
We observed that for the mutants FHF473AAA and WPQK444APQA the interaction with 
VP16H1 was completely abolished while it was strongly impaired for the mutants 
W408A and KKIF519AAIA (figure 17A). The cluster of lysines KKK518 seems to play a 
critical role in VP16 complex formation since also the ACID domain alone where these 
lysines are mutated to alanine loses binding (figure 17B). The MED25 ACID domain is 
found only in one other protein called PTOV1. PTOV1 contains two repeats of this 
domain (Benedit et al., 2001), the sequences of which are likely conserved with each 
other and with the MED25 ACID domain (figure 17). The importance of K518 was 
confirmed by the observation that the PTOV1_B domain (containing a glutamate in the 
corresponding position) does not bind VP16H1. Interestingly, the same mutants which 
were showing impaired VP16 binding in the in vitro assay (FHF473AAA, 
WPQK444APQA, W408A and KKIF519AAIA) displayed a reduction of transcriptional 
activation capacity in the in vivo functional assay (figure 13, lanes 1–4). This observation 
may indicate the involvement of these residues in the binding to a cellular target, which 
obviously contributes to increase transcription rates. The viral activator may simply 
mimick this mechanism in order to use MED25–bound Mediator to support the viral life 
cycle in the eukaryotic cells.  
The resolution of the structure of the ACID domain would definitly help to understand the 
dynamics behind the complex formation with VP16. Targeting single residues in the 
regions, which were found affected by double or triple mutations may also help to 
identify the amino acids which are essential. However, as reported previously, the 
binding of the ACID domain with VP16 activation domain very likely results from the 
contribution of many residues.  
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Comparing our data with other data where the binding of VP16 with other target protein 
has been studied a model is suggested for the formation of the ACID–VP16 complex. 
K518 seems to play a key role in attracting negatively charged residues (aspartates) in 
the VP16H1 subdomain. The other lysines in the cluster (519, 520), K447 and H474 
may contribute to increase the electrostatic forces. Once in proximity to the ACID 
domain, VP16H1 very likely undergoes conformational change and the binding is 
stabilized by hydrophobic contacts, which seem to involve F473, F475, W444, W408 
and F522 of MED25 ACID domain. 
 
4.3 MED25 is characterized by an intrinsic transcription activation capacity 
 
In contrast to the majority of Mediator subunits, MED25 is neither conserved in yeast nor 
in C.elegans. In line with the general observation, that the evolution of eukaryotes is 
generally accompanied by an increase in complexity of transcriptional control, this 
observation was supporting the hypothesis that MED25 other than representing a 
Mediator subunit could also have an additional function specific for higher eukaryotes.  
In a recent work published by Kim et al., (2004) the role played by single subunits of 
Drosophila Mediator in transcription activation is investigated. Using small interference 
RNA technology (siRNA) each Mediator subunit was individually knocked down in 
Schneider SL2 cells. With this approach the authors could demonstrate that the 
depletion of each of 13 of the 23 investigated subunits caused significant defects in 
transcriptional activation of Attacin A and Hsp26 genes, revealing functional specificity of 
Mediator subunits. In addition, a screen for activator–binding Mediator subunits proved 
that MED23, MED17, MED25 and MED16 were physically interacting with the 
transcription activators of the affected genes, Dif (dmNF–κB) and HSF. Interestingly, the 
portion of Drosophila MED25 (amino acids 573–863) shown to bind these activators 
includes part of the ACID domain and part of the carboxyl–terminal region of the protein. 
While the mammalian homologues of MED17 and MED23 have been also identified as 
specific binding partners for the cellular activators p53, STAT2 and Elk–1, respectively, 
no cellular target has been yet identified for the mammalian homologue of MED25.  
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In this work the transcriptional activation assay performed with MED25 GAL–tagged 
deletion constructs revealed that MED25 has an intrinsic transcription activation capacity 
(figure 11). This is indicated by the observation that the VWA–domain lacking constructs 
still activate transcription, even though with reduced rates as compared to the constructs 
containing the Mediator–interaction domain. Based on this observation a model is 
proposed to explain the behaviour of MED25 derivatives in this assay (figure 33).  
 
The capability of GAL–MED251–290 to activate transcription is probably exclusively 
related to the recruitment of Mediator to the promoter (figure 33A). The increased 
transcription rate as a consequence of C–terminal prolongation of the protein indicates 
that an additional activity comes into play, which synergistically contributes to the effect 
of Mediator (figure 33B). This activity may bind to the ACID domain, while the 
surrounding regions may help to stabilize this binding (290–393 and 543–715). 
Alternatively, more than one factor could be bound to this part of the protein (290–715), 
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Figure 33. Model to explain the intrinsic 
capacity of MED25 to activate transcription. (A) 
Transcriptional activation observed with the 
VWA domain containing construct is mediated 
by the recruitement of Mediator to the  
promoter. (B) The stronger transcription 
activation rate oberved by the addition of the 
290–715 region to the N–terminous 1-290 may 
result from the binding of an unknown activity 
to this region. This activiy may contribute to the 
recruitment of the transcriptional machinery to 
the promoter. (C) The unknown activity 
mediates activation in a MED25 derivative 
lacking the Mediator–binding domain. 
DISCUSSION  129 
the presence of which could sterically or functionally influence the others; however this 
still needs to be clarified. Finally, the GAL–MED25 derivatives lacking the VWA domain, 
are still able to activate transcription through the recruitment of an unknown activity, 
which may recruit the Pol II transcription machinery to the reporter's promoter (figure 
33C).  
Initial immunoprecipitation experiments using a GAL4 antibody, have demonstrated that 
Mediator and Pol II coprecipitate with GAL–MED251–290 as well as with GAL–MED251–
715. However, the construct GAL–MED25290–685 failed to precipitate both, Mediator and 
Pol II. This observation may be indicative for an indirect recruitment of the transcriptional 
machinery by the presumptive unknown activity, an hypothesis, which is supported by 
the reduced effect observed in the luciferase assay. Functional data showing impaired 
transcription activation of ACID–domain mutants (figure 13, lanes 1–4) suggest that the 
unknown activity described above may specifically bind the ACID domain of MED25. 
Even though the identity of this factor is not yet known, the possibility of an interaction 
with CBP should be considered and further investigated in vivo. In fact, recent 
experiment have shown that MED25 is able to bind CBP at least in vitro (Uhlmann, 
2006). In this view, a model can be proposed where MED25 bound to activators at 
promoters serves as a platform to recruit chromatin–related cofactors (i.e. CBP) and the 
Mediator complex. While one factor would serve to open the promoter, the other one 
would target the transcription machinery to it. Mass–spectrometric identification of 
proteins interacting with GAL–MED25290–715 might be employed to reveal the 
mechanisms that contribute to activation through MED25. 
 
4.4 A role for MED25 in cell cycle control 
 
Microarray analyses were carried out in this study led to identification of cellular targets 
for MED25. Using different cellular systems genes were found that are important for the 
cell cycle regulation: cJun and FosB were repressed 10 hours after induction of ER–
MED25 in NIH3T3 cells. These genes have been shown to drive entry into S–phase of 
the cell cycle thereby promoting cell proliferation. This is reflected by the transforming 
capacity of mutant versions of these cellular proto–oncogenes. The downregulation of 
these factors through MED25 raises the possibility that MED25 is critical for the control 
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of cell proliferation. Another factor involved in cell cycle regulation was identified in an 
independent screen in 721–B–cells, where a dominant–negative MED25 variant was 
employed to reveal genes whose expression is under the control of this protein. GSK3β 
was downregulated already 1 hour after induction of ER–MED25–NTD in 721–B–cells. 
Considering the dominant negative function of MED25–NTD, this result indicates GSK3β 
as a direct target of MED25. In line with this finding cyclin D1 protein levels have been 
reported to be increased following overexpression of PTOV1, a MED25 homolog lacking 
the Mediator interaction domain (Santamaria et al., 2003). Cyclin D1 promotes transition 
from G1 to S phase, increasing the cellular proliferation rate in prostate cancerogenesis. 
GSK3β phosphorylation has been also shown to be involved in cytoplasmic localization 
of cyclin D1 and promote its degradation (Diehl et al., 1998).  
Furthermore transient transfection experiments indicate that the cyclin dependent kinase 
inhibitor p21 is upregulated by MED25. Since p21 itself negatively regulates G1–S 
progression this could underline the function of MED25 in controling cell proliferation. 
A schematic view of cell cycle regulation is depicted in figure 34. 
 
Together these findings indicate that MED25 may negatively influence cell proliferation 
via downregulation of c–Jun and FosB on the one hand and upregulation of GSK3β, a 
negative regulator of cyclin D1, on the other hand. The positive effect of MED25 on 
GSK3β expression might be counteracted by PTOV1, which has a positive influence on 
cyclin D1 levels (see above). A model can be proposed for the antagonistic regulation of 
Figure 34. Effects of AP–1 proteins 
and other factors in cell cycle 
regulation. c–Jun stimulates G1 to S 
phase transition by inducing cyclin 
D1 and repressing p53, which in turn 
reduces p21 levels. c–Fos and Fos–
B have redundant functions in the 
stimulation of S phase entry and the 
induction of cyclin D1 expression. 
JunB inhibits G1 to S phase 
progression by inducing p16 and 
repressing cyclin D1. JundD inhibits 
S phase entry and increases the 
numbers of resting cells by 
modulating the Ras/p53 patway. 
(After (Jochum et al., 2001)) 
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this gene by MED25 and PTOV1. Under normal conditions binding of MED25 to a 
transcriptional activator localized on the GSK3β promoter will recruit chromatin–related 
factors and Mediator to this site leading to expression of the gene (figure 35A). 
However, in transformed cells high PTOV1 expression levels might lead to binding of the 
chromatin–related factors in solution thereby sequestring it from promoters (figure 35B). 
This factor could be titrated out by PTOV1 impairing transcriptional activation of this 
gene. 
 
 
Figure 35. Proposed model for antagonism of PTOV1 with MED25. (A)                                       
MED25 induces GSK3β                      which in turns regulates levels of cyclin D1 promoting its 
degradation. (B) In tumorgenic cells, overexpressed PTOV1 sequesters important factors for 
transcriptional activation of the GSK3β therefore blocking its expression. This leads to upregulation of 
cyclyn D1 with consequent aberrant cell proliferation. 
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4.5 Possible implication of MED25 in EBNA2 activation 
 
The analysis of the gene expression profile upon over–expression of ER–MED25–NTD 
in the nucleus was carried out in 721–B–cells, which constitutively express the Epstein–
Barr Virus Nuclear Antigen 2 (EBNA2). Noteworthy, the viral activator EBNA2 is 
essential for regulation of virus and cell gene transcription and B lymphocyte 
transformation into a lymphoblastoid cell line (LCL). The possible implication of MED25 
in EBNA2 function is based on experiments, which show that increasing amounts of 
MED25–NTD dramatically reduce the activation of a GAL4–luciferase reporter by 
GAL4–EBNA2 in a transient transfection assay (Laux, personal communication). In 
analogy with the viral activator VP16, the dominant negative effect exerted by MED25–
NTD mutant could reflect the involvement of MED25 in the transactivation mechanism of 
EBNA2. In analogy to VP16, the recruitment to promoters of basal and activation–
related transcription factors (TAF40, TFIIB, TFIIH, p300/CBP, PCAF histone 
acetyltransferases) and the transcriptional coactivator p100 (Wang et al., 2000) by 
EBNA2 has been already reported. Moreover, EBNA2 contains a highly acidic 14–amino 
acid activation domain that directly activates transcription and is required for 
transformation. Although the activation domains of EBNA2 and VP16 share less than 
50% amino acid identity, they have certain structural features in common. Both domains 
contain several negatively charged amino acids, a putative α–helical structure, and 
hydrophobic amino acids that can be aligned in a similar pattern (figure 36).  
 
Figure 36. Alignment of the amino acid sequence of the transcriptional activation region of EBNA2 with a 
region of the VP16 H1 subdomain. Idrophobic amino acids are in light blue while negatively charged 
residues are framed in red.  
 
Chimeric EBV virus containing part of the VP16 activation domain instead of the EBNA2 
activation domain was able to transform B cells and transactivate expression of EBV 
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and B cells (Cohen, 1992). This finding supports the hypothesis that EBNA2 and VP16 
may share similar biochemical mechanisms of transcriptional activation. 
 
The results from the mycroarray analysis contribute to support our theory of a 
relationship between MED25 and EBNA2. Experiments carried out in Kieff's laboratory 
(Zhao et al., 2006) have identified EBNA2–regulated genes comparing RNA levels in 
LCLs expressing WT EBNA2 and in LCLs expressing a Tamoxifen inducible EBNA2 
(E2HTF). Based on the assumption that ER–MED25–NTD would act dominant 
negatively on EBNA2 we compared the genes downregulated in our array analysis with 
the genes upregulated by EBNA2. Table 16 lists the genes found in this work, which are 
also reported to be EBNA2–target genes (Zhao et al., 2006). All the genes shared by the 
two studies seem to respond rather early to the translocation of ER–MED25–NTD in the 
nucleus (1 hour after OHT induction) arguing for a direct effect. Five of these genes 
(RGS1, TRIO, CCL5, CD300A and GADD45ß) were also found to be upregulated by 
latency III (LTIII) infection from EBV in Burkitt lymphoma (BL41) lymphoblasts (Cahir-
McFarland et al., 2004; Carter et al., 2002; Zhao et al., 2006). Although Bcl2 is not 
present in the EBNA2 target gene list, its contribution to B–cell immortalisation is well 
known. EBV–transformed LCLs are resistant to apoptosis as a consequence of LMP1–
mediated NF–κB activation and induction of Bcl2 together with other antiapoptotic 
proteins like A20, Bfl1 and Mcl1 (Cahir-McFarland et al., 2004; Cahir-McFarland et al., 
2000; Gregory et al., 1991; Henderson et al., 1991; Laherty et al., 1992). EBNA2 also 
contributes to cell survival through upregulation of GADD45ß. (growth arrest and DNA–
damage–inducible, beta) protects cells from c–Jun N–terminal kinase–mediated 
apoptosis (De Smaele et al., 2001). Other EBNA2–induced genes encode proteins 
involved in cell signalling like chemokines, cell–surface receptor molecules and 
intracellular mediators such as CCL5, CMKOR1, CD300A (leukocyte membrane 
antigen, Irp60), ATP1B1 and RGS1. CD300A belongs to the Ig protein super–family, 
which is characterized by an intracellular tail that has an immunereceptor tyrosine–
based inhibitory motif able to associate with SHP–1 (Cantoni et al., 1999). CMKOR1 is a 
G protein–coupled receptor that binds to CXCL12 and is also an HIV coreceptor 
(Balabanian et al., 2005). CCL5 and RGS1 are also LMP1–induced and are likely to 
regulate B cell chemotaxis (Cahir-McFarland et al., 2004). Other chemokines such as 
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CCL4 and CCL3 were also found to be EBNA2 targets (Kempkes, personal 
communication). In addition, a transcript named EBI3 (Epstein–Barr virus induced gene 
3) was down–regulated 1 hour and 24 hours after OHT induction in 721–ER–MED25–
NTD cells. 
 
Table 16. List of genes which were downregulated upon MED25–NTD overexpression and upregulated 
upon EBNA2 overexpression. In light blue are genes which were also found to be upregulated by latency 
III (LTIII) infection from EBV in Burkitt lymphoma (BL41) lymphoblasts. 
 
GENES BIOLOGICAL FUNCTION 
Bcl2 antiapoptotic 
CCL4 Chemotactic factor for monocytes 
MAFF v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog F, transcription regulator 
CCL3 Chemotactic factor for monocytes 
SNX9 regulator of dynamin function in chlatrin–
mediated endocytosis 
RGS1 regulaor of G protein signaling, Immediate–early 
response gene 
TRIO Rho guanine nucleotide exchange factor 
ATP1B1 Na,K-ATPase pump 
CCL5 Chemotactic factor for monocytes 
CD300A leukocyte membrane antigen 
CMKOR1 G protein–coupled receptor 
GADD45ß growth arrest and DNA–damage–inducible 
RBBP6 cell cycle regulation 
 
Furthermore overexpressed MED25–NTD acts as a dominant allele also on transcription 
of another subset of cellular genes that are not targeted by EBNA2. Regulation of these 
genes might indicate another biological pathway in which MED25 is involved. Taken 
together the microarray results argue for a role for MED25 in transcriptional control of a 
certain subset of cellular genes in addition to a function for MED25 in host–virus 
interaction on the level of gene regulation. 
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4.6 MED25 and Charcot–Marie–Tooth disease (CMT) 
 
It has been recently reported that a point mutation in MED25 (A335V) directly correlates 
with an autosomal–recessive form of Charcot–Marie–Tooth disease found in a Costa 
Rican family that is characterized by an axonally pronounced myelin degenerative 
process (Rautenstrauss and collaborators, personal communication). In this study the 
proline–rich region surrounding A335 was predicted to be a potential SH3–ligand region. 
According to this hypothesis, both MED25 wild type and mutant represent interaction 
partners of the SH3 domain of the Abelson tyrosine kinase family. However, the 
mutation also shows an affinity to the SH3 domains of the Src–family of kinases, which 
results in a decreased binding specificity of the MED25 A335V mutant. Fluorescence 
binding experiments using peptides representing the regions involved in this predicted 
interactions confirmed this theory at least in vitro. The transcription assay carried out on 
a GAL4–luciferase reporter and the immunoprecipitation assay presented in this study, 
helped to rule out the possibility of impaired Mediator–interaction related to this mutation 
(figures 18 and 19). On the other hand, the mutation could affect transcription activation 
at the level of specific genes regulating myelin expression and/or Schwann cell 
differentiation, as a consequence of impaired binding of mutated MED25 to a 
transcription factor. In fact, autosomal types of CMT characterized by hypomyelinating 
neuropathy have been found to be associated with mutations in the early growth 
response gene 2 (EGR2/Krox20), a transcription factor necessary for the transition from 
promyelinating to myelinating stage of Shwann cell development. Moreover mutations in 
the genes encoding the myelin proteins PMP22 and P0 cause other forms of CMT 
(CMT1A and CMT1B) (Kamholz et al., 1999). Another possible explanation could be the 
regulation of MED25 activity by phosphorylation from tyrosine kinases. An interesting 
example is represented by the YT521–B protein, a nuclear protein which is located in a 
dynamic nuclear compartment called YT body. YT521–B is involved in splicing 
processes, and binds to several proteins implicated in splice site selection, which it can 
influence in a concentration dependent manner (Hartmann et al., 1999). YT521–B has 
been shown to bind to and be phosphorylated by c–Abl and c–Src kinases in the 
nucleus and in the cytoplasm, respectively (Rafalska et al., 2004). Phosphorylation 
causes insolubility of the protein which associates to nuclear structures and gets 
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dispersed throughout the nucleus, thereby losing association with actively transcribed 
genes. Due to its insolubility and spatial distribution, phosphorylated YT521–B is 
removed from pre–mRNA processing events and can no longer influence splice site 
selection (Rafalska et al., 2004). Interestingly, the phosphorylation affects mainly the 
localization of the protein, but not its ability to change splice sites in vitro (Cazalla et al., 
2002). In an analogous way, MED25 participation in transcription could be regulated by 
c–Abl phosphorylation. However, in the case of the CMT disease one can imagine a 
scenario where the phosphorylation of A335V mutant is no longer controlled, and 
becomes aberrant therefore causing dispersion of the protein in an inactive state in the 
nuclear or in the cytoplasmic compartment. According to this theory, MED25 could be 
sequestered from transcriptionally active sites of neuronal cells. This could alter 
regulation of genes involved for example in myelin expression. Considering that the 
A335V mutation is located in a region which was contributing to the intrinsic transcription 
activation capacity of MED25 and which was also predicted as potential tyrosine kinase 
interaction domain, it is interesting to investigate whether MED25 associates with the 
relevant promoters and/or binds transcription factors or tyrosine kinases in order to 
modulate myelin expression, and whether the A335V mutant would interfere with such a 
mechanism.  
 
4.7 An attempt to create a MED25 conditional knock–out mouse 
 
The manipulation of the mouse genome represents an elegant tool to characterize the 
function of an unknown gene, and has facilitated the study of many biological processes. 
However, not all physiological processes can be assessed by constitutive gene–
inactivation or transgene–expression strategies. Null mutations can result in embryonic 
lethality that is preventing analysis of a putative gene function later in development. For 
this reason conditional mutations of the target gene are employed. Moreover, conditional 
mutations that are confined to a particular cell lineage are extremely helpful in the 
analysis of gene function in a given lineage or tissue.  
Hence, we decided to create a MED25 conditional knock–out mouse. Insights gained 
from the phenotype of these animals could have complemented the molecular biological 
and biochemical studies of MED25 that were carried out in parallel. First of all, the 
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conditional MED25 KO mouse could have been crossed with a mouse ubiquitously 
expressing CRE recombinase, in order to find out if and eventually at which stage of 
development MED25 is of vital importance. Preliminary experiments carried out in our 
laboratory using siRNA suggest that the knock–down of the protein to 10–20% does not 
affect cell growth at least for the first 36 hours after transfection. This observation 
together with the fact that MED25 is not present in yeast and C.elegans raises the 
possibility that it is not an essential gene. Moreover, the generation of a MED25 null cell 
line could have been used as a tool in biochemical assays to study the position of 
MED25 relative to other Mediator subunits. This approach has been exploited for other 
Mediator subunits (MED23 and MED24) revealing the existence of Mediator modules 
(Ito et al., 2002; Stevens et al., 2002).  
On a second stage of our study it would have been interesting to investigate whether 
MED25 has a tissue–specific function. In addition to the known relationship between 
MED25 and VP16 we have reasons to believe that MED25 might be involved in the 
mechanism of other viral activators. It has been recently reported (Roupelieva, 2005) 
that MED25 physically interacts with the latency–associated nuclear antigen 1 (Lana–1) 
of the Kaposi's sarcoma associated Herpes virus (KSHV). Moreover, the observation 
that MED25–NTD acts dominant negatively on activated transcription driven by EBNA2 
(Laux, personal communication) togheter with our array data, link MED25 to EBV. 
Together these observations lead to the hypothesis that via targeting of MED25 the 
viruses would not only support their viral life cycle, but also manipulate cellular functions 
(i.e. immune response) by titrating out MED25–associated Mediator complexes (A–
Med).  
Other Mediator subunits have been shown to be implicated in antiviral immunity 
pathways, i.e. the interferon (IFN)–activated gene regulation. Med17 binds STAT2 but 
does not enhance IFN–responsive transcription; Med23 facilitates IFN–driven 
transcription without binding the ISGF3 activation complex; Med14 shows both features 
(Lau et al., 2003). Since some of these subunits have been found to share other 
activating partners with MED25 (VP16, Dif, HSF), it is intriguing to think about a 
contribution of MED25 in the interferon–regulated immune response pathway. Crossing 
the MED25 conditional KO mouse with mice expressing CRE recombinase in the 
immune system would have helped to specifically address this question. 
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Even though homologous recombination in ES cells is a rare event compared to random 
integration, and the frequency with which it occurs may strongly vary depending on the 
investigated locus, the efficiency of gene targeting in this study was rather low (one 
homologous recombinant clone among 500). To improve statistics one possibility would 
be to include a longer 3' homologous recombination arm in the targeting vector. In fact it 
has been shown that there is a direct correlation between the length of homology and 
gene targeting frequency (Hasty et al., 1991a; Hasty et al., 1991b). The second 
bottleneck in the process of generating a transgenic mouse is represented by blastocyst 
injection. In the ideal scenario more than one ES cells clone should be injected, since, 
because of unknown reasons, about 50% of the positive clones consist of cells, which 
do not undergo germ line transmission. In our specific case the single ES cells clone 5A 
that was injected generated either non–proliferating chimeras or chimeras producing 
non–germ line transmitted offspring. Therefore we could not proceed with the phenotype 
analysis of MED25 conditional KO derivative mice. Despite the difficulties encountered 
during this first attempt, we believe that the generation of a MED25 transgenic mouse 
represents an important tool to investigate MED25 in vivo function. In the meantime the 
advent of gene–trap ES cells libraries has provided for alternative ways to realize this 
project. In fact, three MED25 ES cells clones, characterized by insertions of the gene–
 trap vector in different introns of MED25 genomic locus, have been found in these 
libraries and are currently used in the Meisterernst laboratory for the generation of 
different MED25 transgenic mice lines. 
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6.1 Supplementary figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure1. Sequence alignment of VWA domains from different species. 
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6.2 Microarray analysis 
 
 
Table 17. Genes downregulated 1 hour after induction of ER–MED25–NTD in 721–B–cells 
FLJ90036 hypothetical protein FLJ90036 84,4 
WDR49 WD repeat domain 49 14,9 
FLJ11016 hypothetical protein FLJ11016 13,0 
ZNF395 /// FBXO16 zinc finger protein 395 /// F-box protein 16 10,6 
LIN7B lin-7 homolog B (C. elegans) 8,0 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 4,0 
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 3,7 
SLC2A11 solute carrier family 2 (facilitated glucose transporter), member 11 3,7 
BCL2 B-cell CLL/lymphoma 2 2,8 
CCL4 chemokine (C-C motif) ligand 4 2,8 
MFN1 Mitofusin 1 2,8 
APOL1 apolipoprotein L, 1 2,6 
JMJD2B jumonji domain containing 2B 2,6 
MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) 2,6 
SRRM2 serine/arginine repetitive matrix 2 2,6 
SSH2 Slingshot homolog 2 (Drosophila) 2,6 
TRIP12 Thyroid hormone receptor interactor 12 2,6 
CCL3 /// CCL3L1 /// 
MGC12815 
chemokine (C-C motif) ligand 3 /// chemokine (C-C motif) ligand 3-like 1 /// chemokine (C-C motif) 
ligand 3-like, centromeric 2,5 
FLJ14503 hypothetical protein FLJ14503 2,5 
PIK3C2A Phosphoinositide-3-kinase, class 2, alpha polypeptide 2,5 
SGOL2 shugoshin-like 2 (S. pombe) 2,5 
TULP4 Tubby like protein 4 2,5 
BBP Beta-amyloid binding protein precursor 2,3 
BNIP3L 
BCL2/adenovirus E1B 19kDa interacting protein 3-like /// BCL2/adenovirus E1B 19kDa interacting 
protein 3-like 2,3 
EGR2 early growth response 2 (Krox-20 homolog, Drosophila) 2,3 
EGR3 early growth response 3 2,3 
FLJ13855 hypothetical protein FLJ13855 2,3 
FLJ20054 hypothetical protein FLJ20054 2,3 
HSD17B12 Hydroxysteroid (17-beta) dehydrogenase 12 2,3 
KIF3A kinesin family member 3A 2,3 
Lrp2bp low density lipoprotein receptor-related protein binding protein 2,3 
MGC19764 hypothetical protein MGC19764 2,3 
PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 2,3 
SENP6 SUMO1/sentrin specific protease 6 2,3 
CCNG2 cyclin G2 2,1 
DUSP4 dual specificity phosphatase 4 2,1 
FLJ90709 hypothetical protein FLJ90709 2,1 
HIG2 hypoxia-inducible protein 2 2,1 
LOC153222 adult retina protein 2,1 
MGC20460 hypothetical protein MGC20460 2,1 
PCTK2 PCTAIRE protein kinase 2 2,1 
PDK1 pyruvate dehydrogenase kinase, isoenzyme 1 2,1 
PICALM Phosphatidylinositol binding clathrin assembly protein 2,1 
PSCD1 Pleckstrin homology, Sec7 and coiled-coil domains 1(cytohesin 1) 2,1 
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RNPC2 RNA-binding region (RNP1, RRM) containing 2 2,1 
RPL23 Ribosomal protein L23 2,1 
SAT spermidine/spermine N1-acetyltransferase 2,1 
SNX9 sorting nexin 9 2,1 
TAOK1 TAO kinase 1 2,1 
YEATS2 YEATS domain containing 2 2,1 
ZCCHC6 Zinc finger, CCHC domain containing 6 2,1 
ZNF395 zinc finger protein 395 2,1 
AFTIPHILIN Aftiphilin protein 2,0 
DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 2,0 
DUSP5 dual specificity phosphatase 5 2,0 
GAS7 growth arrest-specific 7 2,0 
GSK3B glycogen synthase kinase 3 beta 2,0 
JMJD1A jumonji domain containing 1A 2,0 
LOC284757 hypothetical protein LOC284757 2,0 
MBTD1 mbt domain containing 1 2,0 
MLL3 myeloid/lymphoid or mixed-lineage leukemia 3 2,0 
NEK1 NIMA (never in mitosis gene a)-related kinase 1 2,0 
SGPP2 sphingosine-1-phosphate phosphotase 2 2,0 
SOX9 SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) 2,0 
TRA2A Transformer-2 alpha 2,0 
UHMK1 U2AF homology motif (UHM) kinase 1 2,0 
ZA20D3 Zinc finger, A20 domain containing 3 2,0 
 
 
Table 18. Genes upregulated 1 hour after induction of ER–MED25–NTD in 721–B–cells 
SIPA1L2 signal-induced proliferation-associated 1 like 2 19,7 
CXCL11 chemokine (C-X-C motif) ligand 11 13,9 
NRAP nebulin-related anchoring protein 13,0 
SCHIP1 Schwannomin interacting protein 1 13,0 
CFH /// CFHL3 complement factor H /// complement factor H-related 3 11,3 
GNG2 Guanine nucleotide binding protein (G protein), gamma 2 11,3 
MGC3234 Hypothetical protein MGC3234 9,8 
CELSR1 cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog, Drosophila) 9,2 
BCL10 B-cell CLL/lymphoma 10 8,6 
MBD2 methyl-CpG binding domain protein 2 8,6 
MYH10 myosin, heavy polypeptide 10, non-muscle 8,6 
FAT3 FAT tumor suppressor homolog 3 (Drosophila) 8,0 
LOC203510 similar to High mobility group protein 4 (HMG-4) (High mobility group protein 2a) (HMG-2a) 8,0 
KELCHL kelch-like 7,5 
C10orf51 chromosome 10 open reading frame 51 7,0 
SRC V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 7,0 
SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 6,5 
ZNF638 Zinc finger protein 638 6,5 
MAP2K6 mitogen-activated protein kinase kinase 6 6,1 
ADAMTS6 A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 6 5,3 
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A /// 5-hydroxytryptamine (serotonin) receptor 2A 5,3 
RPA4 replication protein A4, 34kDa 5,3 
IL7R Interleukin 7 receptor 4,9 
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ARMC8 Armadillo repeat containing 8 4,6 
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 4,6 
LOC283140 hypothetical protein LOC283140 4,6 
BLCAP Bladder cancer associated protein 4,3 
MGC10765 Hypothetical protein MGC10765 4,0 
WDR6 WD repeat domain 6 4,0 
DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 13 3,7 
GAL3ST2 Galactose-3-O-sulfotransferase 2 3,5 
ATF7 activating transcription factor 7 3,2 
LOC163131 hypothetical BC331191_1 3,2 
IL1RAPL1 Interleukin 1 receptor accessory protein-like 1 3,0 
KRTAP4-9 keratin associated protein 4-9 3,0 
POLR3A polymerase (RNA) III (DNA directed) polypeptide A, 155kDa 3,0 
TNRC6A trinucleotide repeat containing 6A 3,0 
ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 2,8 
DAPK1 death-associated protein kinase 1 2,8 
DGUOK deoxyguanosine kinase 2,8 
SUHW4 suppressor of hairy wing homolog 4 (Drosophila) 2,8 
BCAP29 B-cell receptor-associated protein 29 2,6 
C14orf114 chromosome 14 open reading frame 114 2,6 
CNOT3 CCR4-NOT transcription complex, subunit 3 2,6 
CPSF6 Cleavage and polyadenylation specific factor 6, 68kDa 2,6 
EPHA10 EPH receptor A10 2,6 
MRGX1 G protein-coupled receptor MRGX1 2,6 
QDPR Quinoid dihydropteridine reductase 2,6 
SVH SVH protein 2,6 
PSPH phosphoserine phosphatase 2,5 
TFRC transferrin receptor (p90, CD71) 2,5 
TP73L tumor protein p73-like 2,5 
CALR calreticulin 2,3 
DKFZp434H1419 hypothetical protein DKFZp434H1419 2,3 
FGD6 FYVE, RhoGEF and PH domain containing 6 2,3 
ITGAL integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) 2,3 
LMAN1 lectin, mannose-binding, 1 2,3 
SFN stratifin 2,3 
STK4 serine/threonine kinase 4 2,3 
ZNF17 zinc finger protein 17 (HPF3, KOX 10) 2,3 
AMOTL2 angiomotin like 2 2,1 
ANKRD7 ankyrin repeat domain 7 2,1 
C10orf18 chromosome 10 open reading frame 18 2,1 
CCNE2 cyclin E2 2,1 
CHS1 Chediak-Higashi syndrome 1 2,1 
DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 2,1 
FREB Fc receptor homolog expressed in B cells 2,1 
FRS2 fibroblast growth factor receptor substrate 2 2,1 
FUS fusion (involved in t(12;16) in malignant liposarcoma) 2,1 
TTTY5 Testis-specific transcript, Y-linked 5 2,1 
UGCGL1 UDP-glucose ceramide glucosyltransferase-like 1 2,1 
C21orf86 Chromosome 21 open reading frame 86 2,0 
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C9orf71 chromosome 9 open reading frame 71 2,0 
CASQ1 Calsequestrin 1 (fast-twitch, skeletal muscle) 2,0 
DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, S. cerevisiae) 2,0 
FABP7 fatty acid binding protein 7, brain 2,0 
GNB1 Guanine nucleotide binding protein (G protein), beta polypeptide 1 2,0 
KIAA0674 KIAA0674 2,0 
KIAA1102 KIAA1102 protein 2,0 
KRT25A keratin 25A 2,0 
NEDL1 NEDD4-like ubiquitin-protein ligase 1 2,0 
NUTF2 Nuclear transport factor 2 2,0 
RKHD1 ring finger and KH domain containing 1 2,0 
SRPR signal recognition particle receptor ('docking protein') 2,0 
TAF1L TAF1-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 210kDa 2,0 
THAP5 THAP domain containing 5 2,0 
 
 
Table 19. Genes dowregulated 10 hours after induction of ER–MED25–NTD in 721–B–cells 
FLJ90036 hypothetical protein FLJ90036 52,0 
FAM12A family with sequence similarity 12, member A 19,7 
SLC10A2 solute carrier family 10 (sodium/bile acid cotransporter family), member 2 13,9 
WDR49 WD repeat domain 49 12,1 
BCL11B B-cell CLL/lymphoma 11B (zinc finger protein) 9,8 
RGS5 regulator of G-protein signalling 5 4,6 
MCF2L2 MCF.2 cell line derived transforming sequence-like 2 2,5 
PAWR PRKC, apoptosis, WT1, regulator 2,0 
 
 
Table 20. Genes upregulated 10 hours after induction of ER–MED25–NTD in 721–B–cells 
MGC35130 hypothetical protein MGC35130 17,1 
CALD1 caldesmon 1 13,0 
AREG Amphiregulin (schwannoma-derived growth factor) 9,8 
SPAG16 sperm associated antigen 16 9,8 
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 7,5 
C20orf26 chromosome 20 open reading frame 26 5,7 
MRE11A MRE11 meiotic recombination 11 homolog A (S. cerevisiae) 5,7 
AQP3 aquaporin 3 5,3 
ELMO2 Engulfment and cell motility 2 (ced-12 homolog, C. elegans) 4,3 
KIR3DL2 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 4,3 
ABLIM2 actin binding LIM protein family, member 2 3,2 
C20orf22 chromosome 20 open reading frame 22 3,2 
RICS Rho GTPase-activating protein 3,0 
STK38 Serine/threonine kinase 38 3,0 
PFTK1 PFTAIRE protein kinase 1 2,8 
ADAM6 a disintegrin and metalloproteinase domain 6 2,6 
ZNF230 Zinc finger protein 230 2,5 
LOC340351 Hypothetical protein LOC340351 2,3 
PCAF P300/CBP-associated factor 2,1 
SEC61B Sec61 beta subunit 2,1 
DNAJC3 DnaJ (Hsp40) homolog, subfamily C, member 3 2,0 
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SLC38A6 solute carrier family 38, member 6 2,0 
ZNF20 zinc finger protein 20 (KOX 13) 2,0 
 
 
Table 21. Genes downregulated 24 hours after induction of ER–MED25–NTD in 721–B–cells 
LOC400581 GRB2-related adaptor protein-like 21,1 
ALS2CR14 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 14 16,0 
PCGEM1 prostate-specific non-coding gene 14,9 
FLJ38564 Hypothetical protein FLJ38564 8,6 
ITIH2 inter-alpha (globulin) inhibitor H2 8,0 
CASR Calcium-sensing receptor (hypocalciuric hypercalcemia 1, severe neonatal hyperparathyroidism) 4,9 
PRG1 Proteoglycan 1, secretory granule 4,6 
FLJ21103 hypothetical protein FLJ21103 3,7 
DKFZP566D1346 hypothetical protein DKFZp566D1346 3,0 
HABP2 hyaluronan binding protein 2 2,8 
CLDN1 claudin 1 2,5 
LEPR leptin receptor 2,5 
DACT1 dapper homolog 1, antagonist of beta-catenin (xenopus) 2,3 
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta 2,3 
KARS Lysyl-tRNA synthetase 2,1 
FCHSD2 FCH and double SH3 domains 2 2,0 
SLC39A3 Solute carrier family 39 (zinc transporter), member 3 2,0 
 
 
Table 22. Genes upregulated 24 hours after induction of ER–MED25–NTD in 721–B–cells 
KLF12 Kruppel-like factor 12 26,0 
LOC399947 similar to expressed sequence AI593442 19,7 
RNF152 ring finger protein 152 13,9 
C10orf84 chromosome 10 open reading frame 84 13,0 
CFH /// CFHL3 complement factor H /// complement factor H-related 3 10,6 
CHRNA1 
cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) /// cholinergic receptor, nicotinic, alpha 
polypeptide 1 (muscle) 8,6 
FLJ21963 FLJ21963 protein 7,5 
DYX1C1 dyslexia susceptibility 1 candidate 1 4,9 
SLC24A6 solute carrier family 24 (sodium/potassium/calcium exchanger), member 6 4,9 
LOC440320 similar to hypothetical protein FLJ36144 4,0 
EPHA5 EPH receptor A5 3,7 
IPO9 importin 9 3,7 
LOC158830 similar to Ab2-183 3,5 
MAML2 Mastermind-like 2 (Drosophila) 3,5 
RICS Rho GTPase-activating protein 3,5 
AHI1 Abelson helper integration site 3,2 
ABAT 4-aminobutyrate aminotransferase 3,0 
RFX3 Regulatory factor X, 3 (influences HLA class II expression) 3,0 
SFRS12 Splicing factor, arginine/serine-rich 12 3,0 
SLC23A3 solute carrier family 23 (nucleobase transporters), member 3 3,0 
GOSR1 golgi SNAP receptor complex member 1 2,6 
ZHX2 Zinc fingers and homeoboxes 2 2,6 
LOC137392 Similar to CG6405 gene product 2,5 
LOC221810 hypothetical protein LOC221810 2,5 
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TMEFF1 transmembrane protein with EGF-like and two follistatin-like domains 1 2,5 
DKFZP434N1817 Hypothetical protein DKFZp434N1817 2,3 
DKFZP586A0522 DKFZP586A0522 protein 2,3 
ERBB2IP Erbb2 interacting protein 2,3 
NUDT4 nudix (nucleoside diphosphate linked moiety X)-type motif 4 2,3 
EVI2A ecotropic viral integration site 2A 2,1 
KCNH5 potassium voltage-gated channel, subfamily H (eag-related), member 5 2,1 
SGPP2 sphingosine-1-phosphate phosphotase 2 2,1 
TAF1B TATA box binding protein (TBP)-associated factor, RNA polymerase I, B, 63kDa 2,1 
UBTD1 ubiquitin domain containing 1 2,1 
C15orf28 chromosome 15 open reading frame 28 2,0 
FLJ38281 hypothetical protein FLJ38281 2,0 
HERC3 hect domain and RLD 3 2,0 
TTBK2 tau tubulin kinase 2 2,0 
ZNF596 zinc finger protein 596 2,0 
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